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General introduction and outline of this thesis
Introduction
Picornaviridae
The virus family Picornaviridae is one of the largest virus families (Figure 1) and includes 
many important human and animal pathogens. The diseases caused by picornaviruses vary 
greatly in severity, ranging from the common cold to potentially fatal diseases such as en-
cephalitis and myocarditis. This will be further expounded on in the next paragraphs.
Enterovirus
Genus
Human enterovirus B
Human enterovirus C
Human enterovirus D
Human rhinovirus A
Human rhinovirus B
Human rhinovirus C
Human enterovirus A
Coxsackievirus B3
Polioviruses
Enterovirus 71
Serotype
Enterovirus 70
Human rhinovirus 2
Human rhinovirus 14
Saffold virus
5 animal enterovirus species
Species
Parechovirus
Hepatovirus
Aphthovirus
Cardiovirus
12 other genera
Foot-and-mouth disease virus
Hepatitis A virus
Human parechovirus
Equine rhinitis A virus
Encephalomyocarditis virus
Theilovirus
Picornaviridae
Family
Figure 1. Classification of the virus family Picornaviridae. The clinically most important genera are 
depicted. For a selection of these, the species and some examples of serotypes are given.
Enteroviruses
This thesis will focus mostly on the genus Enterovirus of the picornavirus family since this 
genus contains the most human pathogens. Overall, it was estimated that around 10-15 mil-
lion symptomatic enterovirus infections occur annually in the United States alone (excluding 
rhinovirus infections)1. The enteroviruses include coxsackie A and B viruses, echoviruses, 
polioviruses, numbered enteroviruses, and rhinoviruses. These viruses have been classified 
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into 12 species, including human enteroviruses (HEV) A-D, human rhinoviruses (HRV) A-C, 
and five enterovirus species that only infect animals (Figure 1)2,3.
While the rhinoviruses are transmitted mostly via aerosols, the viruses within the HEV 
species are spread through the oral-fecal route. Upon ingestion of the human enteroviruses, 
viral replication takes place in the enteric tract and a mild primary viremia occurs. Up until 
this point, most enterovirus infections are mild and asymptomatic. However, in some cases, 
the virus spreads to other tissues which can result in severe, potentially fatal diseases.
Poliovirus is the prototype enterovirus. In the great majority of patients (almost 95%), 
poliovirus infections remain asymptomatic4. However, poliovirus infections can progress to 
non-paralytic aseptic meningitis (in 1-2% of cases) or to poliomyelitis, a form of flaccid pa-
ralysis (in 0.1-1% of cases)4. Two types of poliovirus vaccines are available for the prevention 
of infection: an inactivated poliovirus vaccine (IPV) and an attenuated oral poliovirus vaccine 
(OPV). Worldwide vaccination schemes were started in 1988 by the Global Polio Eradication 
Initiative (GPEI) with the aim to eradicate poliovirus completely. This initiative has man-
aged to reduce the incidence of poliovirus enormously, but despite major efforts, the virus 
remains endemic in three countries (Afghanistan, Nigeria and Pakistan) and sporadic PV 
outbreaks occur5. These outbreaks may be caused by wildtype virus strains or by vaccine-
derived poliovirus (VDPV). VDPV originates from the attenuated OPV. Therefore, as long as 
OPV is used, the risk of epidemics with VDPV remains. For this reason, the GPEI is planning 
a switch to IPV for vaccination, but this is hindered by higher costs and a limited capacity for 
IPV production6.
Coxsackie A and B viruses, echoviruses, and the numbered enteroviruses are associ-
ated with a great variety of manifestations. These include encephalitis, paralysis, meningitis, 
hand-foot-and-mouth disease, respiratory diseases, pleurodynia, herpangina, conjunctivi-
tis, gastroenteritis, myopericarditis, pancreatitis, and hepatitis7. Furthermore, enteroviruses 
have been linked to type 1 diabetes, although this association is still debated8-11. Enterovi-
ruses are the most important cause for viral meningitis, accounting for 85-95% of all cases 
for which an etiological agent was identified12.
Enterovirus 71 (EV71) is an emerging pathogen, with many outbreaks having occurred 
since the late 1990s. EV71 epidemics have been reported worldwide, but mostly in the Asia-
Pacific region13. Hand, foot, and mouth disease (HFMD) is the most common manifestation 
of EV71 and affects mostly children and infants. HFMD is characterized by sores inside the 
mouth and on the hands and feet, a sore throat, and fever. In addition, EV71 infections may 
result in neurological disorders, namely meningitis, encephalitis or poliomyelitis-like acute 
flaccid paralysis (AFP). In some cases, these disorders may be fatal. In recent years, the 
development of a vaccine targeting EV71 has been a major topic of research14. Significant 
advances have been made, with Phase III clinical trials having been completed for three 
independently developed inactivated whole virus vaccines15-17.
Rhinovirus infections are mostly restricted to the upper respiratory tract and are the 
major cause for the common cold. Though on the less severe side of the spectrum of the 
diseases caused by enteroviruses, the common cold results in major costs through among 
other things the loss of working days, amounting in the United States to $40 billion annu-
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ally18. Moreover, rhinovirus infections are a serious threat to patients with asthma, chronic 
obstructive pulmonary disorder (COPD), or cystic fibrosis in whom respiratory tract infec-
tions with rhinoviruses can lead to exacerbations19-29. HRV is subdivided into the species A, 
B, and C. HRV-C has been discovered only recently with the help of molecular diagnostic 
techniques, due to the inability of these viruses to be propagated with standard tissue cul-
ture methods. Initial studies suggested that HRV-C is associated with more severe lower 
respiratory disease than the other species, but later reports suggest that also HRV-A is very 
virulent30.
Other picornavirus genera
The picornavirus family has been classified into 17 genera2,3. The genera Parechovirus and 
Hepatovirus are clinically the most relevant genera for humans after the enteroviruses.
Parechoviruses infect mainly young children and neonates. The virus has a high preva-
lence, but most infections remain asymptomatic. Patients who develop illness most often 
present with similar symptoms as observed for enteroviruses, i.e., gastroenteritis and respi-
ratory disease, but also the more severe diseases neonatal sepsis, meningitis, and encepha-
litis. Especially serotype 3 has been associated with severe neonatal infections31-41.
Hepatitis A virus (HAV) is the sole member of the hepatovirus genus. HAV induces an 
acute form of viral hepatitis and is self-limiting. Despite the availability of an effective vac-
cine against HAV, about 1.5 million clinical cases of hepatitis A occur worldwide annually42, 
demonstrating that HAV still represents a large problem.
Foot-and-mouth disease virus (FMDV), a member of the genus Aphthovirus, is a very 
important animal pathogen. It is an extremely contagious virus that infects domestic and 
wild cloven-hoofed animals. Infections are characterized by vesicular lesions on the feet, in 
and around the mouth, and on the mammary gland. FMDV is enzootic in Africa, and Asia, 
and sporadic infections occur in South America43. The European Union is currently free of 
FMDV, but outbreaks have occurred in the Netherlands in 2001 and in the United Kingdom 
in 2001 and 200744-47. The 2001 outbreak in the United Kingdom was estimated to have cost 
₤6 billion48. Emergency vaccination is available but has the disadvantage that if offers com-
plete protection only after 7 days49.
Viruses in the genus Cardiovirus are classified into two species: Encephalomyocarditis 
virus (EMCV) and Theilovirus. The species EMCV contains one serotype of the same name. 
The natural reservoir of EMCV is rodents, but the virus can infect a wide variety of animals 
such as pigs, elephants, and squirrels. EMCV infections are often asymptomatic, but other-
wise the most common symptoms are myocarditis, encephalitis, member paralysis, type 1 
diabetes, and febrile illness50. The presence of neutralizing antibodies in humans and the 
ability to isolate virus from patients suggest that also humans can be infected with EMCV50. 
However, it appears that EMCV infections in humans are associated with low morbidity. 
The species Theilovirus contains Theiler’s murine encephalomyelitis virus, Vilyuisk human 
encephalomyelitis virus, Thera virus, and the first human cardiovirus, Saffold virus (SAFV). 
SAFV has a high prevalence, with >75% seropositivity already at the age of 24 months and 
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a seroprevalence of >90% in older children and adults for SAFV-2 and SAFV-351-53. The virus 
has been isolated from patients with respiratory and gastrointestinal disease, AFP, or aseptic 
meningitis, but a causal relationship has not been established yet, leaving open the question 
of the pathogenicity of SAFV54.
The need for anti-enteroviral drugs
As illustrated above, picornaviruses, and enteroviruses in particular, represent a major 
medical threat. Unfortunately, the tools available to fight enterovirus diseases are limited. 
Vaccines are only available against PV. Although vaccine development for specific pathogens 
such as EV71 is possible, developing vaccines against all members of the enterovirus genus 
is not feasible due to the sheer quantity of serotypes. Rhinoviruses alone already number 
more than 150 serotypes. In addition, there are 28 coxsackie A viruses, 6 coxsackie B viruses, 
28 echoviruses, 3 polioviruses, and 38 numbered enteroviruses3.
Moreover, no antiviral drugs have been approved for the treatment of enterovirus 
infections, so treatment is currently limited to supportive and symptomatic care. The only 
option available for treatment of neonates or patients with agammaglobulinemia is the ad-
ministration of pooled immunoglobulin from multiple blood donors (intravenous immuno-
globulin, IVIG), but variable success has been achieved with this treatment modality which 
is most likely dependent on the presence of specific neutralizing antibodies in the prepara-
tion55-57.
Clearly, there is a strong need for broad-range antiviral drugs to combat enterovirus 
infections. Apart from treating infected patients, antiviral drugs might aid in the eradication 
of PV by helping to contain VDPV outbreaks and by treatment of immunodeficient patients 
who are chronically shedding poliovirus. Also, antiviral drugs may be useful to contain post-
eradication outbreaks of poliovirus58.
For the development of antiviral drugs, fundamental knowledge is required about the 
replication cycle of enteroviruses. The aspects of enterovirus replication relevant for this 
thesis will be summarized in the next section.
Enterovirus replication cycle
Picornavirus virions and viral genome organization
Picornaviruses are small RNA viruses, hence the name ‘pico’ (=small)-RNA-viruses. Like oth-
er important human pathogens such as hepatitis C virus, SARS-coronavirus, Dengue virus, 
and norovirus, they are positive-strand RNA viruses, meaning that the single-stranded 7-8 
kb genome can immediately be translated into protein. The genome is encapsidated by an 
icosahedral capsid, forming a virion of around 30 nm in size. Picornaviruses are so-called 
naked viruses, i.e., they do not have an envelope.
The enteroviral genome contains a single open reading frame with highly structured 
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untranslated regions (UTR) at the 5’ and 3’ end and a 3’ poly(A) tail (Figure 2A). Unlike cel-
lular mRNAs, enteroviral RNA does not contain a 7-methylguanosine cap at its 5’ terminal 
end. Instead, the 5’ end is covalently coupled to the viral protein 3B, in this context usually 
termed VPg (viral protein genome-linked). The 5’-UTR contains an internal ribosomal entry 
site (IRES) which mediates cap-independent translation. The open reading frame encodes a 
polyprotein that contains structural proteins (VP1-4) in the P1 region and the nonstructural 
proteins (2A-2C and 3A-3D) in the P2 and P3 regions (Figure 2B).
Protein translation and processing
The enteroviral replication cycle, depicted in Figure 3, is initiated by binding to a receptor. 
The receptor used differs per virus59. Subsequently, the virus is internalized and the viral 
RNA is released into the cytoplasm. A single polyprotein is then translated from the open 
reading frame, initiated from the IRES. This polyprotein is proteolytically processed by the 
viral proteases to release the structural and nonstructural viral proteins and some stable 
precursors (Figure 2B). The protease 2Apro is responsible for the primary cleavage between 
the P1 and the P2 region of the polyprotein. The other cleavages (except between VP4 and 
VP2) are carried out by the viral protease 3Cpro and/or its precursors, with the 3Cpro precursor 
3CDpro being responsible for the majority of the cleavages60.
Apart from processing of the viral protein, the viral proteases cleave cellular targets, 
which serves to optimize the environment for viral proliferation. One of these targets is 
AAAAAn
VP0
VP2
VP3
P1 P2 P3
VP1 2A 2BC
2C 3A
3B
3D2B
3AB 3CD
VP4
VPg
3C
3Cpro
2Apro
5’-UTR
IRES
3’-UTR
P1 P2 P3
A
B
Figure 2. Enterovirus genome. (A) Depicted is a schematic representation of the enterovirus genome 
on scale. The enterovirus genome encodes a single polyprotein divided into a P1, P2, and P3 area. 
At the 5’and 3’ end the genome contains untranslated regions (UTR) which are highly structured. 
The 5’-UTR contains a internal ribosomal entry site for cap-independent translation. At the 5’ end, 
the RNA genome is covalently bound to the viral protein VPg which is used as a primer during RNA 
replication. (B) The polyprotein is processed into the viral proteins and some stable precursors by 
the viral proteases 2Apro and 3Cpro (and its precursors).
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eIF4G, an initiation factor required for translation of cellular capped mRNAs. Cleavage of 
eIF4G by 2Apro therefore results in a blockage of translation of cellular proteins, a so-called 
host shut-off61,62. Proteolysis of poly(A)-binding protein (PABP) by 2Apro and 3Cpro also con-
tributes to this effect63. Since picornavirus genomes are uncapped and instead contain an 
IRES for cap-independent protein translation, viral translation is not impaired and even ben-
efits from the host shut-off. In addition, several factors involved in (regulation of) transcrip-
tion, nucleocytoplasmic transport, cytoskeleton organization, and immune activation, are 
cleaved by viral proteases in order to support virus reproduction and/or suppress innate 
antiviral responses64-69.
Figure 3. Enterovirus replication cycle. The enterovirus replication cycle is initiated by binding of the 
virus to the receptor and internalization into the cell. Subsequently, the viral RNA genome is released 
from the virion and translated into a single polyprotein which is then processed by the viral proteases 
to release the viral proteins. Next, the nonstructural proteins mediate the replication of the RNA 
genome via a negative-stranded intermediate. This takes place on replication organelles that are 
formed as a result of an rearrangement of cellular membranes. Newly synthesized positive-stranded 
RNA molecules can then either enter another round of translation and replication (not depicted) or 
they can be packaged into the viral capsid proteins to form new infectious virus particles which are 
released upon cell lysis.
Viral RNA replication
Once liberated from the polyprotein, the nonstructural proteins and the stable precursors 
mediate the replication of the viral genome. RNA genome replication is initiated by uridy-
lylation of the protein primer VPg by the viral RNA-dependent RNA polymerase 3Dpol using 
a secondary RNA structure in the viral genome called cis-acting replication element (Cre) as 
a template70-73. VPgpUpU is then elongated by 3Dpol to produce a negative-sensed interme-
15
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diate which in turn is used as a template for synthesis of positive-sensed RNA molecules. 
Positive-sensed RNA molecules can then either enter another round of translation and rep-
lication or they can be packaged into capsids to produce infectious virus particles.
Typical for positive-strand RNA viruses, replication of the viral RNA takes place on cel-
lular membranes which are drastically reorganized during virus infection74,75. In enterovirus-
infected cells, both single- and double-membrane structures are observed (Figure 4)76,77. 
Two recent electron tomography studies with PV and CVB3 have revealed that early in virus 
infection (when RNA replication is already maximal) single-membrane tubular structures 
are predominant, whereas in later stages these structures appear to flatten, curve, and fuse 
to form double-membrane vesicles (DMV). These DMVs can then be wrapped by multiple 
additional cisternae and form multilamellar structures.
The exact origin of the membranes of these organelles is unclear yet. There was evi-
dence arguing that the membranes originated from the early secretory pathway but also 
that they were derived from the autophagy pathway. The results from the electron tomo-
graphy studies suggest that there may be some truth in both theories, with the early se-
cretory pathway acting as a source for the single membrane tubules and the autophagy 
pathway being involved in DMV formation.
Important observations that support a role for the early secretory pathway in the 
membrane rearrangements are that Brefeldin A (BFA), a well-known inhibitor of ER-to-Golgi 
transport, completely abolishes entervirus replication78-81 and that several proteins from the 
secretory pathway are essential for virus replication and can be detected on replication or-
ganelles. One of these is Golgi-specific BFA-resistance factor 1 (GBF1), which is a target of 
BFA. GBF1 is a guanine nucleotide exchange factor (GEF) of the GTPase ADP-ribosylation 
Figure 4. Extensive membrane rearrangements in enterovirus-infected cells. An electron 
tomographic slice through a serial tomogram (A) and top and side views of the surface-rendered 
model of the boxed area (B) show the presence of single-membrane tubules (green), open (orange) 
and closed (yellow) double-membrane vesicles in a cell infected with coxsackievirus B3 at 5 hours 
post infection. The ER is depicted in blue. Reprinted from Limpens et al., mBio 2011 with permission 
from the authors, © 2011 by the American Society for Microbiology.
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factor 1 (Arf1), which is localized on the Golgi complex and the ER-Golgi intermediate com-
partment. In uninfected cells, GBF1 stimulates GTP exchange of Arf1. Upon activation, Arf1-
GTP becomes membrane-bound and mediates the recruitment of effector proteins such as 
the COP-I coat complex, thereby inducing the formation of secretory vesicles. Arf1 is thus 
a key regulator of protein and lipid transport within the early secretory pathway. Upon in-
fection, the viral protein 3A recruits GBF1 and indirectly Arf1 to replication organelles (i.e., 
virus-induced vesicles plus associated replication complexes) through a direct interaction 
with GBF178,82,83. Through a yet unknown mechanism, this leads to the loss of COP-I from 
membranes (Figure 5), resulting in a disturbance of the secretory pathway and blockage of 
protein secretion82,84-86. This impairs the expression of MHC class I on the cell surface and 
cytokine secretion87,88, indicating that the virus-induced membrane rearrangement not only 
serves to facilitate viral RNA replication but possibly also to suppress infection-limiting host 
immune responses. Meanwhile, virus release is unaffected since this is mediated by cell 
lysis1.
During the course of this PhD project, it came to light that another Golgi-localized pro-
tein is an essential host factor for enterovirus replication, i.e., phosphatidylinositol-4-kinase 
III beta (PI4KIIIβ)84. PI4KIIIβ is a kinase that synthesizes phosphatidylinositol-4-phosphates 
(PI4P) by phosphorylation of phosphoinositides. As a precursor for PI(4,5)P2, PI4P lipids are 
part of PI3K and phospholipase C signaling pathways, but PI4P lipids also recruit proteins 
with a PI4P-binding pleckstrin homology (PH) domain to membranes, thereby regulating 
membrane biogenesis, lipid homeostasis, and vesicle-mediated trafficking at the Golgi com-
plex89-91. During infection, PI4KIIIβ is recruited to replication sites by 3A and consequently 
local levels of PI4P lipids increase84. PI4KIIIβ is an effector protein of Arf1, and therefore it 
was hypothesized that the recruitment of PI4KIIIβ was mediated through the recruitment of 
GBF1 and Arf1 by 3A (Figure 5)84. PI4KIIIβ activity is required for replication, since treatment 
with the PI4KIIIβ-inhibitor PIK93 or depletion of PI4KIIIβ by siRNA-treatment impairs virus 
Figure 5. The proposed role of Golgi-localized host factors in enterovirus replication. Upon 
infection, the membrane-bound nonstructural viral protein 3A recruits GBF1 and indirectly Arf1 to 
membranes. As a consequence, COP-I, an effector of Arf1, is lost from the membranes and instead 
PI4KIIIβ is recruited. This leads to an increased production of PI4P lipids. These bind 3Dpol, thereby 
facilitating viral RNA synthesis. Reprinted from Hsu et al., Cell 2010 with permission from the authors, 
© 2010 by Cell Press. 
recruitment of PI4KIIIb in infected cells, given that PI4KIIIb is
colocalized with GBF1 and coimmunoprecipitated with 3A
(Figures 3A and 3C), where the latter is known to bind GBF1
(Wessels et al., 2006). It also remains to be explored whether
GBF1, Arf1, or any other viral or host proteins may be stimulating
PI4KIIIb activity to reach the high PI4P lipid levels observed
during infection.
HCV, an enveloped flavivirus whose replication enzymes
are sequence- and structure-wise distinct from enteroviral
enzymes (Dubuisson et al., 2002), nevertheless depends on
PI4P lipid-enriched membranes and PI4KIIIb for replication
(Figures 6H–6L). Whereas most enteroviral infections disrupt
secretory trafficking, flaviviruses utilize the secretory pathway
to mature into virions and exit the cell (Mackenzie and West-
away, 2007). HCV RNA is replicated on remodeled ER
membranes whereas structural proteins are located to lipid
droplets (Miyanari et al., 2007). Through a complex assembly
process not yet understood virions bud out of the ER and are
released from the cell through exocytosis. The presence of
high levels of PI4P lipids at ER membranes, in addition to regu-
lating HCV RNA replication, could impact the organization and
kinetics of secretory trafficking and budding/export of HCV.
Indeed secretory trafficking is attenuated in HCV-infected cells
(Konan et al., 2003).
Inmammaliancells,PI4P lipids, themost abundantmonophos-
phorylated inositol phospholipids,werepreviously viewedonlyas
PIP2 precursors (D’Angelo et al., 2008). However independent
functions have recently emerged: several host proteins including
CERT, OSBP, and FAPP1/2 specifically bind PI4P lipids (Lem-
mon, 2008); and PI4P lipids regulate selective autophagy and
ER exit site biogenesis (Blumental-Perry et al., 2006; Yamashita
et al., 2006). PI4P lipids can locally change membrane curvature
(Ishiyamaet al., 2002;McMahonandGallop, 2005). PI4P lipid-en-
riched membranes during viral infection may generate high-
curvature membrane pockets to shield viral components from
host defense. Little is known about how soluble viral RNA poly-
merases are recruited to membranes. PI4P lipids may provide
docking sites to concentrate viral proteins for efficient RNA
synthesis. Enteroviral RdRp 3Dpol preferentially binds PI4P lipids
over all other cellular lipid components, and PI4P depletion
specifically perturbs viral RNA synthesis (Figure 5 and Figure 6).
This raises the possibility that enteroviruses rewire host secretory
machinery to generate PI4P lipid-enriched membranes to recruit
to and concentrate on membrane RNA polymerases. Further-
more,PI4P lipidbindingmayalso induceconformational changes
and modulate RdRp enzymatic activity. The phosphoinositide-
binding domain on 3Dpol is unknown and studies to identify the
lipid-binding site and investigate its occurrence across different
RdRps are underway.
In summary, we show that the PI4P lipid microenvironment
is an important facilitator of plus-strand viral RNA replication.
Enteroviruses reorganize the cellular secretory trafficking
machinery away from building conventional secretory organelles
to generate organelles whose membranes are enriched in PI4P
A
B
Figure 7. Model for Secretory Pathway
Reorganization in Enteroviral Infections
(A) Tail-anchoredmembrane protein 3Abybinding
and modulating GBF1/Arf1 promotes PI4KIIIb
recruitment to the membrane bilayer at the
expense of coat protein COPI. Recruited PI4KIIIb
will catalyze the production of a PI4P lipid micro-
environment (red lipids) that will in turn facilitate
the recruitment of 3Dpol from the cytosolic pool
to the membrane and promote the synthesis of
viral RNA.
(B) Uninfected (0 hr): Steady-state exchange of
membranes, Golgi enzymes, and cargo through
bidirectional trafficking between the ERGIC and
Golgi/TGN compartments. Golgi enzymes and
cargo are sorted out of Sar1/COPII-labeled ER
exit sites into ERGIC compartments whereupon
GBF1/Arf1 and COPI coats mediate the traf-
ficking to and from the Golgi/TGN compartments.
PI4KIIIb enzymes are recruited to Golgi/TGN
membranes by Arf1 and catalyze the production
of PI4P lipids at these membranes.
2 hr: Upon infection, newly synthesized viral repli-
cation enzymes such as the membrane-bound 3A
target to and assemble on secretory organelle
membranes but concentrate and initiate viral
RNA synthesis on the Golgi/TGN membranes,
where the pre-existing (i.e., prior to infection)
steady-state pool of PI4P lipids facilitates viral replication protein assembly and RNA replication. Rising levels of 3A combined with its modulation of effector
recruitment by GBF1/Arf1 will enhance the recruitment of PI4KIIIb over COPI, leading to a decreased rate of anterograde transport out of the ERGIC and subse-
quent disassembly of the Golgi/TGN organelles.
4 hr: Enhanced recruitment of PI4KIIIb over COPI results in the formation of uncoated PI4P lipid-enriched organelles adjacent to ER exit sites. The PI4P lipid-
enriched microenvironment of these organelles facilitates the ongoing assembly of newly synthesized viral replication proteins such as RdRp 3Dpol and viral RNA
replication.
808 Cell 141, 799–811, May 28, 2010 ª2010 Elsevier Inc.
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replication84. In vitro, PI4P lipids specifically bound 3Dpol, suggesting that they may serve to 
recruit the viral polymerase to replication complexes84, but firm proof for this idea is lacking. 
Alternatively, or additionally, the function of PI4P lipids in virus replication may be to re-
cruit PH domain-containing proteins for example with membrane-altering effects. However, 
these possibilities need further investigation.
DMVs are reminiscent of autophagosomes with respect to their appearance and for-
mation, which originated the idea that the autophagic pathway is involved in the formation 
of replication organelles. A role for the autophagy pathway is substantiated by the detec-
tion of autophagic marker LC3 on replication organelles and the lipidation of LC3, which is a 
hallmark for autophagy92-94. The recent observation that DMVs occur mostly in later stages 
of infection suggests that this pathway is mostly important in the advanced stages of mem-
brane rearrangements76,77. Inhibition of the autophagy pathway impairs viral replication, but 
only to a modest extent94,95, which is consistent with the observation that maximal RNA 
replication takes place in the early stages when single-membrane structures are predomi-
nant76,77. In the autophagy pathway, vesicles become acidified when autophagosomes fuse 
with endosomes. The endosomal marker LAMP1 has been found on replication organelles, 
suggesting that also during virus infection this fusion takes place94. A recent publication has 
provided evidence that vesicular acidification promotes maturation of PV particles (i.e., VP0 
cleavage, see next section), implicating a role for autophagy and DMVs in the last step of 
the replication cycle96. Furthermore, it has been suggested that the DMVs might be involved 
in non-lytic release of virus particles by fusion with the plasma membrane, challenging the 
dogma that enteroviruses egress only through cell lysis. Since this only results in the loss of 
one membrane, the other membrane was hypothesized to be shed either before fusion with 
the plasma membrane or after because of instability in the extracellular space. Together, 
these data suggest that the early secretory pathway and the autophagy pathway have a 
distinct, but important function during enterovirus replication.
Genetic and biochemical evidence suggest that the viral 2BC and 3A proteins are in-
volved in the formation of replication organelles during infection97-99. These proteins have 
hydrophobic domains and extensively interact with cellular membranes. 3A is probably 
important in membrane reorganization through its interactions with GBF1, Arf1, and pos-
sibly also PI4KIIIβ. 2B is a viroporin that enhances the permeability of ER and Golgi mem-
branes100-104. Overexpression of 2B leads to disturbed ion homeostasis, impaired transport 
of proteins through the Golgi complex, and increased targeting of endocytic vesicles to the 
Golgi complex85,102,105,106. How and if these activities are involved in the formation of repli-
cation organelles is unknown. 2C has been postulated to contribute to the membrane re-
modeling by insertion of its hydrophobic domains in the membranes, as well as through its 
interaction with reticulon proteins107. These latter proteins are membrane-shaping proteins 
that induce and stabilize positive membrane curvature, and may be involved in the forma-
tion of the positively curved membranes that are essential for the morphogenesis of the 
viral replication organelles.
As has become clear from this brief overview, membrane remodeling involves many 
viral and host proteins and is a very complicated process that is not completely understood.
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Morphogenesis and virus release
Once synthesized, viral RNA of positive polarity is encapsidated by capsid proteins to form 
new virions. After release of the P1 capsid precursor from the polyprotein, it is folded by the 
chaperone protein Hsp90 and processed by 3CDpro to VP0 (a precursor of VP4 and VP2), VP1, 
and VP360,108. In a stepwise process, 60 copies of each capsid protein then assemble to form 
a provirion. The last step is a maturation of the virion by RNA-induced cleavage of VP0 into 
VP2 and VP4, yielding an infectious virus particle. As is common for non-enveloped viruses, 
newly formed infectious particles are released by lysis of the host cell, although recently it 
was suggested that DMVs might mediate non-lytic virus release at stages prior to cell lysis96.
Antiviral drugs
Antiviral therapy can have a variety of mechanisms of action and each step of the virus rep-
lication cycle can be a target for antiviral compounds. Virus replication can be impaired by 
targeting either viral proteins or host factors that are required for virus replication.
Several issues complicate the development of antiviral drugs against enteroviruses. 
First of all, broad-spectrum antiviral activity is desired, especially because standard diagnos-
tics does not include serotyping/genotyping. Secondly, the emergence of drug resistance 
is a big problem. The mutation frequency for RNA polymerases is relatively high, with esti-
mates for poliovirus 3Dpol varying between 10-3 and 10-6, depending on the method used109. 
As a result, a virus population can be described as a quasispecies. The presence of virus 
variants in a virus population allows flexibility to adapt to changing circumstances, such as 
the presence of antiviral drugs. Drug-treatment will select for virus mutants with a selective 
advantage, allowing the outgrowth of resistant virus mutants and rendering the antiviral 
therapy ineffective. For this reason, compounds to which the virus cannot (easily) develop 
drug resistance are highly wanted. One strategy believed to help with both of the issues 
above, is to develop antiviral drugs that target host factors. Many essential host factors are 
common to all viruses within a genus, which allows targeting an entire genus without the 
problem of variable drug pockets in the viral proteins. Also, it is highly unlikely that a host 
factor will become resistant to the drug in response to therapy. A finding that supports this 
hypothesis, is the inability to obtain resistant poliovirus when passaging virus in the pres-
ence of geldanamycin, an inhibitor of the host chaperone protein Hsp90 which is required 
for virus assembly108.
Decades of searching for compounds with antipicornaviral activity has yielded a range 
of compounds that inhibit enterovirus replication, although none of them have reached 
approval for clinical use. The current status of research on and development of antivirals 
against enteroviruses is summarized here below.
Capsid binders. The two compounds that are currently under clinical evaluation are 
pleconaril (Viropharma, licensed to Schering-Plough in 2003) and BTA798 (Biota). Both 
compounds are viral capsid binders and target the first steps in the viral replication cycle, 
i.e., receptor attachment and/or viral uncoating. Pleconaril displays broad-spectrum activ-
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ity against enteroviruses and had some beneficial effects in clinical trials110-115, but was re-
jected by the FDA in 2002 for the treatment of the common cold due to safety issues116. 
Hereafter, two clinical phase II trials have been performed to test the efficacy of pleconaril 
in infants with enteroviral sepsis syndrome and in preventing asthma exacerbations and 
common cold symptoms in asthma patients challenged with rhinovirus117,118. The results of 
these trials have not been reported at the moment of writing. The compound BTA798 is 
currently under investigation for the treatment of HRV infections in asthmatic patients. In 
March 2012, a clinical phase IIb trial testing the efficacy of BTA798 in asthma patients with 
naturally acquired rhinovirus infections was completed119. Biota reported significant reduc-
tions in symptoms upon treatment with BTA798 and is currently planning phase III trials.
Protease inhibitors. Other antiviral compounds that have made it to clinical studies 
are the 3Cpro inhibitors AG7088, and AG7404. The compound AG7088 (also known as rupin-
trivir) was developed as a potent inhibitor of rhinovirus 3Cpro, but further studies revealed 
that AG7088 also inhibits replication of other enteroviruses120-124. AG7088 is an irreversible 
peptidomimetic with an α,β-unsaturated ester. Because of limited activity in clinical trials 
with natural HRV infections125, the clinical development was halted. AG7404 (also known as 
compound 1) was developed as an analogue of AG7088 with improved oral bioavailability 
compared to AG7088126. AG7404 displays antiviral activity in vitro and is safe and well-tole-
ra ted in vivo, but clinical development was discontinued125.
Polymerase inhibitors. 3Dpol is the RNA-dependent RNA polymerase that executes the 
replication of the viral RNA genome. Evidently, inhibition of 3Dpol is detrimental for virus 
replication and is therefore an attractive strategy for antiviral approaches. There are two 
classes of polymerase inhibitors. The nucleoside analogs are compounds that have struc-
tural similarity to endogenous nucleosides. Incorporation of these analogs by 3Dpol results 
in chain termination and/or incorporation of incorrect nucleosides leading to mutations. 
One such compound is ribavirin, a synthetic purin analog. Treatment with ribavirin leads 
to lethal mutagenesis127,128. The other class of polymerase inhibitors encompasses the non-
nucleoside inhibitors. These inhibitors can have a variety of mechanisms of action, but for 
most compounds this has been poorly characterized. Up to now, no 3Dpol inhibitors have 
been tested in clinical trials.
2C-targeting compounds. Another group of inhibitors is that of compounds that se-
lect for mutations in 2C. The nonstructural protein 2C is an extremely multifunctional pro-
tein. Its functions are not fully understood, but the protein has been implicated in RNA 
replication107,129-134, RNA binding135-137, the induction of membrane rearrangements98,99,138,139, 
encapsidation140-142, and uncoating143. On the basis of several conserved motifs, 2C was also 
predicted to be a helicase144, although the RNA unwinding activity has not yet been experi-
mentally confirmed. 2C has a nucleoside triphosphate-binding motif and displays ATPase 
activity145,146. A variety of antiviral compounds have been shown to target 2C (guanidine 
hydrochloride, HBB, MRL-1237, and TBZE-029)147-151, but their mechanisms of action have 
not been resolved yet and none of these compounds have progressed to in vivo studies in 
humans.
Enviroxime. In the late 1970s, the compound enviroxime was reported to have potent 
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antiviral activity against enteroviruses152. Further experiments with the compound revealed 
that enviroxime inhibits plus-strand RNA synthesis153. In an attempt to elucidate the mecha-
nism of action of the compound, resistance culturing was undertaken to select for virus vari-
ants with reduced susceptibility to the compound. These variants displayed mutations in the 
nonstructural protein 3A153-155. Despite the testing of several functions of 3A or its precursor 
3AB, the mechanism of action of enviroxime remained elusive154. In several clinical studies 
the compound was able to reduce symptoms, but overall the in vivo efficacy was disappoint-
ing156-161. This in combination with gastrointestinal side-effects and a poor pharmacokinetic 
profile caused the clinical development to be halted160.
At the start of this PhD project, besides BFA and geldanamycin, very few compounds 
were known to inhibit virus replication through host targets.
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Outline of this thesis
As described above, there is a strong need for antiviral drugs to combat picornavirus infec-
tions. Although a variety of small molecule picornavirus inhibitors have been described, the 
assortment of compounds with potential for use in vivo remains limited. Therefore, the aim 
of this PhD project was to identify new small molecule compounds with antiviral activity. 
This was done by automated high-throughput screening at KU Leuven or manual screening 
of small molecule libraries to identify novel compounds that inhibit enterovirus replication. 
Furthermore, the mechanism of action was characterized of hits identified in the screens 
and of several other compounds described previously. By this we hope to achieve multiple 
goals: first, to identify more compounds with antiviral activity and secondly, by studying 
the mechanism of action of these compounds we hope to expand our knowledge on virus 
replication mechanisms and its requirements. This knowledge may in the future serve as a 
foundation for rational design of antiviral strategies.
CHAPTERS 2 to 5 report on compounds that target host factors for the inhibition of 
virus replication, whereas CHAPTERS 6 to 8 deal with compounds that impair virus replica-
tion by targeting of viral proteins.
GBF1, a protein essential for Golgi complex assembly and function, is an essential host 
factor for enteroviruses and inhibition of GBF1 by Brefeldin A has a strong inhibitory effect 
on enterovirus replication. Based on reports that the compounds AG1478 and Golgicide A 
are novel putative GBF1 inhibitors, in CHAPTER 2 we examined the effects of these com-
pounds on enterovirus replication.
CHAPTERS 3 to 5 describe the identification of small molecules TTP-8307 (CHAPTER 
3), the c-Raf kinase inhibitor GW5074 (CHAPTER 4), and the antifungal itraconazole (CHAP-
TER 5) as compounds with antiviral activity against enteroviruses. Passaging virus in the 
presence of TTP-8307 yielded virus variants with mutations in 3A that were cross-resistant 
to all of these compounds as well as to the previously discovered antiviral compound envi-
roxime. In CHAPTER 4, evidence is presented that enviroxime and GW5074 inhibit entero-
virus replication by targeting PI4KIIIβ, and the mechanism of resistance of the 3A mutant 
viruses is investigated. In CHAPTER 5, it is shown that itraconazole does not inhibit PI4KIIIβ 
activity, but that it targets OSBP and ORP4, two cellular sterol-binding proteins with a PH 
domain implicated in binding of PI4P lipids, the product of PI4KIIIβ.
CHAPTER 6 reports the results of a small-scale screen for inhibitors of CVB3 using NIH 
Clinical Collection, a library with highly drug-like compounds that have been tested in clini-
cal trials. In this screen, the antidepressant fluoxetine was found to have antiviral activity 
against viruses of the HEV-B and HEV-D species. CVB3 with mutations in 2C had a fluoxetine-
resistant phenotype, suggesting that fluoxetine is a novel 2C-targeting compound.
In CHAPTER 7, the identification of a novel polymerase inhibitor, GPC-N114, is de-
scribed. This compound had broad-spectrum antiviral activity, inhibiting replication of en-
teroviruses and cardioviruses. A combination of resistance mapping, X-ray crystallography, 
and biochemical studies revealed that GPC-N114 inhibits polymerase activity by interfering 
with template binding to 3Dpol, making this the first antipicornaviral compound with this 
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mechanism of action.
Lastly, CHAPTER 8 describes a cell-based protease assay which can be used for testing 
the inhibitory activity of (putative) inhibitors of viral proteases. This assay was applied to 
test the activity of established and novel inhibitors against 3Cpro of a variety of enteroviruses 
and other picornaviruses.
The results described in this thesis will be summarized and discussed in CHAPTER 9.
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Abstract
A novel compound, TTP-8307, was identified as a potent inhibitor of the replication of sev-
eral rhino- and enteroviruses. TTP-8307 inhibits viral RNA synthesis in a dose-dependent 
manner, without affecting polyprotein synthesis and/or processing. Drug-resistant vari-
ants of coxsackievirus B3 were all shown to carry at least one amino acid mutation in the 
nonstructural protein 3A. In particular three mutations located in a nonstructured region 
preceding the hydrophobic domain (V45A, I54F and H57Y) appeared to contribute to the 
drug-resistant phenotype. This region has previously been identified as a hot sport for mu-
tations that resulted in resistance to enviroxime, the sole 3A-targeting enterovirus inhibitor 
reported thus far. This was corroborated by the fact that TTP-8307 and enviroxime proved 
cross-resistant. It is hypothesized that TTP-8307 and enviroxime disrupt proper interactions 
of 3A(B) with other viral or cellular proteins that are required for efficient replication.
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Introduction
Enteroviruses comprise several pathogens that are implicated in an large variety of clinical 
manifestations that range from mild illnesses to more serious or even life-threatening dis-
eases, such as meningitis, encephalitis, myocarditis, pancreatitis, acute paralysis or neonatal 
sepsis1,2. Enteroviruses are small, nonenveloped, and spherical in shape with a diameter of 
about 30 nm. The icosahedrally shaped capsids are assembled from 60 protomers, each 
composed of four structural proteins, designated VP1 (for viral protein 1), VP2, VP3, and 
VP43,4. The enteroviral genome consists of a single-stranded, positive sense RNA of approxi-
mately 7,500 bases in length. The coding region of the viral genome is divided into three 
primary precursor molecules which contain the four structural (derived from P1) and 10 
nonstructural viral proteins (derived from P2 and P3).
The nonstructural protein 3A and its precursor 3AB are derived from P3 and are indis-
pensable for viral replication. A feature of 3A - that has been the subject of many studies - is 
its ability to serve as a membrane anchor through the presence of a 22-residue hydropho-
bic domain that forms an amphipathic helix near its C-terminus5. In infected cells, both 3A 
and 3AB are found in association with membranes6. In the context of the viral replication 
complex, 3AB serves to deliver the basic protein VPg (3B) at the 5’ ends of plus- and minus-
strand RNA during replication7,8 and, hence, to recruit the other proteins of the replication 
complex to the cellular membranes, the site of viral replication. The 3B protein then serves 
as a primer for the initiation of RNA synthesis, probably only after it has been cleaved from 
the 3A portion and not when it is still in the 3AB membrane-bound state6. Cleavage of 3AB 
is mediated by 3Cpro/3CDpro, and can only occur when the protein is membrane bound9. 
Moreover, this proteolysis was shown to be enhanced in the presence of purified 3AB but 
not 3A9-11. Stimulation of catalytic activity by 3AB has also been observed for the 3Dpol, both 
when 3AB is membrane bound and purified, and this has been suggested to occur via stabi-
lization of the primer-template/3Dpol complex9,12-15. 3AB but not 3A shows nonspecific RNA-
binding activity but binds specifically to the 5’ RNA cloverleaf of the viral RNA genome when 
it is complexed with 3CDpro 15-17. The protein also binds to the 3’ untranslated region but in 
contrast to binding at the 5’ cloverleaf, binding at the 3’UTR can also occur in the absence of 
other proteins16. Moreover, 3AB has been shown to induce membrane permeability in bac-
terial but not mammalian cells5,18-20, to induce membrane alterations in the endoplasmic re-
ticulum (ER) 21, to form homodimers9,22,23, and to be involved in host range pathogenicity24-27.
Apart from these features that are directly or indirectly associated with viral repli-
cation, 3A and 3AB are also involved in processes that specifically affect the host cell. It 
is well documented that protein 3A is able to interfere with cellular protein secretion via 
inhibition of ER-to-Golgi transport, causing accumulation of proteins otherwise destined for 
export28-30. Determinants for this feature are located at the N-terminus29-33. This inhibition 
of ER-to Golgi transport has been shown to reduce or inhibit the secretion of antiviral cyto-
kines such as interleukin-6, interleukin-8 and beta interferon 34, the concentration of tumor 
necrosis factor receptor on the surfaces of infected cells35 and the presentation of antigen in 
the context of major histocompatibility complex class I molecules36. In doing so, ER-to-Golgi 
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transport inhibition in infected cells might help in evading the host cell’s immune response 
and hence, promote viral replication in an indirect way, although this inhibition is not re-
quired for efficient viral replication per se 30,34.
The indispensable presence of 3A(B) during viral replication makes this protein an at-
tractive candidate as a target for inhibition of viral replication. Thus far, only one compound 
(enviroxime) has been reported to target protein 3A37-39. Despite its potent antiviral activity, 
however, the development of this compound was halted, mainly because of toxicity and an 
unfavorable pharmacokinetic profile40. We here report on a novel compound (TTP-8307) 
that was identified in a screening campaign for inhibitors of the replication of enteroviruses. 
The compound appeared to be a potent inhibitor of the replication of several rhino- and 
enteroviruses.
Table 1. Antiviral effect of TTP-8307 against selected entero- and rhinoviruses
Virus EC
50
 [µM]a
TTP-8307
EC
50
 [µM]a
Enviroxime
Human Enterovirus A CVA16 (G-10) 0.85 ± 0.08 0.12 ± 0.01
EV71 (BrCr) >60 0.15 ± 0.06
Human Enterovirus B CVB3 (Nancy) 1.2 ± 0.1 1.9 ± 1.5
Human Enterovirus C CVA21 (Coe) 5.34 ± 0.93 0.48 ± 0.42
PV1 (Sabin) 0.51 ± 0.05 0.19 ± 0.24
PV2 (Sabin) 0.58 ± 0.05 0.06 ± 0.01
PV3 (Sabin) 0.27 ± 0.23 0.04 ± 0.02
Major Group Rhinoviruses HRV9 >50 0.038 ± 0.001
HRV14 >50 0.11 ± 0.04
HRV15 >50 0.042 ± 0.03
HRV39 0.65 ± 0.51 0.028 ± 0.01
HRV41 >50 0.027 ± 0.003
HRV42 >50 0.11 ± 0.05
HRV45 0.99 ± 0.04 0.25 ± 0.03
HRV63 0.091 ± 0.054 0.027 ± 0.001
HRV70 >50 0.11 ± 0.02
HRV72 >50 0.72 ± 0.03
HRV85 1.22 ± 0.21 0.033 ± 0.006
HRV86 >50 0.14 ± 0.03
HRV89 >50 0.10 ± 0.04
Minor Group Rhinoviruses HRV2 0.80 ± 0.12 0.026 ± 0.022
HRV29 0.77 ± 0.38 0.029 ± 0.005
a 50% effective concentration
Data are mean values ± SD for at least 3 independent experiments
Cytotoxicity of TTP-8307 was determined on confluent Vero and HeLa cells and TC
50
 values (50% 
cytotoxic concentration) were >100 µM
Compound solubility limit in assay medium is 100 µM
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Results
TTP-8307 inhibits replication of several enteroviruses
TTP-8307 was identified in a screening campaign as a selective inhibitor of CVB3 replication 
in Vero cells. The effect of TTP-8307 (Figure 1A) was next evaluated against a selection of 
entero- and rhinoviruses in an MTS-based cytopathic effect (CPE) reduction assay. TTP-8307 
inhibits the replication of coxsackievirus B3 and the three poliovirus Sabin strains, as well as 
coxsackieviruses A16 and A21 (Table 1). TTP-8307 inhibits human rhinoviruses (HRVs) 2, 29, 
39, 45, 63 and 85, but not other rhinovirus serotypes (HRV serotypes 9, 14, 15, 41, 42, 70, 
72, 86 and 89) or enterovirus 71. Coxsackievirus B3 (CVB3), the prototype of the non-polio 
enteroviruses, was used to further study the particular characteristics of the antiviral activ-
ity of TTP-8307. TTP-8307 inhibited CVB3 replication in a dose-dependent manner (Figure 2) 
when monitored either by (i) CVB3-induced CPE formation (Figure 2A) or (ii) CVB3-induced 
plaque formation (Figure 2B).
Figure 1. Structural formulae of TTP-8307 and enviroxime.
TTP-8307 Enviroxime
Figure 2. Dose-dependent inhibition of viral replication by TTP-8307. Vero cell cultures infected 
with CVB3 were treated with different concentrations of TTP-8307 and the effect on viral replication 
was monitored at day 3 postinfection. (A) Effect on virus- induced CPE formation (using an MTS-
based cell protection assay). (B) Plaque reduction. The data represent averages ± the standard 
deviations from three independent experiments.
BA
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TTP-8307 acts at a stage that coincides with CVB3 viral RNA replication and polyprotein 
synthesis/processing
Time of drug addition studies were carried out to obtain a first indication about the stage 
in the viral replication cycle where TTP-8307 exerts its antiviral activity. Maximal inhibition 
of viral replication was maintained when the drug was added within the first 3 h postinfec-
tion (Figure 3A). Addition of the drug at a time point later than 3 h postinfection, which 
coincides with the onset of viral RNA synthesis, resulted in a gradual decrease in antiviral 
activity. It can thus be concluded that TTP-8307 does not hamper early (attachment, entry, 
and uncoating) or late (assembly and release) events, but rather interferes with intermedi-
ate processes, such as viral RNA replication, viral polyprotein synthesis, and/or processing.
Figure 3. TTP-8307 inhibits accumulation of CVB3 viral RNA without affecting polyprotein 
processing. (A) Time of drug addition. TTP-8307 (25 µM) was added to CVB3-infected cell cultures 
at 1-h intervals, starting at 1 h before infection. At 8 h postinfection, the time needed for a single 
replication cycle, intra- and extracellular viral RNA was collected and quantified by means of real-time 
qRT-PCR. Values were standardized to 0-h time point. The data represent averages ± the SD from two 
independent experiments. (B) Analysis of viral RNA accumulation with subgenomic replicon pCB53/
T7-Luc. Accumulation of viral (+)RNA was monitored after transfection of BGM cells (in the presence 
or absence of TTP-8307) with RNA derived from a chimeric subgenomic replicon (pCB53/T7-Luc). At 
the indicated times posttransfection, the luciferase activity was quantified and expressed in (relative) 
light units [(R)LU]. The data represent averages ± the SD from three independent experiments. (C) 
Effect of TTP-8307 on polyprotein processing. BGM cells grown to confluence in 24-well plates were 
infected with CVB3. At 5h30 min postinfection, cells were pulse-labeled for 30 min with Met35[S] 
after starvation in methionine-free medium for 30 min, either in the presence (25 µM) or absence 
of TTP-8307. Cells were lysed and translation products were analyzed by SDS-polyacrylamide gel 
electrophoresis. The data represent averages ± the SD from three independent experiments.
A C
B
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TTP-8307 inhibits accumulation of CVB3 viral RNA
The accumulation of viral RNA in the absence or presence of TTP-8307 was monitored upon 
transfection of BGM cells with an infectious subgenomic replicon of CVB3 (in which the P1 
region was replaced with a luciferase marker). Transfection in the presence of TTP-8307 (25 
µM) led to a complete inhibition of viral RNA accumulation, whereas an increase in lucifer-
ase activity was measured in the absence of compound (Figure 3B). The replication inhibitor 
guanidine hydrochloride (2 mM) was included as a reference compound and resulted in the 
inhibition of viral RNA accumulation as well.
TTP-8307 does not affect CVB3 polyprotein synthesis or processing
Viral protein synthesis and polyprotein processing were monitored in a pulse-labeling ex-
periment in the presence (25 µM) or absence of TTP-8307. From Figure 3C it is evident that 
a similar pattern of viral proteins was observed in the presence or absence of TTP-8307. 
Thus, neither the rate of protein synthesis nor the processing of viral proteins was affected 
by the compound. This observation, together with the observed effect of TTP-8307 in the 
subgenomic replicon, points to the synthesis of viral RNA as the potential target of action 
of TTP-8307.
TTP-8307 resistant CVB3 clones share mutations in the nonstructural protein 3A
To identify the molecular target of TTP-8307, drug-resistant CVB3 variants were selected. 
To this end, CVB3 was cultured successively in the presence of increasing concentrations of 
TTP-8307. After 10 passages, five independently cultured pools of CVB3 were obtained, that 
replicated efficiently in the presence of TTP-8307 at concentrations that exceeded the EC50 
Table 2. Mutations in TTP-8307-resistant CVB3 clones
Passage Line
(pool)
Clone Amino acid mutation
2A 2B 2C 3A 3D
1
A I8T
V45A
B N26D H57Y
C N26D H57Y
2
A E59Q I112V I54F
B E64A I8T
C E120Q S109G I54F D397E
3
A R41K V45A
B H57Y V8I
G124R
4
A L47Q H57Y
K51N
5 A I92V H57Y
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more than 10-fold. The virus pools thus obtained were plaque-purified in the presence of 20 
µM TTP-8307 and one or several clones from each pool were picked up. As such, 10 clones 
were selected for genotyping (Table 2). Except for clone 1A, all clones carried mutations in 
two or more different proteins, including 2A, 2B, 2C, 3A and/or 3D. A remarkable observa-
tion, however, was that all clones carried at least one mutation in protein 3A. Furthermore, 
each of the following four mutations in 3A recurred in different clones (either or not if they 
derived from the same pool): I8T, V45A, V54A and H57Y. In contrast, none of the mutations 
observed in the other proteins occurred more than once in clones that were derived from 
independently cultured pools. Moreover, three of the four identified mutations in 3A were 
located in a region that was previously shown to accumulate mutations involved in resis-
tance to the 3A inhibitor enviroxime (see Discussion). The contribution of the 3A mutations 
to the drug-resistant phenotype was therefore studied in more detail.
Recombinant CVB3 3A mutants have plaque phenotypes similar to those of wild-type 
virus
A plasmid (pCB53/T7) encoding an infectious full-length CVB3 genome was used to generate 
four recombinant clones carrying the four identified mutations in protein 3A individually. 
These clones were designated mutant 1 (3A
[I8T]
), mutant 2 (3A
[V45A]
), mutant 3 (3A
[I54F]
), and 
mutant 4 (3A
[H57Y]
). Plaque assays with the mutant viruses revealed that infection with these 
mutant viruses do not result in altered plaque phenotypes as compared to wild-type CVB3 
(Figure 4).
Recombinant CVB3 clones carrying mutations in 3A are resistant to inhibition by TTP-
8307 and enviroxime
Next, the four recombinant mutant viruses were evaluated for their ability to form plaques 
in the presence of various concentrations of TTP-8307. Two reference molecules were in-
cluded as a control: enviroxime (previously reported to inhibit enterovirus replication by tar-
geting 3A) and the 2C inhibitor TBZE-02942. The graphs depicted in Figure 5 represent plaque 
forming units (PFU) after infection of Vero cells with wild-type virus or the constructed 3A 
mutants at a given concentration for a given compound.
Figure 4. Plaque phenotypes of wild-type CVB3 and recombinant clones.
WT Mutant 1 
[3A-I8T]
Mutant 2 
[3A-I54F]
Mutant 3 
[3A-V45A]
Mutant 4 
[3A-H57Y]
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In the absence of drug, all clones (as well as the wild-type) resulted in the formation 
of, on average, 10 × 104 to 15 × 104 plaques per ml. TTP-8307 at a concentration of 8 µM or 
higher completely prevented the formation of plaques in virus-infected cultures, whereas 
the recombinant mutant clones were still able to form plaques in the presence of TTP-8307 
at these concentrations. In particular, mutants 2 and 3 (and to a lesser extent mutant 4) car-
rying amino acid mutations V45A and I54F (and H57Y) were still able to generate progeny vi-
rus at higher drug concentrations. Mutant 1 (I8T) remained relatively sensitive to inhibition 
by TTP-8307. A comparable pattern of (lack of) sensitivity of the variant mutants was ob-
served for enviroxime. Enviroxime- and TTP-8307-resistant mutants can thus be considered 
as cross-resistant. Finally, the sensitivity of the different recombinant viruses was assessed 
in the presence of TBZE-029, a compound that we recently reported to target the nonstruc-
tural protein 2C. As expected, TBZE-029 was equipotent in its inhibition of wild-type and 
mutant viruses. Taken together, these data indicate that in particular 3A mutations V45A, 
I54F, and H57Y confer resistance to TTP-8307.
Figure 5. Viral replication of wild-type and recombinant viruses in the presence of TTP-8307, 
enviroxime, and TBZE-029. Each graph represents the number of PFU produced by wild-type CVB3 
or by any of the four constructed 3A mutants—3A[I8T], 3A[V45A], 3A[I54F], and 3A[H57Y]—at 
a given compound concentration. Calculated EC90 values represent averages ± the SD from five 
independent experiments. **P < 0.05.
A
B C
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Discussion
We identified a novel compound, TTP-8307, that potently inhibits the replication of several 
enteroviruses, including coxsackievirus B3 and poliovirus by interfering with the synthesis 
of viral RNA. Contemplating the need for antivirals in the end stages of the worldwide polio 
eradication43,44, TTP-8307 might be considered as an interesting compound for lead opti-
mization, given its potent inhibitory effect on the replication of the three PV Sabin strains.
To determine the viral target of TTP-8307, resistant CVB3 variants were selected. Each 
clone carried at least one of the following mutations in protein 3A: I8T, V45A, I54F or H57Y. 
These mutations were reintroduced in an infectious CVB3 full-length clone and the antiviral 
sensitivity of the resulting viruses was studied. Mutants 2, 3, and 4 (carrying 3A mutations 
V45A, I54F, or H57Y) were shown to form plaques in the presence of concentrations of 
TTP-8307 that did not allow replication of wild-type virus, confirming that these mutations 
contribute to the observed resistance phenotype. The calculated EC90 values of TTP-8307 
for inhibition of these mutant viruses were ca. 8- to 10-fold higher than for wild-type CVB3. 
Moreover, cross-resistance was observed with enviroxime. The specificity of this resistance 
profile was corroborated by the fact that a 2C-targeting compound41,42 inhibited the repli-
cation of the mutants as efficiently as that of the wild-type virus. Mutant I8T allowed for 
some very low replication in the presence of TTP-8307 and enviroxime. The viruses carrying 
the engineered mutations proved phenotypically (formation of plaques) comparable to the 
wild-type virus, suggesting no deleterious effects of the 3A mutations on viral replication. 
It should be noted, however, that the reconstructed mutants carrying single amino acid 
mutations in 3A did not exhibit the same high degree of resistance that we observed with 
the naturally selected clones. In fact, all naturally selected clones were selected and plaque 
purified in the presence of 20 µM TTP-8307 and hence, had EC90 values of > 20 µM. None 
of the reconstructed viruses carrying single amino acid mutations, however, reached EC90 
values of ≥ 20 µM. It may therefore be assumed that other sequence variations (in proteins 
different than 3A) may contribute to a further increase in the level of resistance to TTP-8307.
An amino acid sequence alignment of the 3A proteins of CVB3, PV1, HRV2 and HRV14 
is depicted in Figure 6. Globally, two major regions were reported to be important for resis-
tance to enviroxime38,39,45. The first region involves residues in the hydrophobic domain of 
3A, located near its C-terminus, whereas the second region is located between amino acids 
40 and 60. This latter region, preceding the hydrophobic domain (underlined in green in 
Figure 6), has been predicted to be unstructured, based on the nuclear magnetic resonance 
structure of the soluble domain of PV protein 3A22. Remarkably, the 3A mutations that we 
identified in the present study as major determinants for resistance to TTP-8307 (V45A, 
I54F and H57Y) were also located in this region (arrows in Figure 6A; residues highlighted 
in Figure 6C). Moreover, the very same H57Y mutation that was identified in TTP-8307-re-
sistant CVB3 was also detected in enviroxime-resistant CVB3. In contrast to enviroxime, no 
mutations were detected in the hydrophobic domain of 3A in TTP-8307-resistant CVB3. This 
may be explained by the fact that TTP-8307 and enviroxime interact with the same region 
of 3A but that, given their different chemical structure, the precise molecular interactions 
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with the various amino acids in this region may be (partially) different. Single amino acid 
mutations in the nonstructured region (amino acids 40 to 60) were shown to be sufficient 
to confer a certain degree of resistance to enviroxime38,39, corroborating our present obser-
vations. Florez de Sessions et al. observed that a chimeric CVB3 carrying a HRV2 internal 
ribosomal entry site and that was adapted for growth in a neuroblastoma cell line carried 
the mutation V45A in 3A46. Similar observations were described by Harris and Racaniello47 
who identified mutations in 3A at amino acid positions that correspond to CVB3 residues 
42 and 44, in HRV39 that was adapted for growth in mouse cells. None of these mutations 
substantially affected viral plaque formation46,47, which is in line with our observations. The 
unstructured region preceding the hydrophobic domain may thus allow for adaptation of 
the virus to selective pressure of different kinds (e.g., antivirals or a changing host) without 
compromising viral growth.
A question that remains to be answered is what determines the spectrum of activity of 
TTP-8307. An alignment of the 3A amino acid sequence of TTP-8307-sensitive and -resistant 
viruses did not reveal any particular amino acids or regions in 3A that determined whether 
or not a virus would be inhibited by TTP-8307 (data not shown). For example, CVA16 and en-
terovirus 71 (TTP-8307 sensitive and resistant, respectively) share the N-terminal 3A amino 
acid sequence entirely, despite their difference in sensitivity. A possible explanation might 
be that 3A is a key protein in the replication inhibition, but that proteins other than 3A are 
Figure 6. (A) Sequence alignment of 3A proteins from CVB3, PV1, HRV2, and HRV14. The residues 
that are circled were earlier identified as amino acid mutations in enviroxime- (or analog)-resistant 
variants3,33,35. The arrows indicate mutations in TTP-8307 resistant CVB3, identified in the present 
study. The residues between brackets form a 22-residue hydrophobic region involved in membrane 
anchoring of 3A/3AB. The region underlined in green is suggested to be a “hot spot” for viral 
mutations when virus is selected in the presence of TTP-8307 or enviroxime. (B) Predicted solution 
structure of the N-terminal soluble domain of the PV 3A protein. The two cylinders represent two 
α-helices that form an α-helical hairpin. Adapted from Wessels et al.68. (C) Location of the three 
predominant amino acid mutations involved in CVB3 resistance to TTP-8307 in a structural model 
of protein 3A.
A
B
C
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involved in this inhibition as well.
Therefore, despite the fact that 3A was identified as a prime target for TTP-8307 as 
well as for enviroxime, the precise mechanism of action for inhibition of viral inhibition by 
these compounds remains to be elucidated. In contrast to 2CATPase, 3C(D)pro, and 3Dpol, protein 
3A is not thought to be associated with any enzymatic activity and, hence, the inhibition of 
this protein by a compound cannot be assessed in a simple in vitro enzymatic assay. Rather 
than hampering a catalytic reaction, 3A-targeting drugs are likely to mediate hindrance of 
certain interactions of 3A with other (viral or cellular) proteins in the viral replication com-
plex, an idea than can be supported given the multitude of interactions that have been 
ascribed to this protein48,49. For enviroxime, it was recognized that replication inhibition is 
probably not only occurring through targeting of 3A but may also depend on interactions 
with other proteins in the replication complex45. More precisely, a HRV14 mutant was identi-
fied that carried, in addition to 3A mutations, mutations in 3Dpol. These additional mutations 
resulted in a higher degree of resistance. These findings are in line with our observations 
that several of the identified mutants carry amino acid changes in proteins other than 3A 
(Table 2). However, these mutations were identified in various proteins (2A, 2B, 2C, and 3D) 
and at different residue positions. Based on the hypothesis that TTP-8307 and enviroxime 
interfere with 3A through inhibition of certain interactions with other proteins, one could 
postulate that mutations in 3A are necessary for resistance, but that the level of resistance 
is increased by additional mutations in other proteins (that interact with 3A). Interestingly, 
recently CVB3 was selected that was resistant to amiloride; resistance was shown to map 
to the 3Dpol, but the resistant variant carried also a mutation at 3A residue I54 (similar to 
clones 4 and 6 identified in the present study)50. The contribution of this 3A mutation to the 
resistant phenotype was however, not further determined.
In conclusion, we identified a novel enterovirus replication inhibitor that targets the 
nonstructural protein 3A. Mutations conferring the highest levels of resistance mapped to 
the nonstructured region preceding the hydrophobic domain, a region that was also re-
ported to contain mutations in enviroxime-resistant viruses. The precise mechanism of viral 
inhibition by targeting 3A remains to be addressed in future studies.
Materials & Methods
Cells and viruses
Vero cells (ATCC CCL-81), Buffalo Green Monkey (BGM) cells (ECACC 90092601) and HeLa 
cells (ATCC CCL-2) were grown in minimal essential medium (MEM) (Gibco) supplemen-
ted with 10% heat-inactivated fetal bovine serum (Integro), 5% bicarbonate (Gibco) and 
5% L-glutamine (Gibco). Cells were grown at 37°C in a 5% CO2 incubator. Coxsackievirus 
B3 (CVB3) was derived from plasmid pCB53/T7, which contains a full-length cDNA of CVB3 
strain Nancy behind a T7 RNA promoter33. For assays involving virus growth, 2% fetal bo-
vine serum was used instead of 10% fetal bovine serum. Rhinoviruses were offered by Dr. 
K. Andries and the poliovirus Sabin 1, 2 and 3 strains were from Prof. B. Rombaut (Vrije 
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Universiteit Brussel, Brussels, Belgium). Enterovirus 71 (BrCr), and coxsackieviruses A16 (G-
10) and A21 (Coe) were obtained from the Rijksinstituut voor Volksgezondheid en Milieu 
(The Netherlands).
Compounds
The synthesis of TTP-8307 (436 g/mol) will be reported elsewhere. The purity of the com-
pound used in the present study was determined to be >96% by spectroscopic (nuclear 
magnetic resonance) and chromatographic (liquid chromatography-mass spectrometry) 
techniques. TBZE-029 and enviroxime were synthesized as reported elsewhere41. Guanidine 
hydrochloride was from Sigma (Bornem, Belgium). All compounds were solubilized in di-
methyl sulfoxide at 20 mM and stored at 4°C. For working solutions, the dimethyl sulfoxide 
stocks were diluted in minimal essential medium to the desired concentration.
In vitro RNA transcription and transfection
Prior to in vitro RNA transcription, plasmid p53CB3/T7 was linearized with SalI (Promega). 
The digest was purified (Gel and PCR purification kit, Promega) and 2.5 µg of DNA was used 
for in vitro RNA transcription (Ribomax large-scale RNA production system; Promega). The 
transcription reaction was carried out at 37°C for 4 hours, after which the reaction mix-
ture was DNase treated and RNA was purified (RNA Cleanup System, Qiagen). Transfections 
were carried out in 25-cm² culture flasks in Vero cells, grown to ~75% confluence. Reaction 
mixtures, containing 2 ml OptiMEM (Gibco), 2.5 µg of purified RNA, and 10 µl of DMRIE-C 
transfection reagent (Invitrogen) were incubated for 4 h at 37°C. Subsequently, the medium 
was replaced with fresh growth medium and incubated until the cultures exhibited an ex-
tensive cytopathic effect (CPE). At this point, the flasks were subjected to three rounds of 
freezing-thawing, and the collected supernatant was titrated for infectious virus content by 
endpoint titration.
Multicycle CPE reduction assays
The antiviral activity of the selected compound was initially determined by using an MTS 
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenol)-2-(4-sulfophenyl)-2H-tetrazo-
lium, inner salt]-based CPE reduction assay. Briefly, cells grown to confluence in 96-well 
plates, were infected with 100 50% cell culture infective dose (CCID50) of virus. After an ad-
sorption period of two h at 37°C (35°C for rhinovirus), virus was removed and serial dilutions 
of the compounds were added. The cultures were further incubated at 37°C for 3 days, until 
complete CPE was observed in the infected and untreated virus control (VC). After removal 
of the medium, 90 µl of culture medium and 10 µl of MTS/PMS (Promega, Leiden, The 
Netherlands) were added to each well. After an incubation period of 2 h at 37°C, the opti-
cal density at 498nm (OD498) of each well was read in a microplate reader. CPE values were 
calculated as follows: % CPE = 100 × ([OD
CC
 - OD
virus+compound
]/[OD
CC
 - OD
VC
]). In these formulae, 
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OD
CC
 corresponds to the optical density of the uninfected and untreated cell cultures, OD
VC
 
represents the infected and untreated cell cultures, and OD
Virus+Compound
 are virus-infected 
cell cultures treated with a given concentration of compound. The 50% effective concentra-
tion (EC50) was defined as the concentration of compound that resulted in 50% protection 
against virus-induced CPE and was calculated by using logarithmic interpolation.
Viral plaque assays
For determination of viral plaques, Vero cells, grown to confluence in six-well plates, were 
infected with CVB3 at 37°C with slight shaking at 55 rpm. After 2 h, the virus was removed, 
the cells were washed twice with phosphate-buffered saline (PBS), and the growth medium 
was replaced with agar (final concentration, 0.4%) in the presence or absence of compound. 
After 3 to 4 days, plaques were visualized. Briefly, cells were fixed with 2 ml of a solution 
containing 4% formaldehyde, after which the agar was removed. A 2% Giemsa solution was 
used to stain the cells.
Analysis of viral RNA accumulation with subgenomic replicon pCB53/T7-Luc
Accumulation of viral (+)RNA was monitored by transfecting cells (in the presence or ab-
sence of 25 µM TTP-8307) with RNA derived from the SalI-linearized plasmid pCB53/T7-Luc, 
which contains a subgenomic CVB3 replicon, carrying a luciferase gene in place of the capsid 
coding P1 region. At the indicated times posttransfection, the cells were washed three times 
with PBS and lysed with 75 µl of lysis buffer. The luciferase activity was measured in a liquid 
scintillation counter with the luciferase assay system according to the recommendations of 
the manufacturer (Promega). The luciferase activity was expressed in (relative) light units.
Quantitative analysis of CVB3 RNA by real-time qRT-PCR assays
Real-time quantitative reverse transcription-PCR (qRT-PCR) was performed with an ABI 
Prism 7000 sequence detection system (Applied Biosystems, Foster City, CA). Primers and 
probes were developed using Primer Express software (Applied Biosystems) as described 
elsewhere42. The following primers and probe were used: a forward primer specific for nu-
cleotides 2937 to 2957 (5’-ACG AAT CCC AGT GTG TTT TGG-3’), a reverse primer specific for 
nucleotides 3003 to 2982 (5’-TGC TCA AAA ACG GTA TGG ACA T-3’), and a Taqman probe 
specific for nucleotides 2960 to 2977 (5’-FAM-CGA GGG AAA CGC CCC GCC-TAMRA-3’). 
Each reaction was performed in 25 µl of a PCR reagent mixture (One-Step qRT-PCR Mix, 
Eurogentec) containing 900 nM of each primer and 200 nM of the specific Taqman probe. 
The PCR consisted of an RT step (30 min at 48°C), a Taq activation step (10 min at 95°C), and 
50 cycles of denaturation (15 s at 94°C) and annealing/extension (1 min at 60°C). The RNA 
copy number in each sample was determined by a standard curve generated from increas-
ing copy numbers of a synthetic transcript corresponding to 67 nucleotides of the CVB3 
genome.
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Time of drug addition studies
Vero cells, grown to confluence in 24-well culture plates, were infected with 104 CCID50 of 
coxsackievirus B3. After an adsorption period of 1 h at 37°C, virus was removed and re-
placed with 500 µl of growth medium. At 1-h intervals, 500 µl of medium containing a 2x 
compound solution was added (final concentration, 25 µM). At 8 h postinfection, the super-
natant, as well as intracellular RNA of the infected cultures was collected, and viral RNA was 
quantified by means of real-time qRT-PCR. The levels of viral RNA were compared to their 
untreated controls.
Analysis of viral polyprotein processing in vivo
BGM cells, grown to confluence in 24-well plates were infected with coxsackievirus B3 at 
a multiplicity of infection (MOI) of 50. At 5 h postinfection, the medium was replaced with 
300 µl of methionine-free medium. Thirty minutes later, the cultures were pulse-labeled in 
methionine-free medium containing 1 μl of Met35[S]/well in the absence or presence of TTP-
8307 (25 μM final concentration) for 30 min. At 6 h postinfection. cells were washed once 
with PBS and lysed in 75 μl of cold lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM 
NaCl, 1 mM EDTA, 1% Nonidet P-40 and 0.05% sodium dodecyl sulfate (SDS). Translation 
products were analyzed on a 12.5% polyacrylamide gel containing SDS. The gels were fixed 
in 30% methanol-10% acetic acid, rinsed in dimethyl sulfoxide, fluorographed with 20% 
2,5-diphenyloxazole in dimethyl sulfoxide, dried, and exposed to Kodak XAR film.
Generation of TTP-8307-resistant coxsackievirus
Drug-resistant virus was generated by growing virus in the presence of gradually increasing 
concentrations of TTP-8307 on confluent Vero cultures in 48-well culture plates. After 4 to 
5 days of culture, culture supernatant was collected from cultures that exhibited full CPE 
in the presence of the highest concentration of compound used. This virus was used for 
a successive round of infection, a procedure that was repeated until full CPE was noticed 
at concentrations of TTP-8307 (20 µM) that did not allow replication of wild-type virus. 
Subsequently, the resistant virus pool was subjected to plaque purification (in the presence 
of 20 µM compound), and individual clones were used for sequencing.
Site-directed mutagenesis
Four mutant CVB3 clones were constructed, containing single amino acid replacements at 
positions 8, 45, 54 and 57 in protein 3A. The four clones were designated mutant 1 (3A
[I8T]
), 
mutant 2 (3A
[V45A]
), mutant 3 (3A
[I54F]
), and mutant 4 (3A
[H57Y]
). The corresponding synthetic 
oligonucleotides (and their complementary reverse oligonucleotides) were used for site-
directed mutagenesis: (1) 5’-GGA CCA CCA GTA TAC AGA GAG ACC AAA ATT AGC GTT GCA 
CC-3’, (2) 5’-GAA AAA GGA TGG TTG GCT CCT GAG ATC AAC TCC ACC C-3’, (3) 5’-C TCC ACC 
CTC CAA TTT GAG AAA CAT GTC AGT CGG G-3’ and (4) 5’-CC CTC CAA ATT GAG AAA TAT GTC 
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AGT CGG GCT TTC-3’. The mutated sequences are underlined. Site-directed mutagenesis 
was performed with plasmid pCB53/T7 using the XL Blue Large Site-directed mutagenesis kit 
(Stratagene, Amsterdam, The Netherlands), according to the manufacturer’s instructions. 
After mutagenesis, the individual clones were verified by sequencing. Next, a 711-bp frag-
ment containing the desired mutations was isolated using the enzymes BssHII and XbaI, and 
reintroduced in an original, nonmutagenized clone of the same plasmid pCB53/T7. From 
these mutants, RNA transcripts and infectious viruses were generated as described earlier.
Sequencing
PCR fragments that cover the entire CVB3 genome were generated and analyzed using the 
cycle-sequencing method (ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction 
kit). Both DNA strands were sequenced. Sequencing data were obtained with an ABI 373 
Automated Sequence Analyzer (Applied Biosystems), and sequences were analyzed with the 
Vector NTI software (Invitrogen).
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Abstract
The genus Enterovirus, belonging to the family Picornaviridae, includes well-known patho-
gens, such as poliovirus, coxsackievirus, and rhinovirus. Brefeldin A (BFA) impedes repli-
cation of several enteroviruses through inhibition of Golgi-specific BFA-resistance factor 1 
(GBF1), a regulator of secretory pathway integrity and transport. GBF1 mediates the GTP 
exchange of Arf1, which in activated form recruits coatomer protein complex I (COP-I) to 
Golgi vesicles, a process important in transport between the endoplasmic reticulum and the 
Golgi. Recently, the drugs AG1478 and Golgicide A (GCA) were put forward as new inhibi-
tors of GBF1. In this study, we investigated the effects of these putative GBF1 inhibitors on 
secretory pathway function and enterovirus replication. We show that both drugs induced 
fragmentation of the Golgi vesicles and caused dissociation of Arf1 and COP-I from Golgi 
membranes, yet they differed in their effect on GBF1 localization. The effects of AG1478, 
but not those of GCA, could be countered by overexpression of Arf1, indicating a difference 
in their molecular mechanism of action. Consistent with this idea, we observed that GCA 
drastically reduced replication of coxsackievirus B3 (CVB3) and other human enterovirus 
species, whereas AG1478 had no effect at all on enterovirus replication. Time-of-addition 
studies and analysis of RNA replication using a subgenomic replicon both showed that 
GCA suppresses RNA replication of CVB3, which could be countered by overexpression of 
GBF1. These results indicate that, in contrast to AG1478, GCA inhibits CVB3 RNA replication 
by targeting GBF1. AG1478 and GCA may be valuable tools to further dissect enterovirus 
replication.
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Introduction
The Enterovirus genus, belonging to the Picornaviridae family, includes many important hu-
man pathogens, such as poliovirus, human rhinovirus, echovirus and coxsackievirus. These 
are small, nonenveloped viruses that contain a single-stranded RNA genome of positive po-
larity. The genome is approximately 7.5 kb in length and encodes a single large polyprotein, 
which is processed into capsid proteins, encoded in the P1 region, and the nonstructural P2 
and P3 region proteins that mediate viral RNA replication.
Brefeldin A (BFA), a fungal metabolite, is a well-known inhibitor of enteroviruses. BFA 
blocks transport of cargo from the endoplasmic reticulum (ER) to the Golgi vesicles by dis-
rupting the Golgi vesicles and ER-Golgi intermediate compartment (ERGIC) integrity through 
inhibition of several guanine nucleotide exchange factors (GEFs), including Golgi-specific 
BFA-resistance factor 1 (GBF1), BFA-inhibited GEF 1 (BIG1), and BIG21,2. These GEFs regulate 
the activity of GTPase ADP-ribosylation factor 1 (Arf1) by stimulating GTP exchange. Upon 
activation, Arf1-GTP binds to Golgi membranes where it induces formation of secretory 
vesicles via recruitment of coatomer protein complex I (COP-I), a coatomer protein involved 
in the transport between the Golgi and the ER. The inhibitory effect of BFA on enterovirus 
replication is attributed to the inhibition of GBF1, and does not seem to involve BIG1 or 
BIG23,4. Besides enteroviruses, other plus-strand RNA viruses, such as mouse hepatitis virus 
and hepatitis C virus, also seem to rely on GBF1 for efficient replication3-6. The viral protein 
3A of the enteroviruses poliovirus and coxsackievirus B3 (CVB3) has been shown to interact 
directly with GBF17,8, but the exact function of this interaction remains to be established.
Recently, two compounds, AG1478 and Golgicide A (GCA), have been proposed to 
specifically inhibit GBF1. AG1478 was identified by screening a library of compounds for 
their ability to induce Golgi complex disassembly9. AG1478, known as an inhibitor of the epi-
dermal growth factor receptor (EGFR), had effects on the Golgi membranes highly similar to 
those of BFA through a mechanism not involving the inhibition of EGFR. Arf1-GTP pulldown 
assays showed that AG1478 inhibited Arf1 activation. Furthermore, overexpression of GBF1 
was shown to counter the effect of AG1478 on COP-I localization. Based on these results, 
AG1478 was proposed to be a GBF1 inhibitor.
GCA was identified in a high-throughput screen for small molecules that protected 
Vero cells from the effects of Shiga toxin10. Similar to AG1478 and BFA, GCA was reported to 
fragment the Golgi vesicles and to inhibit Arf1 activation. Furthermore, overexpression of 
either wild-type GBF1 or the BFA-resistant mutant GBF1-M832L relieved the effects of GCA. 
In addition, the authors constructed a structural model of the catalytic Sec7 domain of GBF1 
in complex with GCA, showing that GCA binds GBF1 at the same site as BFA. Collectively, 
their results provided convincing lines of evidence that GCA specifically inhibits GBF1 in a 
manner similar to BFA and does not act on BIG1 and BIG2.
BFA has been instrumental in elucidating the membrane requirements for enterovirus 
replication. Therefore, we investigated the effects of AG1478 and GCA on enterovirus repli-
cation after first characterizing the effects of these drugs on BGM cells, the cell line that we 
routinely use in our studies on coxsackievirus B3 replication. Treatment with either AG1478 
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or GCA fragmented the Golgi vesicles and caused dissociation of Arf1 and COP-I from Golgi 
membranes, yet these drugs had different effects on GBF1 localization. Interestingly, the 
effects of AG1478, but not those of GCA, could be countered by overexpression of Arf1. 
Next, GCA was found to abrogate enterovirus replication, whereas surprisingly AG1478 did 
not affect replication at all. Together these results indicate that AG1478 on one hand and 
GCA and BFA on the other hand have different mechanisms of action, leading to a disparate 
effect on enterovirus replication.
Results & Discussion
AG1478 and GCA inhibit cargo transport through the secretory pathway
We determined the effect of the putative Golgi-specific BFA resistance factor 1 (GBF1) inhib-
itors AG1478 and Golgicide A (GCA) on the function of the secretory pathway in BGM cells, 
the cell line that we routinely use in our studies on enterovirus replication. First, we inves-
tigated the transport of the membrane-associated VSV-G protein by use of a temperature-
sensitive mutant that is retained in the ER at a temperature of 40°C. When the temperature 
is switched to 32°C, the VSV-G protein is allowed to progress further along the secretory 
pathway to the plasma membrane (Figure 1A). In BFA-treated cells the VSV-G protein was 
absent from the plasma membrane after the temperature switch. Instead it displayed a re-
ticular and punctate staining which was previously identified to be the ER and ER exit sites7. 
Treatment with either AG1478 or GCA had a similar effect, indicating that all drugs tested 
inhibit transport of membrane-bound proteins.
Second, we tested the effects of the drugs on secretion of soluble proteins by use of 
Gaussia luciferase (Gaussia-luc), a novel form of luciferase that is secreted by the cells in 
the supernatant19,20. At 16 h after transfection of BGM cells with pCMV-Gluc, the medium 
was replaced and drugs were added to the cells. After 2.5 h, the supernatant was analyzed 
for Gaussia-luc activity. The supernatant of untreated cells exhibited high luciferase activity, 
whereas a severe decrease in luciferase activity was detected upon treatment with BFA, 
AG1478 or GCA (Figure 1B).
Together, these results show that, similar to BFA, AG1478 and GCA inhibit transport of 
both membrane-anchored proteins and secreted soluble factors.
AG1478 and GCA cause Golgi dispersal and inhibit COP-I recruitment
Next, we determined the effects of AG1478 and GCA on the Golgi integrity and localization 
of GBF1, Arf1 and COP-I in BGM cells. All drugs caused Golgi dispersal as shown by the frag-
mented localization of cis-Golgi matrix protein GM130 after a 1-h treatment (Figure 1C). In 
untreated cells, GBF1, the putative target of the drugs, is localized to the Golgi apparatus 
(Figure 1C). Upon addition of BFA or GCA, GBF1 redistributed to a more diffuse localization. 
In contrast, GBF1 displayed a punctate pattern in AG1478-treated cells. Although AG1478 
and GCA had a different effect on GBF1 localization, they had similar effects on Arf1 and 
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Figure 1. AG1478 and GCA disturb the secretory pathway. (A) BGM cells were transfected with 
pVSVG3(ts045)-GFP, a construct encoding a temperature-sensitive GFP-tagged mutant of the VSV-G 
protein, and incubated at 40°C. At this temperature, the VSV-G protein is folded incorrectly and 
retained in the ER. At 30 min after the addition of BFA, AG1478, or GCA, the temperature was 
switched to the permissive temperature of 32°C for 2 h, which allows the VSV-G protein to fold 
properly and traffic through the secretory pathway to the plasma membrane. (B) Cells expressing 
Gaussia luciferase (Gaussia-luc) were treated with BFA, AG1478, or GCA for 2.5 h. Subsequently, 
the medium was analyzed for luciferase activity. The experiment was performed in triplicate and 
the bars represent means ± standard error of the means (SEMs) (error bars). Upon drug-treatment, 
a significant reduction in luciferase activity was detected in comparison with untreated cells (P < 
0.001, Student’s t test). (C) BGM cells were treated with AG1478, GCA, or BFA for 1 h, after which 
cells were fixed and stained with antibodies against GBF1, Arf1, COP-I or GM130. 
A B
C
58 Chapter 3
COP-I localization. Arf1 and COP-I localized to the Golgi apparatus in untreated BGM cells, 
but drug-treated cells displayed a diffuse staining of Arf1 and COP-I with no apparent differ-
ence between the drugs (Figure 1C).
The effects of GCA can be countered only by overexpression of GBF1, while the effects of 
AG1478 can also be countered by overexpression of Arf1
Previously it was shown that the effect of BFA on COP-I can be countered by overexpres-
sing GBF11,14,21 and that the BFA-resistant GBF1-M832L mutant was even more effective14. 
Figure 2. Overexpression of GBF1 counters the effects of BFA, GCA, and AG1478, while 
overexpression of Arf1 counters only the effects of AG1478. (A) Plasmids encoding GBF1 or Arf1 
were transfected into BGM cells. At 24 h posttransfection, the cells were treated for 1 h with BFA, 
AG1478, or GCA. Subsequently, the cells were fixed and stained with an antibody against COP-I. 
GBF1-wt, wild-type GBF1. (B) A Gaussia-luc construct was cotransfected with GBF1-M832L or Arf1 
constructs into cells. The next day, the medium was replaced with (drug-containing) medium and 
after 2.5 h the supernatant was analyzed for luciferase activity. Gaussia-luc activity is expressed as a 
percentage of luciferase activity in supernatant of untreated cells. The experiment was performed in 
triplicate and the bars represent means ± SEMs (error bars).
A
B
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This mutant was also reported to confer resistance to GCA10. To test the ability of GBF1 to 
counter drug-induced COP-I dissociation, cells overexpressing GBF1 or Arf1 were treated for 
1 h with the different drugs, after which COP-I was stained. Figure 2A shows that COP-I was 
present on membranes in drug-treated cells that overexpress yellow fluorescent protein 
(YFP)-tagged GBF1 (GBF1-YFP), while COP-I appeared cytosolic in untransfected, drug-treat-
ed cells. Also, the Golgi apparatus morphology seemed to be restored in the drug-treated, 
transfected cells with GBF1-YFP localizing to the Golgi apparatus. Thus, expression of GBF1 
was indeed able to prevent the dissociation of COP-I from membranes induced by the differ-
ent drugs. Overexpression of GBF1-M832L showed similar results (data not shown).
In addition, we tested whether overexpression of Arf1, the effector of GBF1, was able 
to counter the effects of the drugs on COP-I localization. Figure 2A shows that in cells treated 
with either BFA or GCA, both COP-I and the overexpressed Arf1-GFP have a diffuse distribu-
tion, indicating that the effects of BFA or GCA could not be countered by overexpression of 
wild-type Arf1, which is consistent with previous observations22. The constitutively active 
mutant Arf1-Q71L was also not able to counteract the effects of BFA and GCA (data not 
shown). Surprisingly, overexpression of Arf1 did counter the effects of AG1478 on COP-I 
localization, since COP-I localized to Arf1-GFP-containing membranes in transfected cells.
Next, we examined whether overexpression of GBF1-M832L or Arf1 could relieve the 
effects of the drugs on a functional level by measuring the secretion of Gaussia-luc. Gaussia-
luc secretion was inhibited by all three drugs, but in all cases this effect could be countered 
by overexpression of GBF1-M832L (Figure 2B). The inhibitory effect of AG1478, but not that 
of BFA or GCA, could be relieved by overexpressing Arf1 or, to a stronger extent, by overex-
pressing the Arf1-Q71L mutant (Figure 2B). Collectively, these results imply that AG1478 has 
a different mechanism of action than BFA and GCA.
GCA, but not AG1478, inhibits enterovirus replication
GBF1 is a crucial factor for the replication of enteroviruses3,4. Therefore, we tested wheth-
er AG1478 and GCA were able to inhibit replication of coxsackievirus B3 (CVB3), a human 
enterovirus B species (HEV-B species) member. A representative growth curve of CVB3 is 
shown in Figure 3A, which shows that virus production reaches a plateau after about 8 h. 
Therefore, we evaluated the effects of AG1478 and GCA on CVB3 replication by determining 
the virus yield at 8 h.p.i. Interestingly, AG1478 did not inhibit replication of CVB3, not even in 
concentrations higher than those required for fragmentation of the Golgi apparatus (Figure 
3B). GCA, however, impaired CVB3 replication as shown in Figure 3C. Concentrations of 1 or 
3 µM GCA had no effect on the virus yield, but with 10 µM GCA, the concentration used by 
Saénz et al.10 which also in our hands had a very strong effect on BGM cells, virus replication 
was strongly inhibited. Virus replication was completely abolished in the presence of 30 µM 
GCA with virus yields being similar to input levels. As GCA has been reported to specifically 
inhibit GBF1 and not the other guanine nucleotide exchange factors (GEFs), such as BIG1 
and BIG210, these results provide further evidence that GBF1 is the only GEF that is required 
for enterovirus replication.
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The spectrum of GCA activity on replication of picornaviruses was examined by testing 
its effect on two other enterovirus species: enterovirus 71 (EV71), a member of the HEV-A 
species, and coxsackievirus A21 (CVA21), a member of the HEV-C species. In addition, we 
tested whether mengovirus, a member of the cardiovirus genus known to be resistant to 
BFA23,24, is sensitive to treatment with GCA. BGM cells (CVB3/EV71), HeLa cells (CVA21), 
and BHK-21 cells (mengovirus) were infected with the different viruses and incubated in 
the presence or absence of GCA. We determined the virus yield after 8 h, since at later time 
points (determined at 16 h), we observed partial recovery of the Golgi structure and the 
GBF1 localization (data not shown), which might be caused by metabolism of GCA or alter-
natively by a cellular compensatory mechanism. Consistent with this observation, the inhi-
bition of CVB3 replication by GCA was also somewhat decreased after 16 h as measured by 
virus growth curves (data not shown), providing further evidence for a correlation between 
enterovirus replication and GBF1 activity.
Figure 3D shows that besides CVB3, the two other enteroviruses tested (EV71 and 
CVA21) also showed sensitivity to GCA. Mengovirus, on the other hand, was resistant to 
GCA and replicated to titers in the presence of GCA that were similar to the titers in the 
absence of this drug in both BHK-21 cells (Figure 3D) and HeLa cells (data not shown). Taken 
Figure 3. GCA, not AG1478, inhibits replication of enteroviruses. (A) BGM cells were infected with 
CVB3 at an MOI of 5. Total virus titers were determined at the indicated time points. The virus 
titer was measured as log 50% cell culture infective doses per ml (log CCID50/ml). (B) Various 
concentrations of AG1478 were added to the cells immediately after infection with CVB3. Virus 
titers were determined after 8 h. (C) The cells were infected with CVB3 and treated with various 
concentrations of GCA. Concentrations of 10 µM GCA or higher significantly inhibited CVB3 
replication (P < 0.001, one-way analysis of variance [ANOVA]). (D) BGM, HeLa, or BHK-21 cells were 
infected with CVB3, EV71, CVA21 or mengovirus and treated with GCA or BFA. Virus titers were 
determined after 8 h. Experiments were performed in triplicate, and the bars represent means ± 
SEMs (error bars).
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together, these results show that the antiviral activity of GCA is strongly reminiscent of that 
of BFA, which supports the idea that GCA targets GBF1 and thereby inhibits virus replication 
in a manner similar to BFA.
GCA impairs enterovirus RNA replication by targeting GBF1
To investigate which stage of the virus life cycle is inhibited by GCA, we first performed time-
of-addition studies, in which we added GCA to the cells after infection with CVB3 at 1-h in-
tervals and determined the virus yield at 8 h.p.i. The life cycle of picornaviruses is rapid with 
virus entry, uncoating, and translation occurring within 2 h.p.i., while viral RNA replication 
is initiated at 2.5 to 3 h.p.i. Virus production starts at 5 to 6 h.p.i (Figure 3D) and reaches a 
plateau after approximately 8 h.p.i25. Figure 4A shows that GCA lost its efficacy when added 
later than 4 h after infection, which suggests that the drug exerts its effect in the stage of 
Figure 4. GCA inhibits enterovirus RNA replication by targeting GBF1. (A) BGM cells were infected 
with CVB3 at an MOI of 5. GCA was added to the cells at 1-h intervals and virus yields were determined 
after 8 h. (B) Cells were transfected with RNA in vitro transcribed from the p53CB3-LUC subgenomic 
replicon, and subsequently treated with GCA or BFA. At 2, 4, 6, or 8 h.p.i., the cells were lysed and 
the firefly luciferase activity (in relative light units [RLU]) was determined as a measure of RNA 
replication. (C) BGM cells were infected with CVB3 at an MOI of 50. At 5.5 h.p.i., the cells were 
starved in methionine-free medium, and then 35[S]methionine and drugs were added to the cells. 
After 30 min, cells were lysed and proteins were analyzed by SDS-PAGE. (D) Cells transfected with 
plasmids encoding GBF1-M832L or EGFP as a negative control were infected with CVB3 in the 
presence of 2 µg/ml BFA, 10 µM GCA, or 30 µM GCA or in the absence of drugs. Virus yields were 
determined at 8 h.p.i. The experiment was performed in triplicate and bars represent means ± SEMs 
(error bars).
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viral protein translation and viral RNA replication. If the drug was targeting either virus entry 
or assembly, it would have exerted its effect when added early (0 to 2 h.p.i) or late (5 to 7 
h.p.i), respectively.
In vivo labeling studies were performed to examine the possibility that GCA impairs 
translation or processing of the viral proteins. To this end, BGM cells were infected with 
CVB3 in the absence of drugs. At 5.5 h.p.i., a time point when there is efficient virus replica-
tion, BGM cells were pulse-labeled for 30 min with 35[S]-methionine. During these 30 min, 
drugs were also added to the cells to test possible effects on viral protein synthesis and pro-
cessing in a situation where only viral proteins are translated due to host shutdown. Neither 
GCA nor BFA affected translation or processing of viral proteins (Figure 4C).
Subsequently, the effect of GCA on RNA replication was studied directly by use of a 
subgenomic replicon pCB3/T7-Luc, in which the P1 region has been replaced with the firefly 
luciferase gene. The level of luciferase activity in cells is a measure of viral RNA replication. 
Figure 4B shows that, similar to BFA, GCA strongly inhibits firefly luciferase accumulation, 
demonstrating that GCA hinders viral RNA replication.
Since the dissociation of COP-I from Golgi membranes induced by GCA could be coun-
tered by overexpression of GBF1 or GBF1-M832L, we tested whether GBF1-M832L overex-
pression was also able to counter virus replication in the presence of GCA. To this end, BGM 
cells overexpressing GBF1-M832L or EGFP as a negative control were infected with CVB3, 
and virus titers were determined at 8 h.p.i. Overexpression of GBF1-M832L had no effect 
on CVB3 replication in untreated cells. However, in the presence of 10 µM GCA or 2 µg/ml 
BFA, virus titers were significantly higher in cells overexpressing GBF1-M832L than in EGFP-
expressing cells (Figure 4D). Similar results were obtained with 30 µM GCA, a concentration 
that completely blocked CVB3 replication, indicating that GBF1-M832L was able to relieve 
the effect of the drugs on CVB3 replication.
Concluding Remarks
In this study we showed that AG1478, GCA and BFA all inhibited the function of the secre-
tory pathway as shown by defective transport of VSV-G protein and Gaussia-luc. The drugs 
fragmented the Golgi membranes and dispersed Arf1 and COP-I in a similar manner, but 
they differed in their effects on the localization of GBF1. Furthermore, overexpression of 
Arf1 could counter the effect of AG1478, but not of GCA or BFA, on COP-I localization and 
function of the secretory pathway. Finally, unlike GCA, AG1478 did not inhibit replication of 
enteroviruses, which is known to be GBF1 dependent3,4. Together, these results question 
whether AG1478 is a genuine inhibitor of GBF1.
Remarkably, AG1478 did not inhibit enterovirus replication, despite the fact that it has 
many effects in common with BFA and GCA, such as inhibition of the secretory pathway, 
disassembly of the ER-Golgi intermediate compartment (ERGIC) and the Golgi apparatus, 
and dispersal of Arf1 and COP-I. This observation strongly suggests that the inhibitory effect 
of BFA and GCA on GBF1 function and/or its localization is crucial to suppress CVB3 RNA 
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replication.
In sum, AG1478 and GCA disturb the secretory route in a different manner. Thereby, 
these drugs may be useful new tools to study enterovirus replication.
Materials & Methods
Cells and reagents.
Buffalo green monkey (BGM) kidney cells, HeLa cells, and baby hamster kidney-21 (BHK-21) 
cells were grown at 37°C in minimal essential medium (MEM) (Gibco) supplemented with 
10% fetal bovine serum (FBS), penicillin and streptomycin. Brefeldin A (BFA) (Sigma-Aldrich) 
was dissolved in methanol, and dimethyl sulfoxide (DMSO) was used to dissolve AG1478 
(Sigma-Aldrich) and Golgicide A (GCA)10. Unless indicated otherwise, the concentrations of 
BFA, AG1478, and GCA used in experiments were 2 µg/ml (7.1 µM), 25 µM, and 10 µM, 
respectively.
Viruses
Coxsackievirus B3 (CVB3) was obtained by transfecting in vitro-transcribed RNA derived 
from the p53CB3/T7 plasmid. This plasmid contains the cDNA of CVB3 strain Nancy driven 
by a T7 RNA polymerase promoter11. The encephalomyocarditis virus (EMCV) strain used in 
this study is the mengovirus strain, which was obtained upon transfection of in vitro-tran-
scribed RNA from cDNA clone pM16.112. Enterovirus 71 (EV71) (BrCr) and coxsackievirus A21 
(CVA21) (Coe) were obtained from the National Institute for Public Health and Environment 
(RIVM, Netherlands).
Plasmids
The VSVG-GFP plasmid, kindly provided by P. Keller and K. Simons (Max Planck Institute of 
Molecular Biology and Genetics, Dresden, Germany), encodes a green fluorescent protein 
(GFP) fusion of the temperature-sensitive ts045 vesicular stomatitis virus G protein (VSV-G 
protein)13. The plasmid coding for Gaussia luciferase, pCMV-Gluc (CMV stands for cytomega-
lovirus, and Gluc stands for Gaussia luciferase), and the control plasmid, pEGFP-C1 (EGFP 
stands for enhanced GFP),, were purchased from New England Biolabs and Clontech, re-
spectively. Plasmids pEYFP-GBF1 wt (EYFP stands for enhanced yellow fluorescent protein, 
and wt stands for wild type), pEYFP-GBF1-M832L14, pArf1-EGFP wt15, and pArf1-Q71L-EGFP4 
were described previously. DNA transfections were performed with 200 ng plasmid DNA 
and the transfection reagent Fugene (Roche) according to the manufacturer’s instructions 1 
day prior to the assays.
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VSV-G trafficking
BGM cells grown on coverslips in 24-well plates were transfected with pVSVG3(ts045)-
GFP and incubated at 40°C. At 16 h posttransfection, BFA, AG1478, or GCA was added to 
the cells. Following a 30-min incubation, the temperature was switched to 32°C. After 2 h 
the cells were fixed, stained with anti-GFP antibody (diluted 1:100, Molecular Probes) and 
Alexa Fluor 488-conjugated anti-mouse immunoglobulin G (IgG) (diluted 1:500, Molecular 
Probes), and analyzed with a Leica BMR microscope.
Gaussia luciferase secretion assay
At 16 h posttransfection with pCMV-Gluc, BGM cells were treated with BFA, AG1478 or GCA 
for 2.5 h. Subsequently, the supernatant was analyzed for luciferase activity with a Renilla 
luciferase assay kit (Promega).
Immunofluorescence
BGM cells grown to subconfluency on coverslips in 24-well plates were treated with BFA, 
AG1478, or GCA for 1 h at 37°C. After fixation with 4% paraformaldehyde the cells were 
stained with polyclonal anti-COP-I (against α- and γ-COP) antiserum (diluted 1:200; from K. 
Frey and F. Wieland, Biochemie-Zentrum, Heidelberg, Germany), monoclonal anti-GBF1 an-
tibody (1:100, BD Biosciences), monoclonal anti-GM130 antibody (1:200, BD Biosciences), 
or polyclonal anti-Arf1 antibody (1:150, from B. Helms, Biochemie-Zentrum, Heidelberg, 
Germany). The samples were stained with the secondary antibodies Alexa Fluor 594-con-
jugated goat anti-rabbit IgG and Alexa Fluor 488-conjugated anti-mouse IgG (Molecular 
Probes) and analyzed with a Leica BMR microscope.
Virus infections
Replication of CVB3 and EV71 was studied on subconfluent layers of BGM cells, while CVA21 
and mengovirus were studied on HeLa, and BHK-21 cells, respectively. After 30 min of virus 
adsorption, the cells were washed and fresh (drug-containing) medium was added to the 
cells. For the time–of-addition studies, GCA was added to the cells at 1-h intervals. At 8 
hours postinfection (h.p.i.), the cells were freeze-thawed three times to release intracellular 
virus particles and virus titers were determined by endpoint titration by the method of Reed 
and Muench and expressed as 50% cell culture infective doses (CCID50) per ml
16.
Replicon assay
Replicon assays were performed as described previously17. The p53CB3-LUC subgenomic 
replicon used contains the CVB3 cDNA in which the P1 capsid coding region is replaced by 
the firefly luciferase gene11. The plasmid was linearized, purified, and transcribed in vitro by 
T7 RNA polymerase, and transcript RNAs were transfected into BGM cells. After transfec-
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tion, the cells were cultured in the presence or absence of drugs at 37°C. At 2, 4, 6, and 8 h 
posttransfection, the cells were lysed and analyzed for firefly luciferase activity.
Analysis of viral polyprotein processing in vivo
In vivo labeling studies were performed as described previously18. Briefly, BGM cells in a 24-
well plate were infected with CVB3 at a multiplicity of infection (MOI) of 50. At 5 h.p.i., the 
cells were starved by incubating them in methionine-free medium for 30 min. Subsequently, 
35S-labeled methionine was added for 30 min. At 6 h.p.i., the cells were lysed and transla-
tion products were analyzed on a 10% polyacrylamide gel containing SDS, fixed, and then 
exposed to a Kodak XAR film.
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Abstract
RNA viruses can rapidly mutate and acquire resistance to drugs that directly target viral 
enzymes, which poses serious problems in a clinical context. Therefore, there is a grow-
ing interest in the development of antiviral drugs that target host factors critical for viral 
replication, since these are unlikely to mutate in response to therapy. We recently demon-
strated that phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) and its product phosphatidylinosi-
tol-4-phosphate (PI4P) are essential for replication of enteroviruses, a group of medically 
important RNA viruses including poliovirus (PV), coxsackievirus, rhinovirus, and enterovirus 
71. Here, we show that enviroxime and GW5074 decreased PI4P levels at the Golgi complex 
by directly inhibiting PI4KIIIβ. Coxsackievirus mutants resistant to these inhibitors harbor 
single point mutations in the non-structural protein 3A. These 3A mutations did not confer 
compound-resistance by restoring the activity of PI4KIIIβ in the presence of the compounds. 
Instead, replication of the mutant viruses no longer depended on PI4KIIIβ, since their rep-
lication was insensitive to siRNA-mediated depletion of PI4KIIIβ. The mutant viruses also 
did not rely on other isoforms of PI4K. Consistently, no high level of PI4P could be detected 
at the replication sites induced by the mutant viruses in the presence of the compounds. 
Collectively, these findings indicate that through specific single point mutations in 3A, CVB3 
can bypass an essential host factor and lipid for its propagation, which is a new example 
of RNA viruses acquiring resistance against antiviral compounds, even when they directly 
target host factors.
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Introduction
The genus Enterovirus belongs to the family of Picornaviridae, a group of non-enveloped 
positive-strand RNA viruses that includes many important human and animal pathogens. 
Examples of well-known enteroviruses are poliovirus (PV), the causative agent of paralytic 
poliomyelitis, and the human rhinoviruses (HRV), which can cause respiratory tract illnesses 
and exacerbations of asthma and chronic obstructive pulmonary disease (COPD)1,2 Other 
clinically important members are echoviruses and coxsackieviruses, which can cause acute 
clinical manifestations ranging from mild febrile illness to more severe conditions including 
fulminant sepsis in neonates, meningo-encephalitis, and pancreatitis3. Furthermore, cox-
sackieviruses have also been associated with chronic diseases, such as chronic myocarditis 
and type 1 diabetes4. Another significant member of the Enterovirus genus is enterovirus 71 
(EV71), which has caused large outbreaks in South East Asia in recent years. Infection with 
EV71 can result in hand-foot-and-mouth disease, but patients - especially children under 5 
years of age - in severe cases develop a potentially fatal central nervous system disease5. 
Currently, there are no approved antiviral drugs to treat enterovirus infections. Vaccines are 
only available against PV, yet the WHO campaign for eradication of poliomyelitis is encoun-
tering major problems due to the continuous emergence of pathogenic vaccine-derived 
revertants or recombinants. Development of vaccines against the other enteroviruses is es-
sentially impossible given the large number of (sero)types, exemplified by 150 rhinoviruses, 
30 coxsackieviruses, and 30 echoviruses. Thus, there is an urgent need for new tools, such 
as antiviral drugs, to combat enterovirus infections.
The enterovirus genome encodes four capsid proteins (VP1 through VP4) that facili-
tate cellular entry and delivery of the viral genome into the cytosol of the host cell, while 
the seven non-structural proteins (2Apro, 2B, 2C, 3A, 3B, 3Cpro, and 3Dpol) mediate viral RNA 
replication6. The search for inhibitors of virus replication has resulted in the identification 
of various compounds that affect the specific stages of the viral life cycle. One of these 
is enviroxime, a compound already discovered in the late 1970s that inhibits initiation of 
positive-strand RNA synthesis of PV, HRV, and coxsackievirus B3 (CVB3)7-9. Enviroxime-re-
sistant enteroviruses were subsequently isolated in an attempt to identify the target of the 
compound. Enviroxime-resistant PV, HRV and CVB3 were all found to carry mutations in 
3A, but the resistance mechanism has remained elusive7,8,10. Remarkably, PV mutants that 
are resistant to GW5074, a kinase inhibitor that inhibits PV RNA replication, were found to 
contain the same amino acid alteration as mutants resistant to enviroxime11. Intriguingly, we 
recently identified TTP-8307 as another inhibitor of enterovirus replication and found that 
TTP-8307-resistant CVB3 contained other mutations in 3A (i.e., V45A and H57Y) that also 
conferred resistance to enviroxime12.
The enterovirus 3A protein is a small protein that has intrinsic membrane-targeting 
properties due to a hydrophobic domain in its C-terminus. One of the precursor proteins 
present during replication is 3AB, of which the presumed function is to provide the primer 
(3B) for viral RNA synthesis during infection13,14. Additionally, the 3A protein of PV and CVB3 
has the ability to perturb the cellular secretory pathway. Under physiological conditions, 
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Arf1, a small GTPase that is activated by the guanine nucleotide exchange factor (GEF) GBF1, 
is the master regulator of membrane trafficking through the early secretory pathway. Ac-
tivated Arf1 is responsible for the recruitment of the COP-I complex, a coatomer protein 
complex that induces membrane curvature and initiates budding of transport vesicles15-17. 
When expressed in isolation, 3A disrupts ER-to-Golgi transport by blocking the formation 
of COP-I coat complexes on membranes18-21. The 3A protein most likely exerts this effect by 
directly interacting with GBF122,23.
The 3A proteins of PV and CVB3 are also responsible for recruiting phosphatidylino-
sitol-4-kinase type III β (PI4KIIIβ), a critical host factor for viral RNA replication, to the sites 
of RNA replication20. PI4KIIIβ, another downstream effector of Arf1, catalyzes the synthesis 
of phosphatidylinositol-4-phosphate (PI4P) lipids in Golgi membranes. These PI4P lipids are 
not only precursors for the classical inositol cycle important for Ca2+ signaling cascades, but 
have recently also been shown to carry out other functions24-26, such as aiding biogenesis 
and fusion of transport vesicles in the secretory pathway27,28. In enterovirus-infected cells, 
PI4KIIIβ is actively recruited to the replication sites to create a microenvironment rich in 
PI4P lipids. The purpose of this environment may be to attract the RNA-dependent RNA 
polymerase 3Dpol to the replication complex, since 3Dpol specifically binds PI4P over other 
cellular lipids in vitro20.
In this study, we show that our previously identified enviroxime-resistance mutations 
in CVB3 3A (i.e., V45A and H57Y) conferred cross-resistance to GW5074 and PIK93, an in-
hibitor of PI4KIIIβ. Using a genetically encoded PI4P sensor, we furthermore demonstrate 
that enviroxime and GW5074 strongly reduced the amount of PI4P lipids at the Golgi com-
plex by inhibiting PI4KIIIβ. Next, we set out to investigate how the mutations in 3A provided 
resistance against these PI4KIIIβ inhibitors. The mutations in 3A did not restore the activity 
of PI4KIIIβ in the presence of the compounds. Instead, replication of the mutant viruses no 
longer depended on PI4KIIIβ, nor on any other PI4K isoform, as demonstrated by their ef-
ficient replication in cells depleted of these kinases by siRNA-treatment. Finally, we provide 
evidence that, unlike wild-type (wt) virus, the mutant viruses no longer created a PI4P-rich 
microenvironment that supports replication. Collectively, our data indicate that CVB3 can 
bypass an essential host factor for its propagation by a single point mutation in the 3A pro-
tein.
Results
Cross-resistance of CVB3 3A mutants to enviroxime, GW5074, and PIK93
To identify novel inhibitors of CVB3 replication, we screened the Screen-Well Kinase Inhibitor 
Library, which contains 80 kinase inhibitors. The strongest inhibitor was GW5074, which 
reduced CVB3 replication by ~95% (data not shown). GW5074 has previously also been 
reported to inhibit PV and EV71 replication29. Interestingly, PV mutants resistant against 
GW5074 contained the same point mutation (i.e., mutation A70T in the hydrophobic do-
main of 3A) as mutants resistant to enviroxime11. This finding prompted us to test whether 
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our previously identified enviroxime-resistance mutations in CVB3 3A (i.e., mutations V45A 
and H57Y in the cytosolic domain of 3A) also provided cross-resistance to GW507412. To 
this end, we infected cells with either wild-type (wt) CVB3 or mutants carrying mutations 
3A-V45A or 3A-H57Y for 30 min. After removal of the virus, the different compounds were 
added to the cells. At 8 h post-infection (p.i.), when the enterovirus life cycle is (nearly) 
complete, the cells were frozen to release the intracellular virus into the culture medium, 
after which the virus titer was determined by endpoint titration. Replication of wt virus was 
inhibited by enviroxime and GW5074 by 3 to 4 logs (Figure 1A). The inhibitory effect of the 
compounds was not due to cytotoxicity as determined by a cell viability assay (Figure 1C). 
Both 3A-V45A and 3A-H57Y mutations significantly restored the ability of the virus to repli-
cate in the presence of the compounds (Figure 1A).
Recently, we identified PI4KIIIβ as a host factor essential for enterovirus replication 
and showed that 3A recruits this host factor to the replication sites20. Since GW5074 is a 
kinase inhibitor and the resistant viruses harbor mutations in the 3A protein, we speculated 
that the target of GW5074 and enviroxime could be PI4KIIIβ. To study this possibility, we 
Figure 1. CVB3 3A mutants are resistant to enviroxime, GW5074, and PI4KIIIβ inhibitor PIK93. 
(A,B) BGM cells were infected with CVB3 wt, CVB3 3A-V45A, or CVB3 3A-H57Y (A) or transfected 
with the corresponding RNA transcripts of full length infectious CVB3 clones (B). Immediately after 
infection or transfection, enviroxime, GW5074, or PIK93 were added to the cells. After 8 h, cells were 
lysed by freeze-thawing to release intracellular virus particles and the total virus titer was determined 
by endpoint titration. (C) BGM or HeLa cells were incubated with the indicated compounds for 8 h 
using DMSO as a negative control. Subsequently, the cytoxicity of the compounds was determined 
in a cell viability assay. The percentage was set to 100% for DMSO-treated cells. Bars represent mean 
of three samples ± SD. Significant differences compared to wt virus are indicated as follows: *P < 
0.05, **P < 0.01, ***P < 0.001. nd= not detectable.
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tested whether our 3A mutants were also cross-
resistant to PIK93, a well-known and commonly 
used inhibitor of PI4KIIIβ that can also inhibit 
PI4KIIIα but with a significantly decreased po-
tency30,31. Figure 1A shows that treatment with 
PIK93 inhibited replication of wt CVB3 by more 
than 1 log. Consistent with our speculation, the 
mutants could replicate significantly better than 
wt CVB3 in the presence of PIK93. While this 
work was in progress, a similar observation was 
made with the enviroxime- and GW5074-resis-
tant PV A70T mutant7,11, which was also found 
to provide protection against PIK9332.
Resistance of the mutants against the com-
pounds was also observed upon transfection of 
RNA transcribed from infectious cDNA clones, 
followed by endpoint titration analysis of the 
produced virus (Figure 1B). This result demon-
strates that the compounds do not affect cell 
entry or uncoating of the virus. Furthermore, 
this finding shows that only the mutations in 3A 
are responsible for the resistance against the 
compounds.
To demonstrate that our 3A mutations 
rescued virus replication at the step of viral RNA 
synthesis, we utilized CVB3-Rluc, a genetically 
engineered virus that contains Renilla luciferase 
upstream of the capsid coding region. Infection 
of cells with CVB3-Rluc virus yields, besides viral 
proteins, a large amount of Renilla luciferase, 
which serves as a sensitive measure for viral 
RNA replication. We treated cells with the com-
pounds after infection with wt or mutant CVB3-
Rluc and quantified the intracellular amount of 
luciferase at various time points p.i. in order to 
obtain a detailed insight into the RNA replica-
tion kinetics (Figure 2). In the absence of com-
pounds, all viruses (i.e., wt and mutants) repli-
cate with similar kinetics in a single cycle (Figure 
2A), which is in line with the finding that the mutant viruses induced plaque phenotypes 
similar to that of wt virus12. Guanidine HCl, a well-known enterovirus inhibitor that blocks 
viral RNA replication, completely abolished replication of both wt and mutant viruses (Fig-
Figure 2. RNA replication of CVB3 3A 
mutants in the presence of enviroxime, 
GW5074, and PIK93. (A,B) HeLa cells were 
infected with wt or mutant CVB3-Rluc for 30 
min. Immediately after infection, Guanidine 
HCl (GuaHCl), enviroxime, GW5074, or PIK93 
were added to the cells (B). Cells were lysed 
at different time points after infection to 
determine the intracellular Renilla luciferase 
activity.
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ure 2B). In line with the results of Figure 1, replication of wt CVB3-Rluc was also strongly 
impaired by the other compounds, whereas the mutant viruses replicated relatively effi-
ciently, albeit with some delay (Figure 2B). Collectively, these results demonstrate that the 
mutations V45A and H57Y in 3A enable the virus to replicate its RNA in the presence of 
enviroxime, GW5074, and PIK93.
GW5074 and enviroxime decrease PI4P levels on the Golgi complex
The cross-resistance of the 3A mutations to enviroxime, GW5074, and the PI4KIIIβ inhibitor 
PIK93 suggested that enviroxime and GW5074 also target PI4KIIIβ. Recently, it was demon-
strated that GW5074 inhibited PI4KIIIβ directly in an in vitro kinase activity assay32. Here, we 
tested whether enviroxime is also capable of targeting PI4KIIIβ directly in vitro. Enviroxime 
exhibited a ~30-fold preference for PI4KIIIβ over PI4KIIIα and was the most potent inhibitor 
tested (Figure 3). GW5074 inhibited PI4KIIIβ, but not PI4KIIIα, which is in line with previous 
results32. This result shows that enviroxime, similar to GW5074, targets PI4KIIIβ directly.
In addition, we evaluated whether enviroxime and GW5074 impair PI4KIIIβ activity 
in vivo by examining their effects on PI4KIIIβ-catalyzed PI4P synthesis in Golgi membranes. 
PI4P lipids can be detected in intact cells using a plasmid encoding the PI4P sensor FAPP1-
PH-GFP, a GFP-tagged pleckstrin-homology (PH) domain of FAPP1 (four-phosphate-adaptor 
protein 1). This PH domain contains a PI4P-binding pocket as well as an Arf1-binding site, 
which together induce localization of this PI4P sensor to the Golgi complex33-36. In mam-
malian cells, PI4P lipids present in the early secretory pathway can be produced by three of 
the four different isoforms of PI4K, namely PI4KIIα (localized to the Golgi), PI4KIIIα (ER), and 
PI4KIIIβ (Golgi). PI4KIIβ does not localize to the early secretory pathway, but is situated on 
Figure 3. Enviroxime targets PI4KIIIβ directly. Recombinant PI4KIIIβ (A) or PI4KIIIα (B) was incubated 
with the substrate phosphatidylinositol in the form of Triton micelles and radioactively labeled ATP. 
After termination of the enzyme reaction, the radioactive ATP incorporated into the micelles is 
quantified as a measure of PI4K activity. (C) Data were converted to percentage inhibition with 
respect to positive (wortmannin) and negative (DMSO) controls and also presented as IC50. n.a.= 
not applicable.
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the plasma membrane and on endosomes24,25. We first investigated which PI4K isoforms are 
involved in the Golgi-localization of FAPP1-PH-GFP in our cells. To this end, we transfected 
HeLa cells expressing FAPP1-PH-GFP with siRNAs against PI4KIIα, PI4KIIIα, or PI4KIIIβ. In line 
with previous results in COS-7 cells33, we observed that PI4KIIIβ is the major determinant of 
the Golgi-localization of the PI4P sensor (Supplemental Figure S1). Thus, FAPP1-PH-GFP can 
be used to measure the synthesis of PI4P lipids at the Golgi catalyzed by PI4KIIIβ.
Next, we tested the effects of the antiviral compounds on the localization of FAPP1-
PH-GFP. One day after transfection with the FAPP1-PH-GFP plasmid, the cells were treated 
for 1 h with the compounds, after which they were fixed and stained for PI4KIIIβ. In un-
treated cells, FAPP1-PH-GFP was predominantly localized on the Golgi complex, as shown by 
the overlap with PI4KIIIβ (Figure 4A). Treatment with either enviroxime, GW5074, or PIK93 
however resulted in a severe reduction in the amount of FAPP1-PH-GFP present on the 
Golgi membranes (Figure 4A). Although analysis of the FAPP1-PH-GFP fluorescence is not 
Figure 4. Enviroxime and GW5074 decrease PI4P levels at the Golgi complex. (A) HeLa cells were 
transfected with a plasmid encoding the PI4P sensor FAPP1-PH-GFP. The next day, cells were treated 
for 1 h with the indicated compounds and stained with an antibody against PI4KIIIβ. (B) Quantification 
of the percentage of Golgi-localized FAPP1-PH-GFP and PI4KIIIβ, which was determined by dividing 
the fluorescence intensity of the Golgi-area by that of the area of the whole cell. The resulting 
percentage was set to 100% in untreated cells. Bars represent the mean of ten cells from three 
different experiments ± SD. Significant differences compared to untreated cells are indicated as 
follows: ***P < 0.001. (C) GBF1 and Arf1 were stained in HeLa cells treated for 1 h with the indicated 
compounds. 
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the most accurate approach to quantify the effect of the compounds on PI4P levels, we de-
termined the amount of the PI4P sensor present in the Golgi in multiple cells per condition. 
This quantification revealed that at the used concentrations, enviroxime was consistently 
the most effective compound (Figure 4B).
Remarkably, all compounds also induced a significant increase in the intensity of the 
PI4KIIIβ staining on the Golgi membranes compared to untreated cells (Figure 4A and 4B). 
This increase in PI4KIIIβ could in theory be the result of activation of upstream factors of 
PI4KIIIβ that determine its localization. Under physiological conditions, PI4KIIIβ is recruited 
to the Golgi membranes by the small GTPase Arf137. The activation and consequent mem-
brane-association of Arf1 in turn is stimulated by the ArfGEF GBF138. Therefore, we investi-
gated whether the accumulation of PI4KIIIβ on Golgi membranes was due to effects of the 
compounds on either GBF1 or Arf1 using an immunofluorescence assay. The localization 
as well as the amount of GBF1 and Arf1 on Golgi membranes was not altered after a 1-h 
treatment with the compounds (Figure 4C), indicating that it is unlikely that the compounds 
affect these upstream regulators of PI4KIIIβ. Hence, the increase in PI4KIIIβ on the Golgi 
complex is most likely caused by an unknown compensatory mechanism, possibly involving 
phosphorylation of PI4KIIIβ, of the cell39. In conclusion, these results collectively suggest 
that both enviroxime and GW5074 diminish PI4P levels on the Golgi through inhibition of 
PI4KIIIβ activity.
Rescue of CVB3 replication in the presence of enviroxime by expression of a PIK93-
resistant PI4KIIIβ
GW5074 targets a broad and not yet fully defined range of cellular kinases40, which may also 
be the case for enviroxime. Therefore, targets other than PI4KIIIβ could contribute to the in-
hibitory effect of both compounds on enterovirus replication. To test whether PI4KIIIβ is the 
only (major) target of the compounds responsible for their antiviral activity, we conducted 
a “replication rescue assay” using a PI4KIIIβ mutant resistant to the PI4KIIIβ inhibitors wort-
mannin and PIK9330. This PI4KIIIβ mutant contains a single mutation (Y583M) that weakens 
the binding of wortmannin and PIK93 in the ATP-binding pocket without affecting the cata-
lytic activity of the kinase. Cells were transfected with either PI4KIIIβ-wt, PI4KIIIβ-Y583M, or 
as negative controls the kinase-dead PI4KIIIβ-D656A or EGFP. Two days post-transfection, 
the cells were infected with wt CVB3 or CVB3-Rluc in the presence of the compounds. At 8 
h p.i., cells were lysed to determine either the total virus titer or the intracellular amount 
of luciferase. Similar expression levels of all PI4KIIIβ proteins were confirmed in parallel 
in an immunofluorescence assay (data not shown). Figure 5A shows that transfection of 
PI4KIIIβ-wt rescued the replication of CVB3-Rluc in the presence of the compounds only to a 
marginal extent. As expected, EGFP and the kinase-dead PI4KIIIβ-D656A could not counter 
the effects of the compounds on CVB3 replication. The presence of PI4KIIIβ-Y583M however 
markedly restored CVB3 replication in the presence of either PIK93 or enviroxime nearly to 
untreated levels.
The effects of GW5074 on the other hand were not countered by PI4KIIIβ-Y583M, for 
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Figure 5. Mutant PI4KIIIβ rescues the effect of enviroxime on CVB3 replication. (A) Replication 
rescue experiment. BGM cells were transfected with HA-tagged PI4KIIIβ- wt, PI4KIIIβ-Y583M, or as 
negative controls the kinase-dead PI4KIIIβ-D656A or EGFP. Two days post-transfection, cells were 
infected with CVB3 or CVB3-Rluc in the presence of the indicated compounds. After lysing the cells 
at 8 h p.i., the total virus titer or the amount of luciferase activity was determined in the samples. 
(B,C) HeLa cells were co-transfected with plasmids encoding FAPP1-PH-GFP and either HA-tagged 
PI4KIIIβ-wt (B) or PI4KIIIβ-Y583M (C). The next day, cells were treated for 1 h with the indicated 
compounds. Subsequently, cells were fixed and the overexpressed PI4KIIIβ was stained using an 
antibody against HA. The percentage of Golgi-localized FAPP1-PH-GFP was determined by dividing 
the fluorescence intensity of the Golgi-area by that of the area of the whole cell. The resulting 
percentage was set to 100% in untreated cells. Bars represent the mean of 10 cells from three 
different experiments ± SD. Significant differences compared to untreated cells are indicated as 
follows: **P < 0.01, ***P < 0.001.
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which the explanation could be that the Y583M mutation does not provide resistance to 
GW5074. To test this possibility, we co-transfected the plasmids encoding FAPP1-PH-GFP 
with either PI4KIIIβ-wt or PI4KIIIβ-Y583M and evaluated the effect of the compounds on 
the presence of the PI4P sensor on the Golgi. In cells expressing PI4KIIIβ-wt, all compounds 
strongly reduced the presence of the PI4P sensor on Golgi membranes (Figure 5B). Expres-
sion of PI4KIIIβ-Y583M however only restored the Golgi-localization of the PI4P sensor for 
enviroxime and PIK93 (Figure 5C). In line with the observation that PI4KIIIβ-Y583M could 
not rescue CVB3 replication in the presence of GW5074, PI4KIIIβ-Y583M was not resistant 
to GW5074 as shown by the absence of FAPP1-PH-GFP on the Golgi (Figure 5C). Taken to-
Figure 6. 3A-H57Y does not counter the decrease in PI4P levels induced by enviroxime, GW5074, 
and PIK93. HeLa cells were co-transfected with plasmids encoding FAPP1-PH-GFP and myc-tagged 
wt 3A (A) or 3A-H57Y (B). One day after transfection, cells were treated for 1 h with compounds. 
Subsequently, 3A and 3A-H57Y were stained with an anti-myc antibody. The FAPP1-PH-GFP to 3A 
fluorescence was quantified in 10 cells/ condition and expressed as a ratio. Bars represent the mean 
± SD. Significant differences compared to untreated cells are indicated as follows: ***P < 0.001.
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gether, these data suggest that PI4KIIIβ is the major target of enviroxime and PIK93 that is 
responsible for the inhibition of CVB3 replication.
Mutations in 3A do not rescue the activity of PI4KIIIβ in the presence of enviroxime, 
GW5074, and PIK93
Next, we investigated how the mutations in 3A confer resistance to enviroxime, GW5074, 
and PIK93. One could speculate that mutations in 3A could somehow rescue the activity of 
PI4KIIIβ in the presence of the compounds. Another possible explanation for the resistant 
phenotype is that the mutants replicate independently of PI4KIIIβ. To test the first scenario, 
we studied the effect of the compounds on PI4P levels in cells expressing either wt or mu-
tant 3A. To this end, we co-transfected cells with plasmids encoding FAPP1-PH-GFP together 
with wt or mutant 3A-myc, and one day later treated them for 1 h with the compounds. 
In untreated cells, wt 3A was visible in a punctate pattern (Figure 6A), corresponding to a 
localization to dispersed Golgi membranes, as previously described20,23. 3A showed a great 
overlap with PI4P, as detected by FAPP1-PH-GFP. In cells treated with enviroxime, GW5074, 
or PIK93, little if any FAPP1-PH-GFP was present on 3A-containing membranes (Figure 6A), 
which indicates that wt 3A is unable to prevent or restore the compound-induced inhibi-
tion of PI4KIIIβ activity. In cells expressing 3A-H57Y-myc (Figure 6B) or 3A-V45A-myc (data 
not shown), treatment with the compounds also resulted in a nearly complete absence of 
FAPP1-PH-GFP on 3A-containing membranes. The reduction in PI4P levels is not due to an 
absence of PI4KIIIβ, which was recruited equally well by wt 3A, 3A-V45A (not shown), and 
3A-H57Y in the presence of the compounds (Supplemental Figure S2). These results suggest 
that it is unlikely that the resistance mutations in 3A prevent or counter the effect of the 
compounds on PI4KIIIβ activity.
CVB3 3A mutants replicate efficiently in cells depleted of PI4KIIIβ
Next, we investigated whether the mutants still require PI4KIIIβ for replication. To this end, 
we first investigated whether the mutant viruses also recruit PI4KIIIβ to the sites of RNA rep-
lication as wt virus does. Cells were infected with either wt or mutant viruses carrying muta-
tions V45A or H57Y, fixed at 5 h p.i., and stained for PI4KIIIβ and dsRNA, a generally accepted 
marker of viral replication sites. For all viruses, an intense staining of PI4KIIIβ was observed 
at the replication sites (Figure 7A, CVB3 3A-V45A not shown), which demonstrates that all 
viruses induced an active recruitment of PI4KIIIβ to the replication sites. PI4KIIIβ was also 
present on the replication sites of mutant viruses induced in the presence of the compounds 
(data not shown), which is consistent with the observation that the compounds also did 
not alter the PI4KIIIβ recruitment in cells transfected with wt or mutant 3A (Supplemental 
Figure S2).
The presence of PI4KIIIβ on the replication sites induced by the mutant viruses does 
not necessarily prove that this host factor is essential for their replication. We next investi-
gated whether PI4KIIIβ is critical for replication of the mutant viruses by testing the ability 
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of the mutants to replicate in cells depleted of PI4KIIIβ by siRNA-treatment. Cell viability 
assays showed that the knock-down was not toxic for the cells (Supplemental Figure S3). 
Western blot analysis of control- and siRNA-treated cells revealed a knock-down efficiency 
of ~90-95% (Figure 7D). Consistently, IFA analysis showed that 5-10% of the cells were not 
transfected with siRNAs against PI4KIIIβ and, hence, showed normal expression levels of this 
protein (data not shown). These untransfected cells can still support CVB3 replication and 
thereby a maximal decrease in virus titer of 1 to 1.5 log can be achieved. In agreement with 
this transfection efficiency, we observed that replication of wt CVB3 was reduced by ~1.2 
log in PI4KIIIβ-depleted cells (Figure 7B). Surprisingly, replication of both mutants was not 
affected upon knock-down of PI4KIIIβ, which demonstrates that replication of the mutants 
is largely independent of PI4KIIIβ.
Figure 7. Replication of CVB3 3A mutants is largely independent of PI4KIIIβ. (A) HeLa cells were 
infected with wt CVB3 or mutant CVB3 3A-H57Y. At 5 h p.i., cells were fixed and stained with antibodies 
against PI4KIIIβ and dsRNA as a marker for the sites of RNA replication. (B and C) HeLa cells were 
transfected with siRNAs against PI4KIIIβ (B), or PI4KIIα, PI4KIIβ, and PI4KIIIα (C) and scrambled siRNA 
as a negative control. Two days later, siRNA-treated cells were infected with wt virus, 3A-V45A virus, 
or 3A-H57Y virus. Virus titers were determined at 8 h p.i. Bars represent mean of three samples ± 
SD, *P < 0.05. (D) In parallel, efficiency of the knock-down was determined by western blot analysis.
Mutations in 3A render CVB3 replication independent of high levels of PI4P lipids
A possible strategy of cells and viruses to overcome inhibition of crucial factors is to switch 
to other isoforms that are functionally redundant. Hence, we investigated whether the mu-
tant viruses utilized PI4K isoforms other than PI4KIIIβ for the production of PI4P. To this end, 
we tested whether replication of wt or mutant CVB3 was affected by depletion of PI4KIIα, 
PI4KIIβ, or PI4KIIIα by siRNA-treatment. Knock-down of these proteins was efficient and not 
toxic for the cells (Figure 7D, Supplemental Figure S3 and S4). Figure 7C shows that replica-
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tion of neither wt nor mutant viruses was affected by knock-down of PI4KIIα, PI4KIIβ, or 
PI4KIIIα. This result furthermore suggests that the mutant viruses do not rely on high levels 
of PI4P for replication, since they do not require any isoform of PI4K.
Next, we investigated whether the replication sites induced by the CVB3 mutants in 
the presence of the compounds indeed were devoid of PI4P lipids. Initially, we opted for 
transfection of cells with the plasmid encoding FAPP1-PH-GFP followed by virus infection 
and compound-treatment the next day. However, this method resulted in very low numbers 
of cells that were both transfected as well as efficiently infected. Therefore, we switched to 
an immunofluorescence assay for intracellular staining of PI4P lipids using an antibody that 
specifically recognizes PI4P lipids. Cells were infected with either wt or mutant viruses in the 
presence or absence of the compounds, fixed at 5 h p.i., and stained for 3A and PI4P. We did 
not detect expression of 3A in Guanidine HCl-treated cells (data not shown), indicating that 
virus replication is required to generate detectable amounts of 3A. Upon replication, both 
CVB3 wt and the 3A-V45A and -H57Y mutant viruses induced a dramatic increase in PI4P 
levels in the absence of the compounds (Figure 8, CVB3 3A-V45A not shown). No infected 
cells were detected for wt CVB3 in the presence of the compounds, since they inhibit repli-
cation (data not shown). Consistent with the results of Figures 1 and 2, replication of the 
Figure 8. CVB3 3A mutants do not require a high level of PI4P lipids. HeLa cells were infected 
with CVB3 wt or CVB3 3A-H57Y, after which the medium was replaced with (compound-containing) 
medium. At 5 h p.i., cells were fixed and stained with antibodies against 3A and PI4P. (B) The PI4P 
to 3A fluorescence was quantified in 10 cells per condition and expressed as a ratio. Bars represent 
the mean ± SD. Significant differences compared to untreated cells are indicated as follows: ***P < 
0.001.
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mutant viruses was slightly delayed by the compounds, as shown here by the reduced 
amount of infected cells. Accordingly, the pattern of 3A was in some cells more typical for 
the early stage of replication, when the distribution of 3A is still restricted to the Golgi area20. 
Remarkably, the PI4P lipids appeared absent in cells infected with the mutant viruses in the 
presence of enviroxime and GW5074 (Figure 8). Importantly, also no high levels of PI4P lip-
ids were detected in these cells at later time points, when cells were started to round up and 
display cytopathic effects (data not shown). In cells treated with PIK93 however, some PI4P 
lipids could still be detected, which is consistent with our observation that PIK93 at the used 
concentration was the weakest inhibitor of PI4KIIIβ. These observations imply that the mu-
tant viruses can establish replication without the participation of high PI4P levels. Collec-
tively, these data suggest that the mutations 3A-V45A and 3A-H57Y render virus replication 
largely independent of host factor PI4KIIIβ as well as PI4P lipids.
Discussion
The emergence of drug-resistant viruses is a common response to drugs targeting viral pro-
teins due to the genetic plasticity of RNA viruses. To circumvent this problem, there is a great 
interest in the development of antiviral drugs that target host factors, since these factors are 
unlikely to mutate in response to therapy. However, this “host-oriented” approach is also 
based on the assumption that viruses are not capable of mutating in such a way that they 
can overcome drug-induced inhibition of a critical host factor. Here, we present a unique 
example of how viruses by acquiring a single point mutation can bypass a critical host factor 
and replicate efficiently when this factor is inhibited or depleted by siRNA-treatment.
While the development of viral drug-resistance poses serious problems in a clinical 
context, it is a useful tool in studies on the mechanism of action of antiviral compounds. The 
CVB3 mutants studied here, 3A-V45A and 3A-H57Y, exhibited resistance to enviroxime and 
GW5074 as well as the PI4KIIIβ inhibitor PIK93, which suggested that these compounds also 
target PI4KIIIβ. Consistent with this idea, both enviroxime and GW5074 inhibited PI4KIIIβ 
directly in an in vitro kinase activity assay. Furthermore, both compounds caused a decrease 
in localization of the PI4P sensor FAPP1-PH-GFP at the Golgi complex, reflecting a reduc-
tion in PI4P levels. Since PI4KIIIβ was the major determinant of the Golgi-localization of the 
PI4P sensor in our cells, this result indicated that enviroxime and GW5074 also inhibited 
PI4KIIIβ activity in intact cells. Furthermore, CVB3 replication in the presence of enviroxime 
was restored nearly to levels in untreated cells by the expression of a PI4KIIIβ mutant. This 
PI4KIIIβ mutant carries a mutation in its ATP-binding pocket, Y853M, that does not harm the 
catalytic activity of the kinase. The rescue of the effects of enviroxime on CVB3 replication 
by this PI4KIIIβ mutant has three implications. First, the compound only inhibits the enzy-
matic activity of PI4KIIIβ required for CVB3 replication and not an non-enzymatic function. 
Second, PI4KIIIβ and not an as yet unidentified target of enviroxime is responsible for the 
inhibition of CVB3 replication. Third, enviroxime, similar to PIK93, binds in the ATP-binding 
pocket of PI4KIIIβ.
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Our observation that GW5074 inhibits PI4KIIIβ activity in vitro is in line with the results 
of a recent study, which was published while our work was in progress32. Here, we also 
show that GW5074 targets PI4KIIIβ in intact cells by use of a PI4P-sensor. Besides PI4KIIIβ, 
GW5074 inhibits a variety of additional kinases other than its best-known target c-Raf, such 
as the kinases Pim-1, Pim-2, Pim-3, HIPK2, RIP2, GAK, and MST240, and therefore represents 
a typical example of a promiscuous kinase inhibitor. Importantly, previous studies had al-
ready excluded a role of these other GW5074-targeted kinases in enterovirus replication29. 
The effects of GW5074 on CVB3 replication could not be countered by PI4KIIIβ-Y583M, 
which indicates that binding of this compound to PI4KIIIβ does not involve Y583 in the ATP-
binding pocket. The inhibition of kinases by GW5074 can occur in a competitive manner with 
GW5074 acting as an ATP/GTP analog41,42, or alternatively in a non-competitive manner, as 
exemplified by the prevention of hexamer formation of glutamate dehydrogenase43,44. The 
mechanism by which GW5074 inhibits PI4KIIIβ remains to be elucidated in future studies.
After demonstrating that enviroxime and GW5074 inhibit PI4KIIIβ activity in vitro and 
in intact cells, we next investigated how the 3A mutations provide compound-resistance. 
One possible explanation for the drug-resistant phenotype is that the 3A-V45A and 3A-H57Y 
mutations rescued the activity of PI4KIIIβ in compound-treated cells. However, we excluded 
this possibility by showing that in cells expressing either wt or mutant 3A, the compounds 
still induced a strong reduction in the localization of FAPP1-PH-GFP on 3A-containing mem-
branes. Thereafter, we considered the scenario that the mutations rendered viral RNA rep-
lication independent of PI4KIIIβ. Indeed, replication of the mutant viruses was no longer 
sensitive to knock-down of PI4KIIIβ. Additionally, we observed efficient replication upon 
knock-down of the isoforms PI4KIIα, PI4KIIβ, and PI4KIIIα, indicating that the mutants did 
not rely on any isoform of PI4K. This finding raised the question of whether the mutant vi-
ruses still needed PI4P for replication. An immunofluorescence assay in compound-treated 
infected cells with an antibody against PI4P revealed that the mutant viruses were indeed 
able to replicate in cells lacking detectable PI4P levels. However, we cannot exclude the pos-
sibility that there is still a tiny, undetectable amount of PI4P present in these cells on which 
the mutant virus might depend.
The purpose of PI4P lipids in enterovirus replication is currently unknown. Under 
physiological conditions, PI4P lipids were for a long time merely perceived as precursors for 
the production of PIP2 and IP3 in the classical inositol cycle important for intracellular Ca
2+ 
signaling24. However, PIP2 levels at the membranes supporting replication were unaltered 
and even decreased along the course of CVB3 infection20. Recently, PI4P lipids were demon-
strated to have additional important functions in the early secretory pathway through their 
ability to serve as docking sites for various proteins24,26. Consistent with this ability of PI4P, 
the RNA-dependent RNA polymerase 3Dpol of CVB3 was shown to bind preferentially to PI4P 
lipids over other cellular lipids in vitro20. This finding suggests that the purpose of PI4P in 
enterovirus replication might be to recruit 3Dpol to the sites of viral RNA replication and/or 
to stimulate the activity of 3Dpol, yet evidence that this occurs in enterovirus-infected cells 
is lacking.
Another speculative scenario for the role of PI4P lipids during enterovirus infection 
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is that they recruit other cellular factors important for replication. PI4P lipids are bound 
by proteins that contain a pleckstrin homology (PH) domain. Several Golgi-proteins that 
contain a PI4P-binding PH domain are involved in lipid transport, such as FAPP1, oxysterol-
binding protein (OSBP) and ceramide transport protein (CERT)33,36,45. The primary function of 
these proteins is to bind ceramide, cholesterol, and/or oxysterols (i.e., oxygenated deriva-
tives of cholesterol) to mediate non-vesicular transport of these lipids to other compart-
ments in the cell. Therefore, recruitment of these lipid-binding proteins to the enterovirus 
replication sites might lead to accumulation of other specific lipids other than PI4P required 
for viral RNA replication and/or membrane reorganization.
Recently, our view of the roles of lipids in viral infection has been greatly expanded by 
the recognition that positive-strand RNA viruses actively alter cellular lipid signaling, syn-
thesis, and metabolism for formation and function of their replication sites. Similar to en-
teroviruses, the flavivirus Hepatitis C virus (HCV) requires PI4P lipids for replication, which 
are generated via the recruitment of PI4KIIIα46-53. West Nile virus attracts the cholesterol-
synthesizing enzyme 3-HMGA-CoA reductase to replication sites54,55, while dengue virus re-
cruits fatty acid synthase and stimulates its activity56,57. The recruitment of lipid biosynthesis 
machinery can lead to membrane expansion and alteration of the fluidity and curvature 
of the membrane by for instance accumulation of cholesterol or desaturation of lipid fatty 
acid tails. The consequences of lipid synthesis and modification may be important for the 
membrane reorganization that positive-strand RNA viruses induce to create their own mem-
branous environment with a highly specialized lipid composition suited for viral RNA repli-
cation58. Given the accumulating evidence that pre-existing cellular membranes have to be 
expanded and/or modified to accommodate the replication complexes of positive-strand 
RNA viruses, and that modulation of cellular lipid metabolism appears to be a universal 
feature of this group of viruses, it is remarkable that we have identified a mutant virus that 
can efficiently replicate in the absence of an essential lipid. To our knowledge, this is the first 
example of a positive-strand RNA virus that can replicate in the absence of high levels of a 
crucial lipid in the environment of their replication sites, on which the wt virus ultimately 
depends. Currently, we are investigating whether the absence of PI4P affects the three-
dimensional architecture of the enterovirus membranous replication sites.
Since the role of PI4P lipids in enterovirus replication remains elusive, it is difficult to 
explain how our CVB3 mutants can replicate in the absence of high levels of PI4P lipids, albe-
it somewhat less efficiently than when PI4P lipids are present. Replication of the wt virus is 
completely abolished when PI4KIIIβ is inhibited by enviroxime and is also strongly impaired 
upon depletion of this host factor by siRNA-treatment. Since replication of the mutant virus 
was largely unaffected upon inhibition or depletion of PI4KIIIβ, the mutant virus may be able 
to use an alternative pathway without PI4KIIIβ and PI4P to establish replication. Although 
the single point mutations allow CVB3 to replicate in cells lacking PI4KIIIβ and PI4P lipids, we 
speculate that the PI4KIIIβ-dependent pathway offers an evolutionary advantage over the 
alternative pathway. All CVB3 strains isolated to date contain V45 and H57 in their 3A se-
quence, suggesting a selective pressure on the usage of PI4KIIIβ and PI4P lipids. Moreover, 
we found that replication of all tested enteroviruses, including various serotypes belonging 
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to different human enterovirus and rhinovirus species, is strongly inhibited by enviroxime12, 
which further illustrates the functional importance of PI4KIIIβ and PI4P lipids in their replica-
tion cycle. In future studies, it will be of interest to dissect the alternative pathway used by 
the 3A mutant viruses. Intriguingly, the CVB3 resistance mutations 3A-V45A and 3A-H57Y 
are located in the cytosolic domain, whereas mutation 3A-A70T that rendered PV resistant 
to enviroxime, GW5074, and PIK93 is located in the hydrophobic, membrane-anchored do-
main. How these mutations enable the virus to replicate in the absence of active PI4KIIIβ 
remains to be established.
The CVB3 3A mutants are the first example of picornaviruses able to replicate without 
the participation of a crucial host factor. Previously, PV mutants were generated that were 
resistant to Brefeldin A59, a well-known inhibitor of enterovirus replication that perturbs 
secretory pathway transport by targeting GBF1. These PV mutants contained the muta-
tions V80I in 2C and A27V in 3A. PV carrying the single mutations exhibited intermediate 
resistance to BFA, while the double-mutant was fully resistant. Despite the insensitivity to 
Brefeldin A, however, the PV double-mutant could not replicate in cells depleted of the cru-
cial factor GBF1 by siRNA-treatment60.
Virus replication largely independent of a host factor has been described before for 
another positive-strand RNA virus. An HCV mutant resistant against Alisporivir and cyclo-
sporine A was previously isolated that contained a point mutation in NS5A. Alisporivir and 
cyclosporine A exert their antiviral activity by binding to cyclophilins, which are critical host 
factors for HCV. Cyclophilins affect the folding of proteins through their peptidyl-prolyl cis-
trans isomerase activity, which catalyzes the cis-trans isomerisation of the prolyl peptide 
bond preceding proline residues. Due to the resistance mutation, HCV NS5A adopted a con-
formation that was no longer dependent on the cis-trans isomerisation activity of the cyclo-
philins for its function61. These examples of mutant HCV and CVB3 demonstrate that viruses 
can acquire resistance even to compounds that target crucial host factors. Furthermore, 
they disclose the ability of viruses to use an alternative pathway to replicate efficiently in 
a suboptimal environment under selective pressure imposed by antiviral compounds, sug-
gesting that a combination of compounds targeting different host factors may be required 
for successful host-oriented antiviral therapy.
Materials & Methods
Cells and reagents
Buffalo green monkey (BGM) kidney cells and HeLa (R19) cells were grown at 37°C, 5% CO2 in 
minimal essential medium (MEM) (Gibco) supplemented with 10% fetal bovine serum, peni-
cillin, and streptomycin. Enviroxime was synthesized as described previously9. Guanidine 
hydrochloride and GW5074 were purchased from Sigma Aldrich. PIK93 was provided by Dr. 
K. Shokat (University of California San Francisco, San Francisco, California, USA). All com-
pounds were dissolved in DMSO. GW5074 was used at a concentration of 30 µM, envirox-
ime at 0.5 µg/ml (1.4 μM), and PIK93 at 1 µM.
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Antibodies
As primary antibodies we used rabbit polyclonal anti-PI4-KinaseIIIβ (Upstate), mouse mono-
clonal anti-GBF1 (BD Biosciences), rabbit polyclonal anti-Arf1 (kind gift from dr. F. Wieland, 
Biochemie-Zentrum Heidelberg, Germany), mouse monoclonal anti-c-Myc (Sigma Aldrich), 
mouse monoclonal anti-dsRNA (J2, English & Scientific Consulting), mouse anti-PI4P IgM 
(Echelon Biosciences), mouse monoclonal anti-HA (Covance), mouse monoclonal anti-β-
actin (Sigma), and rabbit polyclonal anti-CVB3 3A described previously23. The secondary 
antibodies for immunofluorescence included Alexa Fluor 488- or 594-conjugated goat-anti-
rabbit IgG, Alexa Fluor 488- or 594-conjugated goat-anti-mouse IgG, or Alexa Fluor 594-con-
jugated goat-anti-mouse IgM (Molecular Probes). The secondary antibodies for Western 
Blot analysis included IRDye anti-mouse or anti-rabbit antibodies (Li-Cor Biosciences).
Viruses
CVB3 and CVB3-Rluc, which contains the Renilla luciferase gene upstream of the capsid cod-
ing region, were obtained by transfection of RNA transcripts derived from the full length 
infectious clones p53CB3/T7 and pRLuc-53CB3/T7 in BGM cells as described before21,62. 
CVB3(-Rluc) carrying the V45A or H57Y mutation in the 3A protein were obtained in a simi-
lar manner using plasmids p53CB3/T7-3A-V45A or -H57Y described elsewhere12 or pRluc-
53CB3/T7-3A-V45A or -H57Y. Virus titers were determined by endpoint titration accord-
ing to the method of Reed and Muench and expressed as 50% cell culture infective doses 
(CCID50)63.
Plasmids
The plasmid p3A-myc and the p53CB3/T7 3A mutant full length infectious clones have been 
described previously12,21. To construct the plasmids p3A-V45A-myc and p3A-H57Y-myc, the 
3A gene containing the V45A or H57Y mutation was amplified using the mutant full length 
clones as a template. The forward primer introduced a SalI restriction site and an ATG co-
don (5’-GGG GGG TCG ACC ATG GGA CCA CCA GTA TAC AGA-3’), and the reverse primer 
introduced a BamHI site (5’-GGG GGG GGA TCC TTG AAA ACC CGC AAA GAG-3’). The PCR 
product was cloned into p3A-myc using restriction enzymes SalI and BamHI. To construct 
pRLuc-53CB3/T7 containing the mutations 3A-V45A or 3A-H57Y for the production of mu-
tant CVB3-Rluc, p53CB3/T7 containing the mutations was digested with XbaI and BstEII. The 
insert encoding the region of 3A with the mutations was ligated into pRLuc-53CB3/T7. The 
presence of the mutations in all constructs and produced virus was confirmed by sequence 
analysis. The plasmids encoding FAPP1-PH-GFP, PI4KIIIβ-HA, PI4KIIIβ-Y583M-HA, and ki-
nase-dead PI4KIIIβ-D656A were kindly provided by Dr. T Balla (NICHD, National Institutes 
of Health, Bethesda, Maryland, USA)33,64. The plasmid encoding PI4KIIβ-myc to verify the 
knock-down efficiency by siRNA-treatment was generously provided by Dr. J Albanesi (UT 
Southwestern Medical Center, Dallas, Texas, USA)65.
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Kinase library screen
The Screen-Well Kinase Inhibitor Library containing 80 kinase inhibitors was purchased 
from Biomol. One h prior to infection, the compounds were added to HeLa cells - seeded 
in 96-well plates - to a final concentration of 10 µM. DMSO was used as a negative control. 
Subsequently, cells were infected with CVB3-Rluc virus at low MOI. After lysing the cells at 
8 h post-infection (p.i.), the intracellular Renilla luciferase activity was determined with the 
Renilla Luciferase Assay System (Promega) according to the manufacturer’s instructions.
Virus infections
Subconfluent layers of cells in 24-well plates were infected with CVB3(-Rluc) at an MOI of 
0.1-1. After 30 min virus adsorption, cells were washed and fresh (compound-containing) 
medium was added to the cells. At 8 h p.i., cells were subjected to three cycles of freeze-
thawing after which virus titers were determined by endpoint titration. Alternatively, cells 
were lysed to determine the intracellular Renilla luciferase activity with the Renilla Luciferase 
Assay System (Promega).
RNA transfection
The full length infectious clones of wt CVB3 p53CB3/T7 and the 3A mutants (V45A, and 
H57Y) were linearized with SalI, purified and transcribed in vitro by T7 RNA polymerase. 
The RNA was transfected into BGM cells in a 24-well plate using the DEAE-dextran method 
as described previously66. After transfection, cells were treated with compounds when indi-
cated, and incubated at 37°C. At 8 h post-transfection, the cells were lysed by three rounds 
of freeze-thawing, after which the samples were subjected to titration analysis.
Immunofluorescence assay
HeLa cells were grown to subconfluency on coverslips in 24-well plates. When indicated, 
cells were transfected with 300 ng DNA per construct using FuGENE (Roche) according to 
the manufacturer’s protocol. After 16 h, cells were treated with compounds for 1 h at 37°C. 
Subsequently cells were fixed with 4% paraformaldehyde and permeabilized with PBS con-
taining 0.1% Triton X-100. In case of the PI4P antibody, 0.2% saponin was used to stain only 
intracellular PI4P. Subsequently, cells were stained with primary and fluorescently-labeled 
secondary antibodies. Nuclei were stained with Hoechst. Cells were analyzed with a wide-
field Leica BMR microscope at 400× magnification. Hoechst, GFP/Alexa Fluor 488, or Alexa 
Fluor 594 were excited through bandpass filters of 360/20 nm, 470/20 nm, or 540/20 nm, 
respectively. Longpass filters of 425 nm (Hoechst), 515 nm (GFP/Alexa Fluor 488), or 590 nm 
(Alexa Fluor 594) were used for the fluorescence emission. Fluorescent images of typical ex-
amples of observations that we consistently obtained in three or more experiments are pre-
sented in the figures. Quantification was performed per condition on 10 cells from different 
experiments using ImageJ software. For the quantification of the amount of Golgi-localized 
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FAPP1-PH-GFP and PI4KIIIβ, the fluorescence intensity of the Golgi-area was divided by that 
of the area of the whole cell. The resulting percentage was set to 100% in untreated cells. 
For the quantification of FAPP1-PH-GFP localized to 3A-containing membranes, we deter-
mined the fluorescence intensities of FAPP1-PH-GFP and 3A(-H57Y)-myc in the myc-stained 
areas and expressed this as a ratio. To quantify the PI4P levels in infected and compound-
treated cells, we determined the ratio between the fluorescence intensities of PI4P and 3A 
in the whole cell.
PI4K in vitro activity assay
A radioactive filter plate assay was used to measure the in vitro activity of the compounds 
on PI4KIIIα and PI4KIIIβ. Fivefold serial dilutions of compounds were added to the wells. 
Recombinant PI4KIIIβ (SignalChem) and the substrate phosphatidylinositol (PI): phosphati-
dylserine (PS) (2 mM PI: 8 mM PS) in 0.3% Triton X-100 were diluted in 20 mM Tris pH 7.5, 5 
mM MgCl2, 5 mM EGTA, 2 mM DTT, 0.04% Triton X-100 to a final concentration of 400 ng/ml 
and 75 µM, respectively. For PI4KIIIα (Millipore), the enzyme and the substrate were diluted 
in 20 mM MOPS pH 7.0, 50 mM NaCl, 2 mM MgCl, 1 mM DTT, 0.04% Triton X-100 to a final 
concentration of 300 ng/ml and 15 µM, respectively. The reaction was started by addition 
of 1-5 µM ATP and 0.25 µCi [33P]- g-ATP, and the mixture was incubated at 30°C for 75-90 
min. After termination of the reaction with phosphoric acid, the samples were transferred 
to filter plates and incorporated radioactivity was measured by TopCount NXT™ Microplate 
Scintillation (PerkinElmer). Data were converted to percent inhibition with respect to posi-
tive (wortmannin) and negative (DMSO) controls.
Replication rescue assay
BGM cells were seeded in 96-well plates and transfected with pEGFP (negative control), 
pPI4KIIIβ-HA, pPI4KIIIβ-Y583M-HA, or kinase-dead PI4KIIIβ-D656A (negative control) on the 
next day. Two days post-transfection, the cells were infected with CVB3-Rluc at an MOI of 
0.1 for 30 min. After virus removal, fresh (compound-containing) medium was added to 
the cells. At 8 h p.i., cells were lysed and the intracellular Renilla luciferase activity was de-
termined with the Renilla Luciferase Assay System (Promega). Similar expression levels of 
the proteins were confirmed in parallel in an immunofluorescence assay using an antibody 
directed against HA.
siRNA-treatment
HeLa cells were reversely transfected with 1 pmol of siRNA per well of a 96-well plate using 
RNAiMAX (Invitrogen) according to the manufacturer’s protocol. Scrambled siRNA was ob-
tained from QIAGEN, while the siRNAs targeting PI4KIIα, PI4KIIIα or PI4KIIIβ were purchased 
from Ambion. At 48 h after siRNA-treatment, cells were infected with either wt CVB3, CVB3 
3A-V45A, or CVB3 3A-H57Y at an MOI of 0.1. At 8 h p.i., cells were freeze-thawed three 
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times to determine total virus titers by end-point titration. To verify efficient knock-down of 
the targets by the siRNA treatment, cells of 6 wells were harvested and pooled using TEN 
buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0, 0.1 M NaCl). Following cell lysis, proteins 
were analyzed by SDS-PAGE (10% polyacrylamide). The proteins were blotted on nitrocellu-
lose membranes (Bio-Rad) and stained with primary and secondary antibodies. Imaging was 
done with the Odyssey System. To verify the knock-down efficiency of PI4KIIβ, cells were 
transfected 24 h after siRNA-treatment with a plasmid encoding PI4KIIβ-myc. At 48 h after 
siRNA-treatment, cells were fixed and stained with an anti-myc antibody.
Cell viability assay
One day after seeding cells in a 96-well plate, the compounds were added to the cells and 
incubated for 8 h. Alternatively, cells were transfected with siRNAs and incubated for 48 h. 
Subsequently, the medium was replaced with CellTiter 96 AQueous One Solution Reagent 
(Promega) and optical densities were measured at 490 nm. The obtained densities were 
corrected for background absorbance from wells that lacked cells. The resulting percentage 
was set to 100% for DMSO-treated cells or for cells that were not transfected with siRNAs.
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Supplemental Figures
Figure S2. Enviroxime, GW5074, and PIK93 do not affect PI4KIIIβ recruitment by wt 3A or 3A-H57Y. 
HeLa cells were transfected with plasmids encoding myc-tagged wt 3A (A) or 3A-H57Y (B). One day 
after transfection, cells were treated for 1 h with compounds and subsequently stained for PI4KIIIβ 
and myc.
Figure S1. Golgi-localization of FAPP1-PH-GFP is predominantly determined by PI4KIIIβ. HeLa cells 
were reversely transfected with siRNAs targeting PI4KIIα, PI4KIIIα, PI4KIIIβ or scrambled siRNA as a 
negative control. The next day, cells were transfected with the plasmid encoding FAPP1-PH-GFP. One 
day later, cells were fixed and analyzed for localization of the FAPP1-PH-GFP. Efficient knock-down 
of the different genes was confirmed by western blot analysis of cell lysates (see also Figure 7D).
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Figure S3. SiRNA-treatment does not induce cytotoxic effects on cells. HeLa cells were transfected 
with scrambled siRNA or siRNA targeting PI4KIIα, PI4KIIβ, PI4KIIIα, or PI4KIIIβ. Two days after 
transfection, the cell viability was determined using CellTiter 96 AQueous One Solution Reagent. Cell 
viability of untransfected cells (no siRNA) was set to 100%
Figure S4. Efficient depletion of PI4KIIβ by siRNA-treatment. HeLa cells were transfected with 
scrambled siRNA or siRNA targeting PI4KIIβ. One day after transfection, cells were transfected with 
a plasmid encoding myc-tagged PI4KIIβ. At 48 hours after siRNA-treatment, cells were fixed and 
stained with an anti-myc antibody.
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Abstract
Members of the enterovirus genus of the family Picornaviridae such as poliovirus, coxsackie-
virus, rhinovirus, and enterovirus 71 pose a serious health threat for which currently no an-
tiviral therapy is available. In this study we found that itraconazole, an antifungal agent that 
is also being explored as an anticancer agent, inhibits replication of several enteroviruses as 
well of cardioviruses. Mechanism of action studies demonstrated that human CYP51, the 
homologue of the fungal target of itraconazole, did not mediate the antiviral activity of itra-
conazole, nor did several other known factors or pathways that are targeted by itraconazole, 
such as the Hedgehog pathway. We show that resistance was conferred by mutations in the 
nonstructural protein 3A that also offered protection to inhibitors of the PI4KIIIβ, a Golgi-
localized lipid kinase that is essential for enterovirus RNA replication. However, itraconazole 
had no effect on the activity of this kinase. Instead, evidence is provided that itraconazole, 
as well as the structurally related posaconazole, inhibit virus replication through oxysterol-
binding protein (OSBP) and OSBP-related protein 4 (ORP4). We show that knockdown of 
OSBP and ORP4, both of which are Golgi-localized proteins containing a PH domain impli-
cated in PI4P binding, potentiated cells to the antiviral effect of ITZ. Furthermore, we show 
that ITZ triggers massive accumulation of OSBP at Golgi membranes. Together, these data 
provide an interesting starting point for further studies into itraconazole or related com-
pounds as an antiviral drug and into the role of OSBP and ORP4 in picornavirus replication. 
Moreover, they provide important new insights into the mechanism of action of itracon-
azole that may be related to its use in anti-cancer therapy.
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Introduction
The family Picornaviridae contains many important human and animal pathogens. The ge-
nus Enterovirus of the picornavirus family includes poliovirus (PV), the causative agent of 
poliomyelitis. A worldwide vaccination scheme run by the World Health Organization has 
dramatically reduced the number of new polio cases from 350,000 a year at the start of the 
initiative in 1988 to 222 in 20121. However, the goal to fully eradicate poliovirus has proven 
troublesome and to this date poliovirus is still endemic in the countries Nigeria, Pakistan, 
and Afghanistan1. Another important pathogen in the enterovirus genus is enterovirus 
71 (EV71). Like PV, this virus is associated with flaccid paralysis, but also diseases such as 
hand-foot-and-mouth disease and encephalitis. Worryingly, multiple outbreaks have been 
reported in recent years, mainly in Southeast Asia. Coxsackieviruses can cause a wide range 
of diseases, including myocarditis and aseptic meningitis. In most cases human rhinovirus 
(HRV) infections manifest as the common cold, but they can lead to severe exacerbations in 
patients with asthma or COPD.
Among the other genera in the picornavirus family are the genera Cardiovirus, Aphtho-
virus, and Hepatovirus. The cardioviruses encephalomyocarditis virus (EMCV) and Theiler’s 
murine encephalomyelitis virus infect mostly pigs and mice, respectively. A few years ago a 
human-tropic cardiovirus, Saffold virus, was identified, but the pathogenicity of the virus is 
still unknown (discussed by Himeda and Ohara2). The best-known aphthovirus is foot-and-
mouth disease virus (FMDV), outbreaks of which have had an enormous economic impact 
on livestock farming. Hepatitis A virus (HAV) is the sole member of the genus Hepatovirus. 
Despite the existence of an effective vaccine available against HAV, an estimated 1.5 million 
clinical cases of hepatitis A occur worldwide annually3.
All in all, infections with picornaviruses and especially enteroviruses, pose a large 
medical burden. Currently, no antiviral compounds have been approved for the treatment 
of infections with enteroviruses or any other picornaviruses and vaccines are only available 
for PV, FMDV, and HAV. Therefore, there is a great need for antiviral compounds against 
picornaviruses, preferably with broad-spectrum antiviral activity.
The genome of picornaviruses consists of a 7-8 kb single-stranded RNA molecule of 
positive polarity. It encodes a single polyprotein which is processed by the viral proteases to 
form the structural proteins (VP1, VP2, VP3, and VP4), the non-structural proteins (2A, 2B, 
2C, 3A, 3B, 3C, 3D, and in some cases L), and some stable precursors. The viral RNA is repli-
cated in replication complexes assembled from viral and host proteins. These complexes are 
located on replication organelles which are formed as a result of virus-induced membrane 
remodeling events. The replication organelles are believed to originate from membranes 
derived from the ER and/or the Golgi complex. In enterovirus infection, the non-structur-
al protein 3A plays a major role in the membrane rearrangements through its interaction 
with GBF1, the guanine exchange factor (GEF) of Arf1 which is a master regulator of ER-to-
Golgi transport4-6. In addition, 3A recruits phosphatidylinositol-phosphate-4-kinase III beta 
(PI4KIIIβ), a Golgi-localized lipid kinase that synthesizes phosphatidylinositol-4 phosphates 
(PI4P), to replication organelles7. Whether the resulting high local levels of PI4P lipids serve 
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to modify membrane structures to facilitate virus replication or another function, e.g., to 
recruit 3Dpol to replication complexes7, remains to be elucidated.
Several compounds with anti-enteroviral activity (GW5074, enviroxime, PIK93, and 
T-00127-HEV1) exert their antiviral activity by inhibiting PI4KIIIβ8,9. Despite the general as-
sumption that viruses are less likely to develop resistance to drugs that target host factors 
rather than viral proteins, multiple enteroviruses acquired resistance to PI4KIIIβ inhibitors 
under selective pressure (see 10). Several mutations in viral protein 3A were found to confer 
resistance to these compounds, e.g., V45A, I54F, and H57Y in CVB3, and A70T in PV10,11. Pre-
viously, we showed that the CVB3 mutants 3A-V45A and 3A-H57Y no longer relied on the 
presence of PI4KIIIβ and high levels of PI4P lipids for efficient replication9, but the underlying 
mechanism is yet unknown.
Besides the compounds mentioned above, there are two other compounds for which 
the antiviral activity is counteracted by the 3A-A70T mutation in PV, i.e., AN-12-H5 and T-
00127-HEV212,13. However, unlike the other compounds, AN-12-H5 and T-00127-HEV2 do not 
inhibit PI4KIIIβ activity. Instead, these compounds target oxysterol-binding protein (OSBP) 
and/or OSBP-related protein 4 (ORP4/OSBP2)13, receptors for sterols (reviewed in10,14,15). 
OSBP and ORP4, which are the two members of subfamily I of the OSBP/ORP family, are 
thought to sense and/or transfer (chole)sterol at ER-Golgi membrane contact sites15, but 
their exact function is unknown.
In this study we set out to identify inhibitors of enterovirus replication which resulted 
in the discovery of the antifungal itraconazole (ITZ) as an antiviral compound. ITZ had broad-
spectrum antiviral activity, inhibiting viruses from both the enterovirus and the cardiovirus 
genus. In search for the underlying molecular mechanism, we excluded known cellular tar-
gets of ITZ to be responsible for the antiviral effect of ITZ. Importantly, we show that ITZ in-
hibited virus replication at the stage of RNA replication and that mutations in the 3A protein 
that were previously shown to confer resistance to PI4KIIIβ inhibitors also provided protec-
tion against ITZ. However, PI4KIIIβ activity was not affected by ITZ. Interestingly, knockdown 
of OSBP or ORP4 enhanced the inhibitory effect of itraconazole on PV replication, and OSBP 
relocalized to the Golgi complex upon itraconazole treatment. Collectively, these data sug-
gest that the antiviral activity of ITZ is mediated through OSBP and ORP4.
Results
ITZ is an inhibitor of enterovirus and cardiovirus replication
We screened the small molecule library NIH Clinical Collection part I to identify inhibitors 
of enterovirus replication. This library consists of 446 highly drug-like compounds that have 
been tested in clinical trials for a large variety of indications. BGM cells plated in 96-well 
plates were infected with CVB3 (10 CCID50/well) and 10 µM of compounds was added to the 
cells. At two days post infection (p.i.) the level of cytopathic effect (CPE) was microscopi-
cally assessed to identify compounds with antiviral activity. One of the hits identified in this 
screen was the antifungal triazole itraconazole (ITZ) (Figure 1).
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Figure 1. Structural formulae.
Table 1. Antiviral activity of itraconazole
Virus Species Cell line EC
50
 (μM)
Enterovirus
EV71 HEV-A BGM 0.30 ± 0.02
CVA16 HEV-A Hela H 0.06 ± 0.01
CVB3 HEV-B Vero 0.79 ± 0.06
E11 HEV-B BGM 0.50 ± 0.05
CVA21 HEV-C Hela R19 0.77 ± 0.11
PV1 HEV-C BGM 1.23 ± 0.59
PV2 HEV-C BGM 1.54 ± 0.02
PV3 HEV-C BGM 0.83 ± 0.09
EV68 HEV-D Hela R19 0.43 ± 0.07
EV70 HEV-D Hela R19 0.92 ± 0.06
HRV14 HRV-B Hela R19 0.64 ± 0.08
Cardiovirus
Mengovirus EMCV BGM 0.57 ± 0.02
Aphthovirus
ERAV-1 ERAV BGM  >80
Shown are mean values calculated from at least three experiments 
± SD. The cytotoxicity values (CC
50
) were >100 μM for all cell lines.
102 Chapter 5
To determine the spectrum of antiviral activity of ITZ, we tested the compound with 
representatives from multiple picornavirus genera in a multicycle CPE-reduction assay. This 
entails infection of cells with virus at low multiplicity of infection (MOI) and quantification of 
CPE at 3 days p.i. (with an MTS-based cell viability assay). ITZ exhibited an antiviral effect 
against all tested enteroviruses from the species human enterovirus (HEV) A, HEV-B, HEV-C, 
Figure 2. ITZ inhibits formation of infectious virus particles of enteroviruses and cardioviruses, 
but not the aphthovirus ERAV. (A) Cell viability of BGM and Hela cells determined with MTS assay 
after an incubation of 8 h with a range of concentrations of ITZ. Values are expressed as percentage 
of untreated cells. (B) BGM cells (CVB3, EV71, EMCV, ERAV) or Hela (HRV2, HRV14, SAFV) were 
infected with virus at MOI 1 and treated with ITZ. Virus titers at 8 h p.i. (or 10 h p.i. for SAFV) were 
determined by endpoint dilution assay. The shaded area indicates the increase in the virus titer after 
8/10 h, with the lower edge and upper edge marking the titers of the untreated controls at 0 and 8 
h p.i., respectively. All experiments were performed in triplicate and shown are mean values ± SD.
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Figure 3. ITZ inhibits virus replication at the stage of RNA replication. (A) ITZ inhibits viral RNA 
replication. BGM cells were transfected with RNA of subgenomic replicons pRib-LUC-CB3/T7 or 
pEMCV-Fluc. After transfection, cells were treated with DMSO or 25 µM ITZ or as positive controls 
2 mM GuHCl (CVB3 replicon) or 80 µM dipyridamole (EMCV replicon). Firefly luciferase levels were 
determined at the indicated time points post RNA transfection. Experiments were performed in 
triplicate and mean values ± SD are depicted. (B) ITZ has no effect on polyprotein processing. BGM 
cells were infected with CVB3 at MOI 50. At 4 h p.i. cells were starved for methionine and cystein for 
30 min. Subsequently, cells were incubated with [35S]methionine to label the produced proteins in 
the presence of DMSO or 25 µM ITZ for another 30 min. Proteins were analyzed by SDS-PAGE.
HEV-D, and HRV-B with EC50 values between 0.3 µM and 1.6 µM (Table 1). The aphthovirus 
equine rhinitis A virus (ERAV) proved insensitive to ITZ, but the cardiovirus EMCV (strain 
mengovirus), was inhibited by ITZ demonstrating that the antiviral spectrum of ITZ encom-
passes multiple picornavirus genera (Table 1). ITZ treatment resulted in some adverse ef-
fects on two Hela cell lines. On Vero and BGM cells CC50 values were >100 µM although cell 
viability was somewhat decreased at higher concentrations (e.g., see Figure 4B). The effect 
of ITZ on cell viability was mainly due to an effect on cell proliferation rather than toxicity 
(data not shown).
To exclude that the antiviral effect observed in the multicycle assays was an indirect 
effect of toxicity, we also determined the effect of ITZ on the production of infectious virus 
particles after 8 h, (which represents a single round of infection). At this time point, no toxic 
effects were detectable on BGM and Hela R19 cells (Figure 2A). Importantly, ITZ displayed 
a similar spectrum as observed in multicycle assays upon determining virus titers of CVB3, 
EV71, HRV2, HRV14, EMCV, and ERAV after 8 h of infection in the presence of the compound 
(Figure 2B). Also replication of Saffold virus (SAFV), another cardiovirus, was impaired by 
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ITZ (Figure 2B). Together, these results show that ITZ has antiviral activity against multiple 
genera, including all tested enteroviruses.
ITZ targets the viral RNA replication stage
In order to pinpoint the stage of replication that is affected by ITZ, we determined its effect 
on the replication of subgenomic replicon RNAs of CVB3 and EMCV, representing the en-
terovirus and cardiovirus genera, respectively. In these replicons, (part of) the area coding 
for the capsid proteins has been replaced by the genetic code for firefly luciferase, expres-
sion of which can be used to assess the level of translation and replication. At 2 h after 
transfection of the replicon RNAs, a time point at which no RNA replication has taken place 
yet16, the firefly luciferase levels were unaffected by treatment with ITZ, indicating that ITZ 
does not inhibit translation of the viral genome (Figure 3A). However, at later time points, 
firefly luciferase production by both replicons was decreased, showing that ITZ affects RNA 
replication.
Impaired RNA replication could be due to a defect in processing of the viral polyprotein. A 
possible effect on CVB3 polyprotein processing was investigated by labeling viral proteins 
with [35S]methionine at 4.5 h p.i., when production of host proteins is severely suppressed 
due to the virus-induced shut-off of cap-dependent translation. The levels of the viral pro-
teins were similar in the absence and the presence of ITZ (Figure 3B), indicating that both 
viral polyprotein synthesis and processing were unaffected. Together, these results show 
that ITZ inhibits the RNA replication stage of enteroviruses as well as cardioviruses.
Mutations in 3A confer resistance to ITZ
The typical next step in unraveling the mechanism of action of a newly identified antivi-
ral compound is resistance culturing. In our experience, many compound-resistant viruses 
harbor mutations either in 2C or 3A8,9,12,13,17-19. We therefore first tested the susceptibility of 
two previously obtained mutants with mutations in 2C (CVB3 2C-A224V,I227V,A229V) or 
3A (CVB3 3A-H57Y) to ITZ10,18. The 2C mutant was not resistant to ITZ(data not shown). For 
testing the 3A-H57Y mutant, we used the recombinant viruses CVB3-Rluc and the 3A-H57Y 
mutant which contain the Renilla luciferase gene upstream of the P1 area so that lucifer-
ase levels produced are a measure of the amount of replication that has taken place. The 
3A-H57Y mutant of CVB3-RLuc proved less sensitive to ITZ than CVB3-RLuc wt (Figure 4A). 
This was corroborated by the observation that in multicycle CPE-reduction assays on BGM 
cells ITZ had lost all activity against the 3A-mutant virus and EC50 values were significantly 
increased from 2.06 ± 0.01 µM for CVB3 wt to >100 µM for CVB3 3A-H57Y (Figure 4B). This 
result implies a link between 3A and the mechanism of action of ITZ.
The mutation 3A-H57Y was previously shown to confer resistance to RNA replication 
inhibitors TTP-8307, enviroxime, GW5074, and PIK939,10. Other mutations that were shown 
to offer protection against these inhibitors include the mutations 3A-V45A and 3A-I54F in 
CVB3 and the mutation 3A-A70T in PV9,10,17. We therefore tested whether subgenomic CVB3 
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and PV replicons that harbor these mutations are cross-resistant to ITZ by measuring lu-
ciferase levels at 7 h post transfection of the replicon RNAs. The mutant replicons indeed 
replicated to higher levels than the respective wt replicons in the presence of ITZ (Figure 4C 
and 4D). Accordingly, the CVB3 mutant replicons proved also cross-resistant to the antiviral 
compounds T-00127-HEV1 and AN-12-H5 for which we previously showed that mutation 
3A-A70T in the PV genome causes a resistant phenotype8,12 (Figure 4C).
ITZ does not inhibit kinase activity of PI4KIIIβ
Enviroxime, GW5074, PIK93, and T-00127-HEV1 exert their anti-enterovirus activity through 
inhibition of the kinase activity of phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ)8,9. PI4KIIIβ is 
an essential host factor for enterovirus replication and is required for the production of 
phosphatidylinositol-4-phosphates (PI4P)7. To study whether ITZ also inhibits PI4KIIIβ activ-
ity, we transfected cells with a plasmid encoding the GFP-tagged pleckstrin homology (PH) 
domain of FAPP1, a genetically encoded sensor for PI4P lipids20. We showed previously that 
the localization of FAPP1-PH-GFP depends on the activity of the IIIβ isoform of PI4K and not 
Figure 4. CVB3 and PV with mutations in the non-structural viral protein 3A are cross-resistant 
to ITZ, AN-12-H5, and T-00127-HEV1. (A) CVB3-Rluc with mutation 3A-H57Y is resistant to ITZ. 
BGM cells were infected with CVB3-Rluc wt and the 3A-H57Y mutant at MOI 0.1. Immediately after 
infection the cells were treated with a range of concentrations of ITZ. Renilla luciferase levels were 
determined at 6 h p.i. and expressed as percentage of DMSO-treated controls. (B) CVB3 3A-H57Y 
displays an ITZ-resistant phenotype in a multicycle CPE-reduction assay. BGM cells were infected 
with CVB3 wt or CVB3 3A-H57Y at low MOI in the presence of a range of concentrations of ITZ and 
cell viability was measured after three days with an MTS assay. (C,D) Mutations in enterovirus 3A 
provide resistance to ITZ, AN-12-H5, and T-00127-HEV1. In vitro transcribed RNA of the subgenomic 
replicons pPV-Fluc mc (wt and 3A-A70T) (C) and pRib-LUC-CB3/T7 (wt, 3A-V45A, 3A-I54F, and 
3A-H57Y) (D) was transfected into RD cells after which the cells were treated with DMSO, 25 µM ITZ, 
25 µM AN-12-H5, or 1.5 µM T-00127-HEV1. At 7 h p.i. firefly luciferase levels were determined and 
plotted as percentage of DMSO-treated controls. All experiments were performed in triplicate and 
shown are mean values ± SD. 
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Figure 5. ITZ has no effect on PI4P levels. (A) ITZ does not affect PI4P levels in uninfected cells. 
Hela R19 cells were transfected with FAPP1-PH-GFP, a genetically encoded sensor of PI4P. The next 
day cells were treated with DMSO, 25 µM ITZ, or 1 µM PIK93 for 1 h and stained with Hoechst and 
an antibody against PI4KIIIβ. (B) ITZ does not affect PI4P levels in infected cells. Hela R19 cells were 
infected with CVB3 at MOI 10 and immediately after infection treated with DMSO or 10 µM ITZ. At 5 
h p.i., the cells were fixed and stained with antibodies against 3A and PI4P.
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on any of the other isoforms9,20. In mock-treated Hela R19 cells, the localization of FAPP1-
PH-GFP overlapped with that of the Golgi-localized PI4KIIIβ (Figure 5), consistent with the 
previously reported localization of PI4P lipids9,20. When cells were treated with PIK93 for 1 
h, the Golgi-localization of FAPP1-PH-GFP was partially or completely lost and the sensor 
was redistributed to the cytoplasm. In addition, PI4KIIIβ showed a more intense staining at 
the Golgi complex which we suggested previously to be the result of a yet to be defined cel-
lular compensatory mechanism9. In contrast, in ITZ-treated cells, FAPP1-PH-GFP localization 
was similar to that observed in DMSO-treated control cells. Furthermore, the intensity of 
PI4KIIIβ staining at the Golgi complex was unaffected.
We also monitored the effect of ITZ on PI4P levels in infected cells. Cells were treated 
immediately after CVB3 infection with 10 µM ITZ and were stained for PI4P lipids at 5 h p.i. 
In this condition, virus replication is not completely blocked (see e.g., Figure 2B or 4A), thus 
permitting the monitoring of PI4P lipids in treated infected cells. Both in untreated and ITZ-
treated cells infected with CVB3, which where visualized by staining of 3A, PI4P levels were 
significantly increased compared to uninfected cells (Figure 5A). These data indicate that, 
despite the cross-resistance of the 3A-mutant viruses, ITZ does not inhibit PI4KIIIβ activity, 
neither in uninfected nor in infected cells.
Virus replication is inhibited by posaconazole, but not ketoconazole, fluconazole, or 
voriconazole
Since ITZ does not impair virus replication through inhibiting PI4KIIIβ activity, we studied 
the possible involvement of reported targets of ITZ. The triazole ITZ is approved for clini-
cal use as an antifungal drug. It inhibits ergosterol synthesis by acting on the fungal cy-
tochrome P450 CYP51, which functions as a lanosterol-14α-demethylase. Ergosterol is an 
important component of fungal cell membranes where it functions similarly to cholesterol 
in animal cells. ITZ also has some inhibitory activity towards the human CYP51 (hCYP51) 
which is involved in synthesis of sterols such as cholesterol, even though reports on the 
potency against hCYP51 vary21-23. In addition, ITZ is an inhibitor as well as a substrate of the 
related cytochrome P450 CYP3A4, an enzyme involved in the metabolism of xenobiotics, 
drugs and carcinogens. Other antifungal azoles also inhibit hCYP51 and CYP3A4 with vary-
ing potencies21-25. A selection of these azoles was tested to determine whether they share 
the antiviral activity of ITZ and whether their potency against hCYP51 or CYP3A4 correlates 
with their antiviral activity. The selection included the triazoles posaconazole, fluconazole, 
and voriconazole and the imidazole ketoconazole (Figure 1). BGM cells were infected with 
CVB3-Rluc wt, the 3A-H57Y mutant or EMCV-Rluc and Renilla luciferase levels were deter-
mined after 6 h of incubation in the presence of compound. Of the tested compounds only 
posaconazole inhibited replication of CVB3-Rluc wt and EMCV-Rluc (Figure 6A and data not 
shown). As observed for ITZ, the H57Y mutation in protein 3A of CVB3 conferred resistance 
to posaconazole. Together with the high structural similarity with ITZ (Figure 1), this sug-
gests that both triazoles exert their antiviral activity through a similar mechanism of action. 
The other antifungal azoles tested had no effect on virus replication. Ketoconazole – which 
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also in a multicycle CPE-reduction assay did not display any antiviral activity against CVB3 
or EMCV (EC50>40 µM) – has been reported to be at least as potent against hCYP51 and 
CYP3A4 as ITZ21-23,25, suggesting that is unlikely that inhibition of the cytochrome P450 en-
zymes hCYP51 or CYP3A4 is the mechanism of action by which ITZ inhibits enterovirus and 
cardiovirus replication. Consistently, we observed that azalanstat, an imidazole developed 
as a potent and specific inhibitor of the human CYP51 (IC50=0.8 nM)
26, did not have any an-
tiviral activity, neither in a single cycle assay with CVB3-RLuc or EMCV-RLuc (Figure 6A and 
data not shown) nor in a multicycle CPE-reduction assay (EC50>500 nM).
Inhibition of the Hedgehog pathway or stimulation of ERα does not inhibit virus 
replication
Besides hCYP51 and CYP3A4, ITZ has been found to inhibit or stimulate multiple oth-
er targets. For instance, ITZ has also been reported to inhibit mTOR and glycosylation of 
VEGFR227,28. The latter was proposed to be the result of a general effect on N-glycan process-
ing at the trans-Golgi network. However, other inhibitors of these targets, i.e., the mTOR 
Figure 6. ITZ does not inhibit virus replication through CYP51/CYP3A4, ERα, or the Hedgehog 
pathway. (A) Only ITZ and posaconazole, but not other azoles that also affect hCYP51/CYP3A4, 
inhibit CVB3 replication. Hela R19 cells were infected with CVB3-RLuc at MOI 0.1 and immediately 
thereafter treated with 10 µM antifungal azoles or 10 nM azalanstat. Renilla luciferase levels were 
determined at 6 h p.i. and expressed as percentage of DMSO-treated infected controls. (B,C) CVB3 
replication is not impaired by treatment with β-estradiol or Hedgehog pathway inhibitors. BGM cells 
were infected with CVB3-RLuc at MOI 0.1 and treated with β-estradiol (B), or DMSO, ITZ (10 µM), 
Sant-1 (100 nM), Sant-2 (100 nM), or cyclopamine-KAAD (100 nM) (C). Renilla luciferase levels were 
measured at 6 h p.i. and expressed as percentage of DMSO-treated infected controls. Experiments 
were performed in triplicate and mean values ± SD are depicted. 
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inhibitor rapamycin and the N-glycosylation inhibitor tunicamycin, have been reported not 
to inhibit virus replication29-31. Furthermore, the ITZ targets p-glycoprotein (ABCB1), UDP-
glucuronosyltransferase (UGT), and estrogen receptor β (ERβ)32-35 are unlikely to mediate 
the antiviral activity of ITZ, because these are at least as potently inhibited by ketocon-
azole32-37, which had no effect on virus replication. For two targets it remained plausible that 
they are responsible for the antiviral effect of ITZ, hence these were further considered.
ITZ is currently under investigation as an anti-cancer drug because of its anti-angio-
genic properties38. The anti-angiogenic effect is at least partially due to an inhibition of the 
Hedgehog pathway39. The Hedgehog signaling pathway plays a role in cell proliferation and 
survival, and is particularly important in embryonic development and cancer cell prolifera-
tion40. ITZ antagonizes this signaling, most likely by acting on the level of Smoothened, a G-
protein-coupled receptor in the Hedgehog pathway39. We tested whether inhibition of the 
Hedgehog pathway had an antiviral effect by measuring virus replication of CVB3-Rluc and 
EMCV-Rluc in the presence of three other antagonists of Smoothened: cyclopamine-KAAD, 
Sant-1, and Sant-241,42. However, these inhibitors did not inhibit replication of CVB3-RLuc or 
EMCV-RLuc, neither on BGM cells nor on the human Hela R19 cells (Figure 6B and data not 
shown).
Recently, Cheng et al. showed that both ITZ, but not ketoconazole, had an agonistic 
effect on ERα32. To test whether this effect could be related to the antiviral activity of ITZ, we 
determined the effect of the endogenous ERα agonist, β-estradiol, on virus replication using 
CVB3-RLuc and EMCV-RLuc. β-estradiol did not affect replication of these viruses (Figure 6C 
and data not shown), not even when using unphysiologically high concentrations up to 100 
nM. Thus, antagonism of Hedgehog signaling and stimulation of ERα do not appear to medi-
ate the antiviral effect of ITZ nor do any of the other to ITZ targets known to us. Therefore, 
we believe ITZ inhibits virus replication through an as yet unidentified target of ITZ.
Knockdown of OSBP enhances the antiviral activity of ITZ against PV
AN-12-H5 and T-00127-HEV2 are two compounds with antiviral activity against enterovi-
ruses that have reduced activity against viruses with mutations in 3A (Figure 4C)12,13. As 
observed for ITZ, these compounds do not inhibit PI4KIIIβ. Recently, we used an siRNA sen-
sitization assay to study if any PI4P-binding proteins were involved in the antiviral activity 
of AN-12-H5 and T-00127-HEV2. Suboptimal concentrations of these compounds inhibited 
virus replication more strongly when the OSBP levels were reduced by siRNA knockdown. 
Therefore, we investigated whether this was also the case for ITZ. To this end, we measured 
replication of PV pseudovirus in the presence of 1.25 µM ITZ in cells in which OSBP or several 
other PI4P-binding proteins were knocked down by siRNA-treatment. Knockdown of OSBP, 
but not any of the other PH domain-containing proteins, enhanced the inhibitory effect of 
ITZ on PV pseudovirus replication, similar as observed for AN-12-H5 (Figure 8A). Knockdown 
of OSBP also enhanced the antiviral activity of T-00127-HEV1, a PI4KIIIβ inhibitor, consistent 
with previous data12,13.A comprehensive testing of all of the members of the OSBP family, 
revealed that also knockdown of ORP4 (OSBP2) sensitized to the antiviral effect of ITZ which 
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is consistent with what was previously observed for the other compounds13. These results 
suggest that OSBP and ORP4 are involved in the mechanism of action of ITZ.
Treatment with ITZ results in a relocalization of OSBP to the Golgi complex
OSBP is a cytoplasmic protein, but can be associated to membranes via ligand binding. Upon 
treatment with its ligand 25-hydroxycholesterol, OSBP relocalizes to the Golgi complex43. 
Using cells overexpressing GFP-tagged OSBP, we observed a massively increased signal for 
OSBP at the Golgi complex, as visualized by staining of PI4KIIIβ, in cells treated for 1 h with 
ITZ (Figure 8). Again, levels of PI4KIIIβ were unaffected by ITZ treatment (Figures 5A and 8). 
Consistent with the pattern observed for the antiviral activity, posaconazole had a similar 
effect as ITZ, but OSBP localization was unchanged in cells treated with either ketoconazole, 
voriconazole or fluconazole. Similar results were obtained using an antibody against OSBP 
(data not shown).
Discussion
In a screen to identify new inhibitors of CVB3, we found that ITZ (used as an antifungal drug) 
inhibited replication. ITZ was found to exert broad-spectrum activity, inhibiting enterovirus-
es as well as cardioviruses. CVB3 variants carrying the H57Y mutation in 3A were resistant 
to ITZ. This mutation was earlier shown to provide resistance to inhibition of PI4KIIIβ, an 
essential host factor for enterovirus replication47. ITZ, however, had no effect on the activity 
of PI4KIIIβ. The possibility that ITZ inhibited virus replication through its inhibitory effect 
on hCYP51 or CYP3A4 was ruled out by the observation that other antifungal azole inhibi-
tors of these factors (i.e., ketoconazole, fluconazole, and voriconazole) did not inhibit virus 
Figure 7. Knockdown of OSBP and ORP4 sensitizes cells to the antiviral effect of ITZ. (A) HEK293 
cells were transfected with siRNAs targeting PI4P-binding proteins. After 72 h, cells were infected 
with PV pseudovirus and incubated in the presence of 1.25 µM ITZ, 1.5 µM AN-12-H5-12-H5, or 0.78 
µM T-00127-HEV1. Normalized PV pseudovirus infection represents the level of firefly luciferase 
activity at 7 h p.i. for compound-treated and siRNA-transfected cells divided by the firefly luciferase 
activity measured in untreated and siRNA-transfected cells. (B) HEK293 cells were transfected with 
siRNAs targeting OSBP family members, infected with PV pseudovirus and incubated in the presence 
of 1.25 µM ITZ. The subfamilies are indicated for the OSBP/ORP family.
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Figure 8. Treatment with ITZ or posaconazole increases OSBP levels at the Golgi complex. Hela 
R19 cells were transfected with OSBP-GFP. The next day, the cells were treated with DMSO, or 10 µM 
of ITZ, posaconazole, ketoconazole, fluconazole, or voriconazole for 1 h. Subsequently, the cells were 
fixed and stained with antibody against PI4KIIIβ.
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Ketoconazole
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OSBP-GFP PI4KIIIβ Merge
Posaconazole
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replication. Also, the possible involvement of other known ITZ targets (e.g., the Hedgehog 
pathway) was ruled out by showing that agonist or antagonists of these targets had no effect 
on virus replication.
While this study was in progress, first evidence for a role of OSBP and ORP4 in entero-
virus replication was reported13. This evidence was obtained in studies on the mechanism of 
action of compounds AN-12-H5 and T-00127-HEV2, both of which were identified as inhibi-
tors of PV replication12,13. Resistance to these compounds was conferred by the mutation 
A70T in 3A, which also offers protection to ITZ and PI4KIIIβ inhibitors8,12,13. However, as we 
observed here for ITZ, these compounds had no effect on PI4KIIIβ activity12,13. Instead, it was 
observed that suboptimal concentrations of AN-12-H5 and T-00127-HEV2 had a stronger 
antiviral effect on PV replication when OSBP or ORP4 was knocked down by siRNA treat-
ment13. Moreover, both compounds were shown to cause relocalization of OSBP13. We here 
observed a similar potentiating effect of ITZ on PV replication upon knockdown of OSBP 
or ORP4, and ITZ also caused massive relocalization of OSBP. Importantly, only the azoles 
that displayed antiviral activity (i.e., ITZ and posaconazole) caused OSBP relocalization, but 
not the azoles that lacked antiviral activity (ketoconazole, voriconazole, and fluconazole). 
Together, these data strongly suggest that ITZ (and posaconazole) inhibits virus replication 
through OSBP and ORP4, similar to AN-12-H5 and T-00127-HEV2.
OSBP and ORP4 together make up subfamily I within the human OSBP family and can 
form heterodimers with each other44,45. OSBP contains a C-terminal sterol binding domain 
and a PH domain for binding of sterols (cholesterol and oxysterols) and PI4P lipids, respec-
tively46-49. There are two splicing variants of ORP4, ORP4L and ORP4S48. Like OSBP, the full-
length splicing variant of ORP4 (ORP4L) contains a sterol binding domain and a PH domain, 
but the PH domain is lacking from the truncated variant ORP4S. Of the two variants, only 
ORP4L is able to bind sterols44,48. Whether it is also capable of binding phosphoinositides 
has yet to be determined. The exact functions of OSBP and ORP4 are not known. They have 
been proposed to sense and/or transfer (chole)sterol at ER-Golgi membrane contact sites15. 
Based on these proposed functions, a possible role of these proteins in virus infection could 
be to alter the membrane lipid composition to optimize it for the formation and/or the func-
tion of the membranous viral replication organelles, making OSBP/ORP4 novel host factors 
for enterovirus and cardiovirus replication. On the other hand, there is also a possibility 
that OSBP and ORP4 are not directly required for viral replication, but that targeting these 
proteins affects the intracellular membranes in such a way that they cannot support virus 
replication.
It is intriguing that the same mutations in the enterovirus 3A protein that confer protec-
tion to PI4KIIIβ inhibitors also lend protection to ITZ (and also AN-12-H5 and T-00127-HEV2). 
The functional interplay between PI4KIIIβ/PI4P and OSBP in virus replication is unknown. 
In an earlier report, OSBP was suggested to be required for maintaining high levels of PI4P 
lipids during virus replication13. This was based on a decrease in PI4P levels observed after 
an overnight treatment with AN-12-H5 or T-00127-HEV2. However, ITZ had no effect on PI4P 
levels, also not after prolonged treatment, arguing against this idea. Based on this latter ob-
servation and on the presence of PH domains in OSBP and ORP4L, the 3A-mediated recruit-
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ment of PI4KIIIβ and the ensuing high levels of PI4P may be involved in mediating binding of 
OSBP/ORP4 to replication organelles. How the requirements for PI4KIIIβ/PI4P and OSBP can 
be bypassed by specific point mutations in 3A remains to be established.
ITZ is currently being explored as an anticancer agent for patients with basal cell car-
cinoma, non-small cell lung cancer, and prostate cancer because of its anti-angiogenic ac-
tivity28,39,50-53. The anti-angiogenic activity of ITZ has been associated with its effects on the 
Hedgehog pathway, mTor, and VEGFR2 function28,39,53,54. These are believed to be a conse-
quence of the effect of ITZ on cholesterol distribution, but the exact mechanism remains to 
be established. Recently, a group of natural products termed ORPphilins were reported to 
inhibit the growth of cultured human cancer cell lines by targeting OSBP and ORP4L, thereby 
implying a role for these proteins in cancer cell survival55. Our observation that ITZ targets 
the sterol-binding proteins OSBP and ORP4 provides a novel explanation for its anti-cancer 
activities that deserves further investigation.
ITZ is an important new tool to further our understanding of picornavirus replication. 
Interestingly, the spectrum of viruses inhibited by ITZ is not identical to that of PI4KIIIβ 
inhibi tors. ITZ inhibited replication of the cardioviruses EMCV and SAFV, whereas PI4KIIIβ 
inhibitors have no effect on these viruses (manuscript submitted). This is an intriguing ob-
servation having in mind that a functional link between the targets is suggested by the fact 
that the same mutations can confer resistance to both groups of inhibitors. The role for 
OSBP and ORP4 in picornavirus replication and the differential requirements for host factors 
between genera of this family need further investigation.
The azoles can be divided into two groups on basis of their antiviral activity: the ac-
tive ITZ and posaconazole and the inactive ketoconazole, voriconazole, and fluconazole. The 
active compounds ITZ and posaconazole are structurally very similar (Figure 1). Since both 
active (ITZ and posaconazole) and inactive (voriconazole and fluconazole) compounds con-
tain a triazole moiety, we cannot draw a conclusion as to whether this is a relevant feature 
for antiviral activity. ITZ and posaconazole both possess a long side chain which is absent 
in voriconazole and fluconazole. Even though ketoconazole contains part of this side chain, 
the compound is inactive against CVB3 and EMCV, suggesting that the additional two rings 
of posaconazole and ITZ and/or the alkyl side chain are important determinants for antiviral 
activity.
A wealth of information has been gathered on the clinical use of ITZ since its discovery 
in 198456. For instance, pharmacokinetic studies have shown that standard antifungal treat-
ment with 200 mg ITZ daily results in a steady-state concentration in the plasma of 2.8 μM. 
Since this concentration had an antiviral effect in vitro, we speculate that ITZ might also 
display antiviral activity in vivo. The steady state concentration of 2.8 µM obtained with 
standard antifungal treatment only results in mild side effects, and ITZ has been reported to 
be safe for use in pediatric patients, the age group in whom enterovirus infections have the 
most severe manifestations57,58. Although its antiviral activity was relatively modest against 
some viruses (e.g., against CVB3), ITZ may provide a novel starting point for the develop-
ment of antiviral drugs to treat enterovirus infections.
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Materials & methods
Cells and reagents
Buffalo green monkey (BGM) kidney cells, HeLa R19 cells, and rhabdomyosarcoma RD 
cells were grown at 37°C, 5% CO2 in DMEM Ready Mix (PAA) containing 10% fetal bovine 
serum. Vero, Hela H and BGM cells used in the multicycle antiviral assays were grown in 
MEM supplemented with 10% FCS (Integro), 2 mM L-glutamine and 20 mM HEPES. The 
following compounds were purchased: itraconazole (Santa Cruz Biotechnology), posacon-
azole (Merck), ketoconazole (Enzo Life Sciences), fluconazole (Pfizer), voriconazole (Pfizer), 
dipyridamole (Sigma Aldrich), guanidine hydrochloride (GuHCl) (Sigma Aldrich), T-00127-
HEV1 (Pharmeks Ltd.), β-estradiol (Sigma Aldrich), Sant-1 (Tocris Bioscience), Sant-2 (Tocris 
Bioscience), and cyclopamine-KAAD (Calbiochem). AN-12-H5 was part of a chemical library 
of the National Institute of Infectious Diseases (Tokyo, Japan). Azalanstat (RS-21607) and 
PIK93 were kind gifts from Dr. S. Sankuratri (Roche Pharma, USA) and Dr. K. Shokat (UC 
Berkeley, USA), respectively. β-estradiol was dissolved according to the manufacturer’s 
instructions. Guanidine hydrochloride was dissolved in water and all other compounds in 
DMSO.
Viruses
CVB3 and CVB3-Rluc, which contains the Renilla luciferase gene upstream of the capsid cod-
ing region, were obtained by transfection of BGM cells with RNA transcripts derived from 
the full length infectious clones p53CB3/T7 and pRLuc-53CB3/T7 linearized with SalI as de-
scribed before59,60. CVB3 and CVB3-Rluc carrying the H57Y substitution in the 3A protein 
were obtained in a similar manner using plasmid p53CB3/T7-3A-H57Y or pRluc-53CB3/T7-
3A-H57Y9,10. EMCV, strain mengovirus, was produced from RNA transcripts of the infectious 
clone pM16.1 (a generous gift from A. Palmenberg), linearized with BamHI. PV pseudovi-
ruses (TE-PV-Fluc mc), i.e., firefly luciferase-encoding PV replicons encapsidated with capsid 
proteins derived from PV1 (Mahoney), were prepared as reported previously61.
The luciferase-expressing EMCV, EMCV-RLuc, was derived from the clone pRLuc-QG-
M16.1. This plasmid contains a cDNA copy of EMCV, strain mengovirus, with an open read-
ing frame that encodes the first six amino acids of the leader protein (L), Renilla luciferase, 
GlnGly (for cleavage by the viral 3C protease) followed by the viral polyprotein (without 
the first Met and amino acids 2-6 of the leader protein encoded by alternative codons to 
prevent recombination). The plasmid was constructed as follows: In the first step, XhoI and 
HpaI sites were introduced into pM16.1 by making the following silent mutations with site-
directed mutagenesis: A738T, A739C, G921T, C922T and T925C (numbering according to 
location in the virus genome). For the second step, a multiple cloning site (XhoI, NheI, SacI/
EcoICRI, NotI), codons for the amino acids GlnGly, and changed codons for amino acids 2-6 
of the leader were introduced into pM16.1(XhoI/HpaI) to generate pM16-MCS-QG-L26. This 
was done by replacing the wt sequence between the XhoI/Hpa sites with an amplicon ob-
tained by PCR from pM16.1(XhoI/HpaI) using forward primer 5’-CGGGCGCTCGAGGCTAGC-
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GAGCTCGCGGCCGCACAAGGCGCAACGACTATGGAGCAAGAGATTTGTGCTCATTCC-3’ (multiple 
cloning site is underlined, codons for GlnGly are in bold, and changed codons for amino 
acids 2-6 of the leader are in italics), and reverse primer 5’-CGGGCGGGCGCCTTGTGTCTC-
GAACACAACTTCC-3’ (HpaI site is underlined). The insert was digested with XhoI and EheI 
and ligated into XhoI and HpaI sites in pM16.1(XhoI/HpaI). For the third step, the Renilla 
luciferase coding region was amplified by PCR from pBind (Promega) with forward primer 
5’-CGGGCGCTCGAGACTTCGAAAGTTTATGATCCAG-3’ and reverse primer 5’-CGGGCGGCG-
GCCGCTTGTTCATTTTTGAGAACTCGC-3’ (XhoI and NotI sites are underlined). Finally, vector 
pM16-MCS-QG-L26 and the Renilla luciferase insert were digested with XhoI and NotI and 
ligated to produce pRLuc-QG-M16.1. Linearization of the infectious clone for in vitro tran-
scription was done with BamHI.
SAFV was described previously62. EV68, EV70, EV71 (strain BrCr), E11 (Gregory) and 
CVA21 (strain Coe) were obtained from the National Institute for Public Health and Environ-
ment (RIVM, the Netherlands). Poliovirus Sabin 1, 2, and 3 strains were obtained from B. 
Rombaut (Vrije Universiteit Brussels, Brussels, Belgium). Human rhinoviruses 2 and 14 were 
a kind gift of Joachim Seipelt (Medical University of Vienna, Austria). ERAV (NM11/67) was 
kindly provided by David Rowlands and Toby Tuthill (University of Leeds, United Kingdom). 
Virus titers were determined by endpoint titration according to the method of Reed and 
Muench and expressed as 50% cell culture infective doses (CCID50).
Antibodies
Primary antibodies used in this study included rabbit polyclonal anti-PI4-Kinase β antibody 
(Upstate), mouse monoclonal α-PI4P antibody (Echelon Bioscience) and rabbit polyclonal 
anti-CVB3 3A5. These antibodies were detected with the secondary antibodies Alexa Fluor 
488- or 594-conjugated goat-anti-rabbit IgG (Molecular Probes) or Alexa Fluor 594-conju-
gated goat-anti-mouse IgM.
Compound library screen
The NIH Clinical Collection part 1 was purchased from the NIH. The 446 highly drug-like 
compounds were screened for inhibitors of CVB3 using reduction of CPE as readout. 
Subconfluent monolayers of BGM cells grown in 96-well plates were infected with 10 CCID50 
of CVB3 per well and compounds were added to a final concentration of 10 µM. The level of 
CPE was visually assessed after two days of incubation at 37°C when full CPE had developed 
in the virus-infected, untreated control wells.
Multicycle CPE-reduction assay
Subconfluent monolayers of the indicated cell lines seeded in 96-well plates were treated 
with serial dilutions of ITZ and infected with virus at the lowest MOI that resulted in full CPE 
within 3 days. The medium contained 2% fetal bovine serum. Subsequently, cells were incu-
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bated at 37°C for three days until complete CPE was observed in the infected and untreated 
virus controls. Cell viability was determined with an MTS assay by incubating the cells with 
AQueous One Solution Cell Proliferation Assay (Promega) and measuring the optical den-
sity of each well at 490 or 498 nm using a microplate reader. Raw optical density values 
were converted to percentage of untreated and uninfected cell controls after subtraction 
of background values obtained with virus controls. The concentration of compound that in-
hibits virus-induced cell death by 50% (50% effective concentration (EC50)) was calculated by 
nonlinear regression analysis. Cytotoxicity of ITZ was assessed in a similar set-up, and 50% 
cytotoxic concentration (CC50) values were derived from cell viability values determined with 
an MTS assay. Each experiment was performed at least in triplicate.
Virus infection
Subconfluent monolayers of cells seeded in 96-well plates were infected with virus at MOI 
0.1-1. After 30 min incubation at 37°C, the virus was removed and fresh (compound-con-
taining) medium was added after which the cells were incubated at 37°C for the indicated 
length of time. For the measurement of infectious virus particles, virus was released from 
the cells by three rounds of freeze-thawing and virus titers were determined by end-point 
dilution assay. In the case of infections with CVB3-Rluc or EMCV-Rluc, cells were lysed at 6 
h p.i. and Renilla luciferase activity was measured with the Renilla Luciferase Assay System 
(Promega) according to the manufacturer’s instructions. Where indicated, a cell viability 
MTS assay was performed in parallel as described above.
Subgenomic replicon assays
Subgenomic replicon assays for CVB3, EMCV and PV were performed as described previous-
ly using the replicons pRib-LUC-CB3/T7 (wt and 3A-H57Y), pEMCV-Luc (a kind gift from Ann 
Palmenberg), and pPV-Fluc mc (wt and 3A-A70T) respectively17,63,64. In these subgenomic 
replicons the P1 area was partially (EMCV) or completely (CVB3 and PV) replaced by the 
sequence encoding the firefly luciferase. The mutation 3A-H57Y was inserted into pRib-LUC-
CB3/T7 plasmid by replacing the wt sequence with an insert with the mutation excised from 
the p53CB3/T7 3A-H57Y mutant with Bst1107I and BlnI. Plasmids were linearized with SalI 
(CVB3), BamHI (EMCV) or DraI (PV) and in vitro transcribed using T7 RNA polymerase.
For CVB3 and EMCV replicons (Figure 3A), BGM cells were transfected with RNA using 
DEAE transfection and incubated with 0.1% DMSO, 25 µM ITZ, 2 mM GuHCl or 80 µM dipyri-
damole at 37°C. At 2, 4, 6 and 8 h post transfection, firefly luciferase activity was analyzed 
using the Luciferase Assay System (Promega).
For CVB3 (wt and 3A-H57Y) and PV (wt and 3A-A70T) replicons (Figure 4B), replicon 
RNA was transfected into RD cells with Lipofectamine RNAiMAX reagent and cells were 
treated with 0.25% DMSO, 1.5 µM T-00127-HEV1, 25 µM ITZ, or 25 µM AN-12-H5. At 7 h 
post transfection, firefly luciferase activity was measured with the Luciferase Assay System 
(Promega).
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Analysis of viral polyprotein processing in vivo
The in vivo metabolic labeling was performed as described previously65. Briefly, BGM cells 
grown in 24-well plates were infected with CVB3 at MOI 50. After 4 h incubation at 37 °C 
cells were starved of methionine and cysteine for 30 min using medium devoid of these 
amino acids. Proteins were then labeled for 30 min using 35S-methionine in the presence 
or absence of compound. At 5 h p.i. cells were lysed. Protein lysates were resolved by SDS-
PAGE (10% polyacrylamide), fixed and analyzed by autoradiography.
Immunofluorescence assay
HeLa R19 grown to subconfluency on coverslips in 24-well plates were transfected with 300 
ng of the plasmid FAPP1-PH-GFP (provided by T. Balla (NICHD, National Institutes of Health, 
Bethesda, Maryland, USA)) using Fugene (Roche) according to the manufacturer’s instruc-
tions20. At 16 h post transfection, the cells were treated with 25 µM ITZ or DMSO for 1 h at 
37°C. Then, cells were fixed with 4% paraformaldehyde and permeabilized with PBS/0.1% 
Triton X-100. Cells were first stained with anti-PI4-Kinase β antibody (Upstate), and then 
with secondary antibody and Hoechst. For the staining of PI4P in infected cells, Hela R19 
cells grown to subconfluency on coverslips were infected with CVB3 at MOI 10 as described 
above. Immediately after infection, cells were treated with DMSO or 10 µM. At 5 h p.i. 
cells were fixed, permeabilized with 0.2% saponin and stained with α-PI4P and α-CVB3 3A 
antibodies followed with secondary antibodies. OSBP-GFP transfected Hela R19 cells were 
treated the next day with 10 µM DMSO or azoles for 1 h. After fixation and permeabilization, 
the cells were stained with PI4KIIIβ antibody, Hoechst, and secondary antibody. Cells were 
analyzed with a Leica BMR microscope.
Target identification by siRNA sensitization (TISS) assay.
TISS assay was performed as previously described13. In short, HEK293 cells in 96-well plates 
were transfected with siRNA pools by using Lipofectamine RNAiMAX transfection reagent 
(Invitrogen) as described5. At 72 h post transfection, these cells were infected with 800 infec-
tious units PV pseudovirus and treated with DMSO, 1.25 µM ITZ, 1.5 µM AN-12-H5-12-H5, or 
0.78 µM T-00127-HEV1. Firefly luciferase activity was measured at 7 h p.i. using Steady-Glo 
Luciferase Assay System (Promega). The effect of siRNA treatment on the sensitivity to each 
compound was determined by calculating the normalized PV pseudovirus infection. This 
number represents the level of firefly luciferase activity for compound-treated and siRNA -
transfected cells divided by the firefly luciferase activity measured in siRNA-transfected cells 
in the absence of compounds.
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Abstract
Although the genus Enterovirus contains many important human pathogens, there is no li-
censed drug for either the treatment or the prophylaxis of enterovirus infections. We report 
that fluoxetine (Prozac)—selective serotonin reuptake inhibitor—inhibits the replication of 
human enterovirus B (HEV-B) and HEV-D but does not affect the replication of HEV-A and 
HEV-C or human rhinovirus A or B. We show that fluoxetine interferes with viral RNA replica-
tion and we identified viral protein 2C as the target of this compound.
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The genus Enterovirus (family Picornaviridae) includes many medically and socioeconomi-
cally important human pathogens (e.g., poliovirus, coxsackievirus, echovirus, rhinovirus and 
enterovirus 71 [EV71]). These can cause a wide range of diseases including acute flaccid 
paralysis, aseptic meningitis, respiratory infections, viral myocarditis, fulminant pancreatitis, 
hand-foot-and-mouth disease, and conjunctivitis. Though often self-limiting, these infec-
tions can result in severe complications that are fatal in some cases fatal. No approved anti-
viral therapeutics currently exist, and treatment remains limited to supportive care.
Enteroviruses are small, nonenveloped viruses. The positive-sense, single-stranded 
RNA genome of around 7.6 kb encodes a single large polyprotein that is autocatalytically 
processed into seven nonstructural (2A to 2C and 3A to 3D) and four structural (VP1 to VP4) 
proteins.
To identify new inhibitors of enteroviruses we screened the 281-compound-containing 
NIH Clinical Collection 2 library (National Institutes of Health) by using a Renilla luciferase-
expressing coxsackie B3 virus (CVB3-Rluc)1. BGM cells were incubated with the different 
molecules (10 µM) and infected with CVB3-Rluc. Luciferase activity was analyzed with the 
Renilla-GloLuciferase Assay System (Promega) at 6 h postinfection (p.i.), a time point at 
which replication is maximal. This assay allows the rapid and cost-efficient antiviral screen-
ing of compound libraries, and allows the detection of inhibitors of viral attachment/entry, 
translation, or replication but not assembly/egress. In parallel, potential cytotoxic effects of 
the drugs were assessed with an 3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium-based assay (CellTiter 96 AQueous One Solution Cell 
Proliferation Assay; Promega). Compounds were selected for further study if they reduced 
luciferase activity by more than 10-fold, had little or no cytotoxicity, and displayed repro-
ducible activity when purchased from another vendor. Using these criteria, we identified 
fluoxetine HCl, a selective serotonin reuptake inhibitor (brand name, Prozac) that is used for 
the treatment of major depression and anxiety disorders (MedlinePlus drug information, 
http://www.nlm.nih.gov/medlineplus/druginfo/meds/a689006.html) as an inhibitor of in 
vitro CVB3 replication. Fluoxetine HCl was recently also identified as inhibitor of CVB3 in an 
independent screening2.
To evaluate the activity of fluoxetine in more detail, we performed a cytopathic-effect 
(CPE)-based multicycle antiviral assay3. The compound inhibited the CPE of CVB3 on Vero 
cells with a 50% effective concentration (EC50) of 3.36 ±0.47 µM (50% cytotoxic concentra-
tion [CC50], 28 µM) (Table 1). Antiviral activity was confirmed on CVB3-infected HeLa R19 
and BGM cells (data not shown). CVB3 is a member of the species HEV-B. Fluoxetine proved 
also active against the other HEV-Bs tested, echovirus 1 (E-1), E-9 and E-9, as well as against 
members of the species HEV-D, EV68 and EV70. However, no activity against members of 
other enterovirus species, i.e., HEV-A and HEV-C and human rhinovirus A (HRV-A) or HRV-
B, was detected. To confirm this antiviral activity further, the effect of fluoxetine in a single 
cycle of viral growth was assessed. BGM or HeLa R19 cells were infected at a multiplicity 
of infection (MOI) of 4 and then incubated with or without the compound for 8 h at 37°C. 
Viruses were then collected by freeze-thawing, and titers were determined by endpoint 
titration4. In the presence of 3 or 10 µM fluoxetine, the titers of CVB3 were reduced by more 
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than 3 log10 units (Figure 1A). Consistent with the CPE-based antiviral assay, no inhibitory ef-
fect on members of the HEV-A or HRV species was observed. Fluoxetine proved also inactive 
against more distantly related picornaviruses, i.e., encephalomyocarditis virus (EMCV; genus 
Cardiovirus) and equine rhinitis A virus (ERAV; genus Aphthovirus). We then tested the ef-
fect of fluoxetine on CVB3 replication in a single-cycle assay over a range of concentrations. 
An EC50 of 1.23 ± 0.38 µM was calculated (Figure 1 B), which is comparable to the effect 
observed in the multicycle assay.
To gain insight into the mode of action of fluoxetine, we tested its effect on the replica-
tion of CVB3 RNA with a firefly luciferase-expressing CVB3 replicon5. In this replicon, firefly 
luciferase is encoded in the modified polyprotein in place of the structural proteins, and 
thus, luciferase levels correspond to the amount of genomic RNA that is synthesized. Fluox-
etine significantly reduced luciferase activity compared to that of the control (Figure 1C), in-
dicating that it inhibits RNA replication. In fact, at a concentration of 3 µM the antiviral activ-
ity of fluoxetine was comparable to that of the well-established enterovirus RNA replication 
inhibitor, guanidine hydrochloride (GuHCl). No change in luciferase counts was observed in 
fluoxetine-treated controls in which RNA replication had been inhibited by the addition of 
GuHCl, confirming that the observed reduction of firefly luciferase activity was not due to an 
effect of the compound on translation or luciferase enzymatic activity (Figure 1D).
To test whether the observed inhibition of RNA synthesis is a result of inhibition of 
polyprotein processing, we labeled CVB3-infected cells with [35S]methionine and incubated 
them with fluoxetine between 4.5 and 5 h p.i., a time when replication is in the logarithmic 
phase and host protein synthesis shutoff has occurred. No change in viral polyprotein pro-
Table 1. Antiviral and cytotoxic activities of fluoxetine against 
various enteroviruses
Virus Species Cell line EC
50
 (μM) CC
50
 (μM)
EV71 HEV-A RD  >40 >40
CVA16 HEV-A Hela Rh  >40 >40
CVB3 HEV-B Vero 3.36 ± 0.47 28
E-1 HEV-B BGM 3.39 ± 0.35 28
E-9 HEV-B BGM 4.58 ± 0.09 28
E-11 HEV-B BGM 5.76 ± 0.22 28
PV1 HEV-C BGM  >28 28
PV2 HEV-C BGM  >28 28
PV3 HEV-C BGM  >28 28
EV68 HEV-D Hela R19 1.35 ± 0.08 29
EV70 HEV-D Hela R19 0.81 ± 0.06 29
HRV2 HRV-A Hela Rh  >40 >40
HRV14 HRV-B Hela Rh  >40 >40
Data are mean values ± standard deviation of at least three 
independent experiments
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cessing was observed (data not shown). We therefore conclude that fluoxetine inhibits viral 
RNA replication but that this inhibition is not due to an effect on polyprotein processing.
When comparing the chemical structure of fluoxetine with that of known inhibi-
tors of enterovirus RNA replication, we noted a certain degree of similarity to TBZE-029 
{1-(2,6-difluorophenyl)-6-(trifluoromethyl)-1,3-dihydro-[1,3]thiazolo[3,4-a]benzimidazole}, 
a viral protein 2C-targeting molecule (Figure 2A). Saliently, TBZE-029 inhibits enteroviruses 
belonging to the species HEV-B and HEV-D, but not those belonging to the species HEV-A 
and HEV-C (3, A.M. De Palma, unpublished data). To study whether mutations in 2C that 
confer resistance to TBZE-029 confer cross-resistance to fluoxetine, BGM cells were trans-
Figure 1. Effects of fluoxetine on selected picornaviruses in a single-cycle assay. (A) Single-cycle 
assay of the effects of 10 µM fluoxetine on the indicated viruses. Briefly, cells were infected with 
the indicated viruses at an MOI of 4 CCID
50
 per cell and treated with fluoxetine or mock treated. 
Viruses were harvested at 8 h p.i. and virus titers were determined by endpoint titration. Assays 
were performed in triplicate and means and standard deviations were calculated. (B) Single-cycle 
assay of the effect of fluoxetine on CVB3 over a range of concentrations. The shaded area shows 
the increase of virus titer after 8 h, where the lower edge and upper edge indicate the titers of 
the untreated controls at 0 h and 8 h p.i. respectively. Assays were performed in triplicate and 
means and standard deviations were calculated. (C) BGM cells were transfected with in vitro-
transcribed CVB3-Luc replicon RNA and treated with the respective compounds. In this replicon, the 
coding region of the structural proteins has been replaced with that of firefly luciferase. The well-
characterized enterovirus inhibitor GuHCl was used at 2 mM as a positive control. At the indicated 
times posttransfection, firefly luciferase activity was determined (displayed in relative light units 
[RLU]). Assays were performed in triplicate and means and standard deviations were calculated. 
(D) Fluoxetine does not affect firefly luciferase activity. BGM cells were transfected with CVB3-Luc 
replicon RNA and treated with the replication inhibitor GuHCl and 3 or 10 µM fluoxetine or 0.1% 
DMSO. Firefly luciferase activity was analyzed 8 h after transfection.
B
A
C D
128 Chapter 6
Figure 2. Fluoxetine inhibits CVB3 by acting on viral protein 2C. (A) Structural formulae of fluoxetine 
and TBZE-029. (B) Schematic of the organization of the genome of CVB3 (top) and of protein 2C 
(bottom). The locations of conserved ATPase motifs A, B and C; active site residue K135; and the 
residues substituted in the TBZE-029-resistant virus (A224V, I227V, and A229V) are indicated. Amino 
acids are numbered according to their positions in protein 2C. (C) BGM cells were transfected with in 
vitro-transcribed full-length genomic RNA of WT CVB3, 2C_A224V,I227V,A229V or 3A_H57Y mutant 
(mut) virus and treated with 3 µM fluoxetine or 0.1 % DMSO. At 8 h p.i., cells were lysed and the virus 
titer was determined by endpoint titration. Titers are displayed as log CCID
50
 per milliliter and means 
and standard deviations were calculated from three replicates. (D) Analysis of the effect of fluoxetine 
on the ATPase activity of protein 2C with Pi ColorLock Gold (Innova Biosiences) in a reaction mixture 
containing 3 µM recombinant protein, 1 mM ATP, 10 mM HEPES (pH 7.5), 150 mM NaCl, and 10 mM 
MgCl
2
. Where indicated, 25 µM fluoxetine was added. Phosphate release was measured through 
determination of absorption at 635 nm at the indicated time points. The background of spontaneous 
phosphate release was subtracted. (E) The assay was performed essentially as described for panel 
D, except that the concentration of fluoxetine was varied as indicated. Absorption was measured 
after 30 min.
BA
C D
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fected with in vitro transcribed full-length genomic RNA of (i) wildtype (WT) CVB3, or the 
(ii) 2C-A224V,I227V,A229V or (iii) 3A-H57Y mutant virus (as a control)6,7. Following transfec-
tion, cells were treated with 3 µM fluoxetine or mock treated. At 8 h p.i., cells were lysed 
and virus titers were determined by endpoint dilution assay. In the presence of fluoxetine, 
the 2C mutant virus replicated to titers similar to those of the control samples, whereas WT 
CVB3 titers were markedly decreased (>4 log10 units) in the presence of fluoxetine (Figure 
2B). Also, the replication of the 3A-H57Y mutant virus was efficiently inhibited. Thus amino 
acid substitutions in protein 2C confer resistance to the compound.
The precise function of protein 2C in the viral life cycle is unknown. Protein 2C has 
been shown to bind to membranes and viral RNA8-12 and to interact with several viral and 
host proteins13-17, and has been implicated in RNA replication, viral rearrangement of in-
tracellular membranes, and genome encapsidation12,14,18-20. Protein 2C is highly conserved 
among enteroviruses. In particular, it contains three highly conserved motifs typical of AAA+ 
translocases, i.e., proteins that use the energy of ATP hydrolysis to translocate along other 
molecules (Figure 2B)21. Congruously, ATPase activity has been confirmed for the 2C proteins 
of several enteroviruses in vitro6,11,22-26. The substitutions that confer resistance to fluoxetine 
are located close to motif C, raising the possibility that this compound affects ATPase activ-
ity. To test this, we analyzed the effect of fluoxetine on the ATPase activity of a CVB3 2C 
recombinant protein from which the 36 N-terminal amino acids were removed (2C-Del36). 
The remaining part of the protein contains the ATPase domain. The sequence was cloned 
downstream of a cleavable thioredoxin coding sequence. The protein was purified under 
nondenaturing conditions in accordance with a previously described protocol27. The mutat-
ed CVB3 protein 2C-Del36 (K135A) was included as an ATPase-negative control, as residue 
K135 is located in motif A and is crucial for ATPase activity24. At 25 µM, nearly 10 times the 
physiological concentration needed for full inhibition of virus replication, phosphate release 
was reduced by only 50% compared to that of the dimethyl sulfoxide (DMSO)-treated con-
trol (Figure 2D). Indeed, at 3 µM, the concentration needed for full inhibition of virus repli-
cation in a single-cycle assay, ATPase activity was reduced by only 15% (Figure 2E). Even at 
the highest concentration tested, 500 µM, ATPase activity was not reduced by more than 
50%. Thus, while some effect of fluoxetine on ATPase activity could be observed, it appears 
unlikely that, as for TBZE-0296, this is the major mechanism of action of this compound.
The effect of various 2C-targeting compounds on 2C’s ATPase activity remains con-
troversial. For example, GuHCl was reported to inhibit the ATPase activity of protein 2C of 
poliovirus type 1 in one study25, whereas it failed to elicit an effect in another11. For other 
2C-targeting inhibitors, i.e., compounds to which resistance was provided by mutations in 
the ATPase domain, no effect on ATPase activity was reported6,11,23. The precise molecular 
mechanism by which these 2C-targeting compounds, including fluoxetine, inhibit viral repli-
cation therefore remains to be established.
The amino acids in protein 2C whose substitution confers resistance to fluoxetine, i.e., 
A224, I227, and A229, are located in a short stretch of amino acids 224AGSINA229 located im-
mediately C terminal of ATPase motif C. The AGSINA motif is conserved in HEV-B and HEV-D 
but is not present in other enteroviruses. The finding that the substitution of some of these 
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residues confers resistance to fluoxetine suggests that they play a role in the sensitivity of 
these viruses to this inhibitor. To test whether the AGSINA motif sensitizes enteroviruses 
to TBZE-029 and fluoxetine, we introduced this motif into the poliovirus replicon. Unfortu-
nately, this mutant construct failed to replicate. Further work, in particular, the elucidation 
of the structure of this protein, is required to resolve this question.
While this report was in preparation, Zuo et al. reported the inhibitory activity of fluox-
etine on RNA replication of CVB1, CVB2, and CVB3, all serotypes of the species HEV-B26. A 
broader analysis of the activity against related species was not undertaken in that study. One 
of the authors of that paper speculated that other serotonin reuptake inhibitors might also 
inhibit enterovirus replication (California NanoSystems Institute webpage, http://www1.
cnsi.ucla.edu/news/item?item_id=207399629). Our finding that fluoxetine selectively in-
hibits HEV-B and HEV-D shows that key differences between closely related enteroviruses 
may exist and emphasize the importance of analyzing representatives of different species 
belonging to this genus. On the basis of the idea that fluoxetine appears to act on a viral 
protein and not on a cellular host factor, we deem it unlikely that other selective serotonin 
reuptake inhibitors would exhibit an antiviral effect, unless they are similar in structure to 
fluoxetine. In fact, we did not observe any inhibitory activity of three other selective sero-
tonin reuptake inhibitors, i.e., citalopram (EC50, >160 µM; CC50, >160 µM), paroxetine (EC50, 
>22.18 µM; CC50, 22.18 ± 0.41 µM), and sertraline (EC50, >17.12 µM; CC50, 17.12 ± 1.17 µM), 
on CVB3, which is further evidence that the antiviral effect of fluoxetine relates to its specific 
pharmacophore interacting with 2C and that the antiviral effect is unrelated to serotonin 
uptake.
Plasma fluoxetine levels in patients receiving the standard dose of 20 mg/day have 
been reported to be in the mid-to-high nanomolar range28 and are thus lower than the 
EC50s for inhibition of enterovirus replication determined in this study. Additionally, fluox-
etine, like other selective serotonin reuptake inhibitors, has been associated with side ef-
fects that might impede its use as an antiviral drug for the treatment of enterovirus in-
fections. Thus, rather than a treatment option, in its current form, fluoxetine provides a 
new scaffold for the design of compounds acting on viral protein 2C. Fluoxetine showed 
an intriguing specificity for enterovirus species B and D, a characteristic shared with 
the—chemically somewhat similar—antiviral TBZE-029. Intriguingly, the TBZE-029- and 
fluoxetine-resistant 2C-A224V,I227V,A229V mutant virus exhibits cross-resistance to HBB 
{2-(alpha-hydroxybenzyl)-benzimidazole}, MRL-1237 {1-(4-fluorophenyl)-2-[(4-imino-1,4-
dihydropyridin-1-yl)methyl]benzimidazole hydrochloride}, and GuHCl6, 2C-targeting com-
pounds that do not possess this sensitivity profile of fluoxetine and TBZE-029. Thus, while 
drug development is generally directed toward compounds targeting a broad range of spe-
cies, we would argue that elucidation of the molecular determinant of this specificity will 
provide information invaluable for the rational design of—at will—narrow or broad range 
inhibitors.
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Abstract
The genus Enterovirus of the family Picornaviridae contains many important human patho-
gens such as poliovirus, coxsackievirus, rhinovirus, and enterovirus 71. Currently, there are 
no antiviral drugs available for the treatment or prevention of infections with these viruses. 
Here, we report a small molecule, GPC-N114 (2,2’-[(4-chloro-1,2-phenylene)bis(oxy)]bis(5-
nitro-benzonitrile)), that exerts broad-spectrum anti-enterovirus activity. GPC-N114 also in-
hibited the replication of viruses of the genus Cardiovirus, but not of the genus Aphthovirus. 
Using subgenomic replicons, we show that GPC-N114 exerted its inhibitory activity at the 
RNA replication stage. Coxsackievirus B3 (CVB3), an enterovirus, has a high genetic barrier 
to resistance against GPC-N114, whereas EMCV, a cardiovirus, rapidly acquired resistance 
due to mutations in the viral RNA-dependent RNA polymerase 3Dpol (M300V and I304V). In 
vitro polymerase assays demonstrated that GPC-N114 inhibited the elongation activity of 
both CVB3 and EMCV 3Dpol, and that mutations M300V and I304V reduced the susceptibility 
of EMCV 3Dpol to the inhibitor. Furthermore, these assays showed that GPC-N114 inhibited 
polymerase activity by affecting the binding of the RNA template-primer duplex to 3Dpol. 
Analysis of co-crystals of the polymerase and GPC-N114 revealed that the binding site of 
the compound overlapped with that of the template, providing a rationale for the mode of 
inhibition. This study presents the first picornavirus inhibitor that acts by interfering with 
binding of the RNA template-primer and identifies a new pocket that can be used for the 
design of broad-spectrum inhibitors of picornavirus replication.
Significance Statement
No antiviral drugs are available for the treatment or prevention of infections with enterovi-
ruses, a group of viruses which can have severe clinical manifestations. Here, we present the 
small molecule GPC-N114, a broad-spectrum inhibitor of enterovirus and cardiovirus repli-
cation. We show that GPC-N114 impairs the activity of the viral RNA-dependent RNA poly-
merase 3Dpol by interfering with binding of the RNA template-primer. This makes GPC-N114 
the first anti-picornaviral compound with this mechanism of action. Moreover, the identi-
fication of the pocket targeted by this compound can serve as a valuable starting point for 
antiviral drug development.
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Introduction
The family Picornaviridae contains 12 genera, and includes many human and animal patho-
gens (reviewed in 1). Among these is the genus Enterovirus which contains four human en-
terovirus species (HEV-A, -B, -C, -D), three human rhinovirus species (HRV-A, -B, -C), simian 
enterovirus, bovine enterovirus, and porcine enterovirus. The HEV species include polio-
virus (PV), coxsackievirus (CV), echovirus, and several numbered enteroviruses (EV). PV is 
the cause of poliomyelitis, which can lead to acute flaccid paralysis. Enterovirus 71, a major 
cause of hand-foot-and-mouth disease, is also frequently associated with flaccid paralysis 
and is a growing concern due to major epidemics in Southeast Asia. Coxsackieviruses are 
the main cause of viral meningitis, conjunctivitis, herpangina, myocarditis, and pancreatitis. 
HRV infections manifest themselves in most cases as the relatively mild common cold, but 
can cause serious exacerbations in patients with asthma or chronic obstructive pulmonary 
disease (COPD). Other well-known picornavirus genera are Hepatovirus, which contains 
hepatitis A virus, Aphthovirus, which contains foot-and-mouth disease virus (FMDV), and 
Cardiovirus, which includes encephalomyocarditis virus (EMCV), Theiler’s murine encepha-
lomyelitis virus, and the recently discovered Saffold virus (SAFV), which, unlike the other 
cardioviruses, is a human-tropic virus.
Currently, the toolbox to control picornavirus infections consists solely of vaccines 
against PV, hepatitis A virus, and FMDV. Prevention of diseases caused by the non-polio en-
teroviruses through vaccination seems unachievable given the great number of serotypes, 
with about 30 coxsackieviruses, 30 echoviruses, 50 numbered enteroviruses, and more than 
150 rhinoviruses2. With this in mind, current efforts are aimed at developing antiviral com-
pounds with broad-spectrum activity, targeting a wide range of viruses within a genus or 
ideally even multiple genera. No specific antiviral drugs have yet been clinically approved for 
the treatment of enteroviruses or any other picornavirus.
Picornaviruses are non-enveloped RNA viruses with a single-stranded 7-8 kb RNA ge-
nome of positive polarity. Upon entry, the viral RNA is translated into a polyprotein which 
is proteolytically processed by viral proteases to release the structural proteins (VP1-4) and 
the non-structural proteins (2A-2B-2C-3A-3B-3C-3Dpol and in some genera L) as well as some 
stable precursors. The genome is replicated via a negative-sense RNA intermediate by 3Dpol, 
the viral RNA-dependent RNA polymerase (RdRP). For this, 3Dpol uses the viral protein 3B, in 
this context usually termed VPg (viral protein genome-linked), as a primer.
The structure of 3Dpol has been studied extensively in the past decades. Crystal struc-
tures have been reported of 3Dpol of the enteroviruses CVB3, PV, EV71, HRV1B, HRV14, and 
HRV16, and of the aphthovirus FMDV3-10. These enzymes adopt a classical right hand archi-
tecture, with fingers, palm and thumb subdomains providing the correct geometrical ar-
rangement of substrate molecules and metal ions at the polymerase active site for cataly-
sis11. In addition, in all picornavirus RdRPs, the conformation of the right hand is closed by 
the connection of fingers and thumb sub-domains through the N-terminal portion of the 
protein and several loops protruding from fingers, named the fingertips. This connection 
leads to the formation of a completely encircled active site and largely restricts the inter-
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domain mobility. Three well-defined channels have been identified in the RdRP structures 
that allow access to the active site of the incoming rNTPs and the RNA template, as well as 
the exit path of the newly synthesized dsRNA product11. Seven conserved structural ele-
ments, termed motifs A–G, have been defined. Motifs A–E, located in the palm subdomain, 
are involved in nucleotide and nucleic acid binding as well as catalysis. Motifs F and G, lo-
cated in the fingers, play a critical role in the binding of nucleoside triphosphates and RNA 
templates12.
Given its critical role in genome replication, 3Dpol is regarded as an attractive target for 
antiviral drugs. Polymerase inhibitors can be subdivided into two classes. One class contains 
the nucleoside/nucleotide analogs, which compete with endogenous nucleotides and act 
as chain terminators and/or mutagens. One example in this class is ribavirin which induces 
lethal mutagenesis13. The second class of polymerase inhibitors are the non-nucleoside in-
hibitors (NNI) which can have a variety of mechanisms of action, e.g., stabilizing the enzyme 
such that necessary conformational changes cannot take place14. A few NNIs active against 
picornaviruses have been discovered, but for most of them, the mechanism of action re-
mains poorly characterized15-21. In this study, we describe a small molecule, GPC-N114, that 
inhibits replication of all enteroviruses tested as well as that of members of the cardiovirus 
genus. Both resistance mapping and biochemical assays indicate that the antiviral activity 
of GPC-N114 is mediated by inhibition of 3Dpol. GPC-N114 does not compete with NTPs but, 
instead, interferes with template-primer binding which is in agreement with the binding site 
on CVB3 3Dpol determined by X-ray crystallography.
Results
GPC-N114 is an inhibitor of enterovirus and cardiovirus replication
We recently described a series of 5-nitro-2-phenoxybenzonitriles that inhibited enterovi-
rus replication22. A further structure-activity relationship study (to be published elsewhere) 
led to the identification of 2,2’-[(4-chloro-1,2-phenylene)bis(oxy)]bis(5-nitro-benzonitrile), 
hereafter referred to as GPC-N114 (Figure 1A), with potent and selective antiviral activity 
against CVB3. This small molecule inhibits CVB3 replication in multicycle CPE-reduction anti-
viral assay with a 50% effective concentration (EC50) of 0.15 ± 0.02 µM (Table 1).
To study its spectrum of activity, GPC-N114 was evaluated in similar multicycle anti-
viral assays with representatives of the different HEV and HRV species, as well as several 
other picornaviruses. All enteroviruses and rhinoviruses included in this study were found 
to be sensitive to the inhibitory effect of GPC-N114, with EC50 values ranging from 0.1 µM to 
1.7 µM (Figure 1B and Table 1). GPC-N114 also inhibited replication of EMCV (strain men-
govirus), a member of the genus Cardiovirus (EC50=5.4 ± 0.49 µM). In contrast, FMDV and 
equine rhinitis A virus (ERAV), two members of the genus Aphthovirus, proved insensitive 
to its inhibitory effect (tested up to 25 μM and 100 µM, respectively). GPC-N114 had little 
adverse effects on most of the cell lines used, with the exception of Hela cells, a cell line on 
which compounds in our experience generally have stronger cytostatic or cytotoxic effects.
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To evaluate the antiviral effect of GPC-N114 in a single round of replication, CVB3 and 
EMCV, as representatives of the enterovirus and cardiovirus genus, were incubated in the 
presence of different concentrations of the compound and virus titers were determined at 
8 h post infection (p.i.). Cell viability assays performed in parallel showed that GPC-N114 
was not toxic at these concentrations (Supplementary Figure S1A). For CVB3, the maximal 
inhibitory effect was obtained with concentrations of 3 µM and higher, although replication 
was not fully abrogated (Figure 1C). Replication of EMCV was fully inhibited at concentra-
tions of 10 µM or higher (Figure 1C). Therefore, a concentration of 10 µM was selected for 
all further cellular assays. Detailed analysis of the kinetics of CVB3 and EMCV replication at 
this concentration showed that GPC-N114 strongly delayed virus replication (Figure 1D and 
Supplementary Figure S1B). Comparable results were observed for a panel of other entero-
viruses (EV71, CVA21, HRV2, and HRV14) and cardioviruses (EMCV and SAFV) (Figure 1E and 
Supplementary Figure S1B). Again, no antiviral activity was observed against the aphthovi-
rus ERAV (Figure 1E).
Together, these results demonstrate that GPC-N114 exerts broad-spectrum antiviral 
activity, inhibiting the replication of a representative panel of viruses belonging to the en-
terovirus and cardiovirus genera from the picornavirus family.
Table 1. Antiviral activity of GPC-N114
Virus Species Cell line EC
50
 (μM)
Enterovirus
EV71 HEV-A RD 0.13 ± 0.05
CVA16 HEV-A Hela H 0.21 ± 0.02
CVB3 HEV-B Vero 0.15 ± 0.02
E11 HEV-B BGM 0.93 ± 0.01
CVA21 HEV-C Hela R19 0.94 ± 0.23
PV1 HEV-C BGM 1.00 ± 0.60
PV2 HEV-C BGM 0.88 ± 0.32
PV3 HEV-C BGM 0.26 ± 0.01
EV68 HEV-D Hela R19 1.44 ± 0.13
EV70 HEV-D Hela R19 1.55 ± 0.28
HRV2 HRV-B Hela R19 0.55 ± 0.03
HRV14 HRV-B Hela R19 1.73 ± 0.25
Cardiovirus
Mengovirus EMCV BGM 5.44 ± 0.49
Aphthovirus
FMDV-O FMDV BHK-21 >25
FMDV-A FMDV BHK-21 >25
ERAV-1 ERAV BGM >100
Shown are mean values calculated from at least three experiments ± SD. 
The cytotoxicity values (CC
50
) were for Hela H cells 8.54 ± 0.42 μM, for 
Hela R19 cells 7.07 ± 0.38 μM, and for RD, BGM, and Vero cells >100 μM
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Figure 1. GPC-N114 inhibits picornavirus replication. (A) Structural formula of GPC-N114. 
(B) Representative curves of multicycle CPE-reduction assays for CVB3, PV1, and EV71. CPE was 
quantified by MTS assay at 3 d p.i. and expressed as percentage of uninfected, untreated controls. 
(C,D) Antiviral activity of GPC-N114 against CVB3 and EMCV. BGM cells were infected with CVB3 (left 
panels) or EMCV (right panels) at an MOI of 0.1. Immediately after infection, GPC-N114 was added at 
the indicated concentrations (C) or at 10 µM (D). The enterovirus inhibitor GuHCl and the cardiovirus 
inhibitor dipyridamole were included as controls. Virus titers were determined by endpoint titration 
after 8 h (C) or at the indicated times p.i. (D). Experiments were performed in triplicate and mean 
values ± SD are depicted. (E) Antiviral activity of GPC-N114 against a range of picornaviruses. Cells 
were infected with the indicated viruses at an MOI of 0.5 after which 10 µM GPC-N114 was added. 
Virus titers were determined at 8 h p.i.. Experiments were performed in triplicate and mean values 
± SD are depicted. Continued on the next page...
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GPC-N114 targets the RNA replication stage of the virus replication cycle
To identify the stage of the replication cycle that is targeted by GPC-N114, we used CVB3 
and EMCV subgenomic replicons in which (a part of) the P1 coding region has been replaced 
with the firefly luciferase gene. Luciferase expression thus allows to quantify replication and 
translation of the viral RNA. At 2 h post-transfection, a time point when no RNA replication 
has taken place yet23, luciferase production from both replicons due to translation of incom-
ing RNA was comparable in the presence and absence of GPC-N114 (Figure 1F), suggesting 
that GPC-N114 does not affect translation. However, at later time points, luciferase levels 
were decreased in GPC-N114-treated cells in comparison with mock-treated control cells for 
both the CVB3 and the EMCV replicon. In agreement with the single cycle assays, the EMCV 
replicon proved more sensitive to the inhibitory effect of GPC-N114 than the CVB3 replicon. 
These results indicate that GPC-N114 targets the viral RNA replication stage.
To determine whether the impaired replication in the presence of GPC-N114 is due to 
a defect in the processing of the viral polyprotein, we visualized the viral proteins by meta-
bolic labeling. CVB3-infected BGM cells were pulse-labeled with [35S]Met in the presence 
or absence of the compound between 5.5 and 6 h p.i., a time when translation of cellular, 
capped mRNAs is shut off by the virus24. The labeled proteins were analyzed by SDS-PAGE 
and autoradiography. The amount and pattern of the viral proteins was similar for treated 
and untreated samples (Supplementary Figure S2), demonstrating that GPC-N114 does not 
affect synthesis or processing of the viral polyprotein.
EMCV variants resistant to GPC-N114 carry mutations in 3Dpol
By serial passaging of virus in the presence of increasing concentrations of GPC-N114, we 
aimed to select for GPC-N114-resistant virus. However, despite 32 passages and several at-
tempts, no compound-resistant CVB3 isolates were obtained, indicating a high resistance 
barrier for this virus to GPC-N114. In contrast, three independent virus pools of EMCV 
Figure 1 (continued). GPC-N114 inhibits picornavirus replication. (F) GPC-N114 inhibits viral 
RNA replication. RNA of subgenomic replicons of CVB3 or EMCV was transfected into BGM cells. 
Subsequently, cells were treated either with 0.1% DMSO, 10 µM GPC-N114, 2 mM GuHCl, or 80 µM 
dipyridamole. Firefly luciferase levels were determined 2, 4, 6, and 8 h after RNA transfection to 
assess the level of replication and translation. Experiments were performed in triplicate and mean 
values ± SD are depicted.
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showed phenotypic resistance after as few as three or four serial passages in the presence 
of suboptimal concentrations of the compound. Viral RNA was isolated from these virus 
pools and the regions coding for the non-structural proteins were sequenced. Interestingly, 
the three virus pools each contained a single missense mutation compared to wt virus. 
These mutations were located either at nucleotide 7115 (A7115G) or 7127 (A7127G) result-
ing in amino acid changes M300V and I304V in the viral RdRP, 3Dpol, respectively (Figure 2A).
Figure 2. Mutations in EMCV 3Dpol confer resistance to GPC-N114. (A) Location of the mutations in 
GPC-N114-resistant EMCV pools and the EC
50
 of recombinant viruses as determined in a multicycle 
CPE-reduction assay. (B,C) Recombinant EMCV 3Dpol mutants are resistant to GPC-N114, as shown 
by multicycle CPE reduction assay (B) or single cycle growth curves (C). For technical details, see 
legend to Figure 1. (D) Ribbon diagram of the model of EMCV 3Dpol shown in the conventional 
orientation, as if looking into a right hand. The two residues mutated in GPC-N114-resistant 
EMCV (M300 and I304) are indicated in red. (E) GPC-N114 inhibits EMCV 3Dpol activity, but not by 
competing with UTP. Polymerase elongation activity in the presence of a range of concentrations of 
GPC-N114 was determined by measuring incorporation of [3H]UTP using poly(rA)/dT15 as template-
primer. Michaelis-Menten plots of the initial velocity of EMCV 3Dpol elongation activity determined 
at different concentrations of UTP and GPC-N114 are depicted. The curves shown are based on a 
non-competitive mode of inhibition. (F) Inhibition constants of GPC-N114 on EMCV 3Dpol wt and 
mutants M300V and I304V. Inhibition constants (Ki) were calculated from at least three experiments 
performed as in (E) and values shown are mean ± SD. Statistical analysis was performed with 
unpaired Student’s t-test.
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To verify the causal relationship between these mutations and the resistance pheno-
type, the mutations were introduced into the EMCV cDNA clone pM16.1 and mutant viruses 
were generated. In the multicycle CPE-reduction assay, the EC50 dramatically increased from 
5.44 ± 0.49 µM for EMCV wt to >100 µM for EMCV 3D-M300V and 3D-I304V, indicating that 
the mutants were resistant to the compound (Figure 2A and B). Accordingly, while the pro-
duction of infectious virus particles by wt virus was strongly inhibited in a single cycle assay, 
virus titers of the mutant viruses after 8 h were unaffected by the presence of 10 µM GPC-
N114 (Figure 2C). As expected, the mutations did not confer resistance to the cardiovirus 
inhibitor dipyridamole. These results demonstrate that the mutations in 3Dpol were indeed 
responsible for the resistance phenotype of the isolated virus pools.
Currently, no X-ray structure is available of EMCV 3Dpol and our efforts to purify and 
crystallize the enzyme have been unsuccessful so far. To visualize the localization of the 
M300V and I304V mutations in the structure of EMCV 3Dpol, we build a homology model 
based on the X-ray structure of FMDV 3Dpol4. In this model (Figure 2D), the amino acids 
M300 and I304 are both located in structural motif B on the same face of helix α11 which is 
part of the palm subdomain of the polymerase, close to the active site4. Both residues are 
buried in the core of the protein and their side chains are involved in hydrophobic interac-
tions that stabilize the local structure. Residues surrounding the amino acids corresponding 
to M300 and I304 were found to interact with the template RNA and the incoming NTP 
substrate in FMDV 3Dpol 4.
GPC-N114 inhibits in vitro polymerase activity
The location of the EMCV resistance mutations suggested that GPC-N114 targets the activ-
ity of 3Dpol. To verify this, we performed biochemical assays using purified EMCV 3Dpol in 
the presence or absence of GPC-N114. Briefly, elongation of a dT15 primer on a poly(rA) 
template by recombinant enzyme was determined by measurement of the rate of incorpo-
ration of [3H]UTP. Elongation activity of EMCV 3Dpol on the poly(A) template was inhibited 
by GPC-N114 in a dose-dependent manner (Figure 2E), which is in line with the resistance 
to the compound mapping to 3Dpol in EMCV. Using the same template-primer and metal ion 
(i.e., Mg2+), GPC-N114 did not affect the elongation activity of the polymerase domain of 
the dengue virus (DENV) NS5 RdRP (Supplementary Figure 3, IC50 > 100 µM), showing that 
the inhibition of EMCV 3Dpol activity was not due to an unspecific interference with these 
components of the assay.
An inhibition constant (Ki) of 1.3 µM was calculated from the EMCV 3Dpol elongation 
activity measured at multiple UTP and inhibitor concentrations (Figure 2F). Figure 2E shows 
representative Michaelis-Menten plots of the results acquired with EMCV 3Dpol. The data 
were fitted by non-linear regression assuming a competitive, noncompetitive, uncompeti-
tive or mixed mode of inhibition. The model of noncompetitive inhibition was the best fit, 
with the maximum velocity (Vmax) of the reaction declining with increasing concentrations 
of the compound. This indicates a noncompetitive mode of inhibition with respect to UTP 
(and presumably NTPs in general). When the activity of the mutant EMCV polymerases was 
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evaluated in the presence of GPC-N114, markedly higher inhibition constants were observed 
for the two resistant mutants (M300V, 26.9 µM; I304V, 10.3 µM) as compared to that for the 
wt enzyme (1.3 µM) (Figure 2F).
Thus, GPC-N114 inhibited EMCV 3Dpol elongation activity, which could be counteracted 
by mutations M300V and I304V.
Table 2. Data collection and refinement statistics
Data collection CVB3 FMDV
Space Group P43212 P41212
Cell dimensions 
a, b, c (Å) 74.74, 74.74, 289.1 93.9, 93.9, 121.5
α, β, γ (°) 90, 90, 90 90, 90, 90
Rmerge 8.1 10.6 
I/σI 7.6 11.5 
Completeness (%) 99.8 99.9 
Multiplicity 3.6 6.5 
Refinement 
Resolution (Å) 72.4 - 2.9 74.3 - 2.1 
No. reflections (unique) 32777 28938
Rwork† / Rfree‡ 21.1/22.9 23.72/26.65 
No. Atoms 
   Protein 3619 3772
   Ligand 134 31
   Water 81 142
B-factors (Å²)
   Protein 69.39 44.10 
   Water + Ligands 65.51 50.72 
R.m.s. deviations 
   Bond lengths (Å) 0.011 0.004 
   Bond angles (°) 1.319 0.815 
Ramachandran plot 
   Residues in preferred regions 370 (89.8%) 467 (98.32%) 
   Residues in allowed regions 42 (10.2%) 7 (1.47%) 
† Rwork = ∑hkl ||Fobs(hkl)| - |Fcalc(hkl)|| / ∑hkl |Fobs(hkl)|, where Fobs 
and Fcalc are the structure factors, deduced from measured intensities 
and calculated from the model, respectively. 
‡ Rfree = as for Rwork but for 5% of the total reflections chosen at random 
and omitted from refinement.
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GPC-N114 binds 3Dpol at the site of the template acceptor nucleotide
To study the binding of the compound to picornavirus polymerases, the structure of the 
complex of CVB3 3Dpol with GPC-N114 was obtained by X-ray crystallography (Table 2). The 
analysis of the difference electron density maps revealed the presence of extra densities to 
position the inhibitor within a pocket located at the bottom of the template channel, mim-
icking the position of the template acceptor nucleotide, the nucleotide which will base-pair 
with the incoming nucleotide (Figures 3A-C and Supplementary Figure S4). Although we 
cannot discard the existence of other binding sites, there was no evidence of those. The 
GPC-N114-binding pocket is in close proximity to the location of the mutated residues in re-
Figure 3. The binding site of GPC-N114. (A) Ribbon diagram of the CVB3 3Dpol structure (green). The 
inhibitor bound to the bottom of the template channel is shown in stick representation in yellow. 
(B) Interaction network between GPC-N114 and its binding pocket of CVB3 3Dpol. The polymerase 
residues in direct contact with the inhibitor are shown with carbon atoms in green and explicitly 
labeled. The omit |Fo|-|Fc| electron density map (contoured at 3σ) is shown as a chicken wire 
in blue. Hydrogen bonds are depicted as dashed lines. (C) Top down cross-sectional view of the 
molecular surface of CVB3 3Dpol with the electrostatic potential, represented in blue and red for 
positive and negative charges, respectively. The trajectory of the RNA template (green) is compared 
with the position of the GPC-N114 inhibitor (yellow). The inset box shows a close up of the position of 
the inhibitor that is coincident with that of the template acceptor nucleotide. The predicted position 
of the RNA template was determined using the FMDV 3Dpol–RNA complex (PDB entry 1WNE) as a 
guide. Continued on the next page...
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sistant EMCV 3Dpol (compare Figure 2D and Figure 3A). The compound bound in a conforma-
tion that perfectly fitted the shape of the pocket formed by residues L107, E108, L110, D111, 
T114 of motif G, R188, Y195, H199 of motif F, T294, S295, I296 of motif B and Y327 of motif 
A (Figures 3A and 3B). Most of these residues are conserved in picornaviral polymerases 
(Supplementary Figure S5). Among all contacts observed, the stacking interaction between 
Y195 and the central chlorophenyl ring of GPC-N114 appeared to be an important determi-
nant of binding. This tyrosine is strictly conserved in enterovirus polymerases but not con-
served in FMDV and EMCV. The first 2-cyano-4-nitrophenyl ring was oriented towards the 
entrance of the template channel, interacting with residues of motif G and B of CVB3 3Dpol, 
whereas the second 2-cyano-4-nitrophenyl ring appeared partially exposed to the solvent, 
occupying the position expected for the template acceptor base (Figure 3C). The interact-
ing residues appear to be in direct contact with the RNA templates in all picornaviral 3Dpol 
–RNA complexes determined so far4,12,25,26. Structural comparisons between unbound and 
Figure 3 (continued). The binding site of GPC-N114. (D) Ribbon diagram of the FMDV 3Dpol–
GPC-N114 complex. (E) Detail of the interactions seen in the inhibitor binding pocket of the 
FMDV polymerase. The polymerase residues in direct contact with GPC-N114 are shown in sticks 
with carbon atoms in blue and explicitly labeled. The inhibitor is depicted with carbon atoms in 
yellow. The blue wire shows an omit |Fo|-|Fc| electron density map (contoured at 3 σ). (F) Surface 
representation of the GPC-N114 binding pocket in two different picornavirus polymerases. CVB3 
3Dpol (green surface, left panel) with bound GPC-N114 shown in sticks in yellow and FMDV 3Dpol (blue 
surface, right panel) with the bound inhibitor depicted in orange stick representation. The structure 
of GPC-N114 in the conformation acquired when it binds CVB3 3Dpol is also modeled in the right 
panel (thin sticks in yellow).
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GPC-N114-bound CVB3 3Dpol showed that the polymerase did not undergo any major con-
formational change upon binding of the compound. This preservation of the template cavity 
conformation extended to the interacting side chains, which maintained their native confor-
mation upon GPC-N114 binding. We also solved the X-ray structure of the complex of CVB3 
3Dpol with a second inhibitor of the GPC series, GPC-N143 (Supplementary Figure S6A). This 
compound contains a central fluorophenyl ring instead of a chlorophenyl ring and displays 
similar antiviral activity as GPC-N114 (Supplementary Figures S6A and S6B). The resolution 
of the CVB3 3Dpol–GPC-N143 complex was slightly higher (2.7 Å) than that with GPC-N114 
(Table 2). As expected, the GPC-N143 binding site is identical to that of GPC-N114, establish-
ing almost equivalent interactions (Figure 3A, Supplementary Figures S4A and S6A). Thus, 
the crystallographic data demonstrate that GPC-N114 specifically interacts with CVB3 3Dpol 
at the template channel without having major effects on the structure of the enzyme.
In addition, we obtained the structure of GPC-N114 in complex with FMDV 3Dpol (Table 
2). Interestingly, despite the fact that FMDV was not sensitive to the antiviral effect of GPC-
N114, the compound bound to FMDV 3Dpol at a pocket approximately equivalent to the 
pocket for GPC-N114 in CVB3 3Dpol. However, the inhibitor showed different conformations 
and different binding modes in the two complexes (Figure 3 and Supplementary Figure S4). 
Compared to the CVB3 complex, GPC-N114 was rotated in the FMDV complex in such a 
way that the central chlorophenyl ring pointed towards the template channel entry and the 
second 2-cyano-4-nitrophenyl ring appeared to occupy a small cavity formed at the bottom 
of the pocket (Figures 3D-F). In this complex, the first 2-cyano-4-nitrophenyl ring remained 
exposed to the solvent (Figures 3D-F). Most likely, this altered fit of GPC-N114 in FMDV 3Dpol 
with very few polymerase-inhibitor contacts precludes inhibition of polymerase activity.
GPC-N114 inhibits 3Dpol activity by interfering with binding of the RNA template-primer 
duplex
We proceeded by analyzing the effects of GPC-N114 on CVB3 3Dpol in more detail. Consistent 
with the data obtained for EMCV 3Dpol, we observed that GPC-N114 inhibited CVB3 3Dpol 
with a noncompetitive mode of inhibition with respect to UTP (Figure 4A). Prompted by the 
overlapping binding sites of GPC-N114 and the template on CVB3 3Dpol, we then performed 
order-of-addition experiments to explore whether GPC-N114 interferes with formation of 
the RNA template-primer duplex. If this is the case, the inhibitor should display an improved 
potency when it is added to the reaction mix before the template-primer as compared to 
after. Picornavirus polymerases become inactivated during incubation in the absence of 
nucleic acid27. Indeed, we observed a lower Vmax when enzyme was pre-incubated with the 
inhibitor before adding the template-primer (data not shown). Therefore, the polymerase 
elongation activity was expressed as percentage of the Vmax observed with DMSO. The IC50 
value observed for GPC-N114 versus CVB3 3Dpol was ~12 times lower when the compound 
was added to the reaction mix before the template-primer (Figure 4B). A similar order-of-ad-
dition effect was observed with EMCV 3Dpol (data not shown). These data support the idea that 
GPC-N114 inhibits polymerase activity by affecting the binding of the template-primer to 3Dpol.
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Discussion
There is a great need for broad-range antiviral compounds to treat infections with entero-
viruses, which includes important human pathogens such as poliovirus, coxsackievirus, 
enterovirus 71, and rhinovirus. Here, we describe a novel small molecule, GPC-N114, that 
exerts broad-spectrum anti-enterovirus activity and also inhibits members of the genus 
Cardiovirus, such as EMCV. Analysis of its mechanism of action revealed that GPC-N114 
inhibits virus replication at the stage of RNA replication. To gain insight into the molecular 
target, we set out to select GPC-N114-resistant viruses. No resistant CVB3 was obtained 
whereas culturing of EMCV in the presence of GPC-N114 rapidly resulted in the selection of 
compound-resistant variants carrying mutations in the viral RdRP, 3Dpol. Consistently, CVB3 
and EMCV 3Dpol elongation activity in vitro was inhibited in the presence of GPC-N114, and 
the resistance mutations identified in EMCV 3Dpol rendered this polymerase less susceptible 
to inhibition. Further characterization of the mechanism of action of GPC-N114 showed 
that the compound did not compete with incoming NTPs, but interfered with binding of the 
template-primer to 3Dpol. This is in agreement with the crystallographic data of the CVB3 
3Dpol–GPC-N114 complex which revealed that the binding site of the compound is located 
at the junction of the palm and the fingers domains, and partially overlaps with the binding 
site of the template. In sum, this study presents a new broad-spectrum antiviral compound, 
Figure 4. GPC-N114 impairs CVB3 3Dpol elongation activity by interfering with primer-template 
binding. (A) GPC-N114 does not compete with UTP. The experiment was performed for CVB3 3Dpol 
as described in Figure 2E for EMCV 3Dpol. (B) GPC-N114 affects the binding of the template-primer. 
Order-of-addition experiments were performed by measuring CVB3 3Dpol elongation activity when 
GPC-N114 was added to the reaction mix before or after poly(rA)/dT15.
149
7
A novel picornavirus polymerase inhibitor
reporting not only the identification of the compound but also an extensive characterization 
of its mechanism of action.
A high barrier to resistance is a desirable feature for antiviral compounds since drug 
resistance represents a major problem in the treatment of viral infections. Importantly, no 
GPC-N114-resistant CVB3 was obtained after several attempts and more than 30 serial pas-
sages of this virus in the presence of the compound. This resistance does not seem to be 
restricted to CVB3 as an equal amount of passages with PV1 or E9 also did not result in the 
isolation of GPC-N114-resistant variants with mutations in 3Dpol. Importantly, attempts to 
produce resistant CVB3 by introduction of the mutations that correspond to those found in 
GPC-N114-resistant EMCV (i.e., 3D-I296V and 3D-M300V in CVB3), also did not result in a 
compound-resistant phenotype (multicycle CPE-reduction assay on BGM cells, EC50: wt=1.22 
± 0.11 µM; 3D-I296V=0.39 ± 0.09 µM; 3D-M300V=0.40 ± 0.15 µM). Also mutation S299T in 
CVB3 3Dpol, which provides resistance against the 3Dpol inhibitor amiloride19, did not confer 
resistance to GPC-N114 (EC50: wt=2.73 ± 1.17 µM; 3D-S299T=2.57 ± 0.22 µM). The reason 
for the inability of CVB3 to develop resistance against GPC-N114 remains to be established. 
A possible explanation is that mutations that would confer resistance to GPC-N114 also im-
pair binding of the template-primer, thereby preventing replication.
The underlying molecular mechanism by which M300V and I304V in EMCV 3Dpol pro-
vide resistance to GPC-N114 remains to be elucidated. The amino acid changes are conser-
vative with all three amino acids having similar properties. Based on the constructed model, 
only one of the residues, M300 (equivalent to I296 in CVB3 3Dpol, see Figure 3B), would be in 
direct contact with the compound. In contrast, I304 seems to be located relatively far away 
of the GPC-N114 binding cavity. Both M300 and I304 are part of conserved structural motif 
B, which not only binds the RNA template in the active site but also participates in the mech-
anism of RNA translocation through fine movements of a loop located at the N-terminus of 
the motif, the B-loop25,28. Structural data from picornavirus polymerases25,28 as well as other 
RdRPs29 suggest that the B-loop is highly dynamic and that its dynamics can be regulated 
by external effectors30. The mutations M300V and I304V may subtly increase or restrict the 
flexibility of this loop, thereby affecting the binding site of GPC-N114 whilst retaining the 
ability to interact with the template-primer. Further efforts are ongoing to obtain crystal 
structures of EMCV 3Dpol wt and mutants to gain insight into the mechanism of resistance.
Both the crystallographic studies as well as the order-of-addition experiment clearly 
indicate that GPC-N114 affects binding of the template-primer by 3Dpol. However, it remains 
to be established whether GPC-N114 inhibits 3Dpol elongation activity by competing with 
the template-primer for binding to 3Dpol or whether binding of the compound results in 
the formation of an unproductive conformation of the polymerase-template complex. This 
question will be addressed in further studies.
GPC-N114 had no effect on replication of FMDV and ERAV, members of the genus 
Aphthovirus. Our crystallographic data provide a plausible explanation for the low activity 
of the GPC-N114 against these viruses. GPC-N114 was able to bind the FMDV 3Dpol template 
channel in a similar position as in CVB3 3Dpol, however, its conformation and interactions in 
the polymerase binding pocket were different. The stacking interaction between Y195 of 
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CVB3 3Dpol and the central chlorophenyl ring of GPC-N114 seems to be an important deter-
minant of binding CVB3 3Dpol (Figures 3B and 3E). In FMDV 3Dpol, this tyrosine is replaced by 
cysteine. The absence of the bulky tyrosine side chain resulted in the formation of a small 
hydrophilic cavity at the bottom of the FMDV pocket that apparently facilitated the binding 
of one of the nitrophenyl rings, which partially occupied the cavity (Figures 3E and F). This 
different mode of binding of GPC-N114 to the FMDV pocket resulted in an important reduc-
tion of the number of polymerase-inhibitor contacts. By consequence, the compound may 
be easily displaced by the RNA template. ECMV 3Dpol also lacks the aromatic residue at the 
position equivalent to Y195 and in consequence, the stacking interaction would be lost as 
predicted by the homology model. How this is compensated in EMCV 3Dpol remains to be 
established, since molecular modeling gave no definitive answer as to how GPC-N114 binds 
to EMCV 3Dpol.
Compounds that interfere with binding of the template-primer have been described 
for polymerases of some viruses, including DENV and HIV31,32, but not for any of the picor-
naviruses. The only known picornavirus polymerase inhibitors with a related mechanism of 
action are two compounds that target the incoming NTP binding site in the PV polymerase15. 
Clearly, the NTP binding site is close to, but distinct from, the GPC-N114 binding site. Hence, 
GPC-N114 is the first picornavirus polymerase inhibitor that binds the site of the template 
acceptor nucleotide. The identification and characterization of GPC-N114 is an important 
contribution to the field of anti-enteroviral compounds, identifying a pocket in the poly-
merase that can be targeted by NNIs.
Materials & Methods
Cells and reagents
Buffalo green monkey (BGM) kidney cells, HeLa R19 cells, baby hamster kidney 21 (BHK-21) 
cells, and human rhabdomyosarcoma RD cells were grown at 37°C, 5% CO2 in Dulbecco’s 
Modified Eagle medium (DMEM) (Gibco) supplemented with 10% fetal bovine serum and 
antibiotics. The Hela H cells, BGM cells, and Vero cells used for the multicycle CPE-reduction 
assays were maintained in Minimal Essential Medium supplemented with 10% FBS, 1% bi-
carbonate, and 1% L-glutamine.
The synthesis of GPC-N114 will be published elsewhere. Guanidine hydrochloride 
(GuHCl) and dipyridamole were purchased from Sigma Aldrich. Dipyridamole was dissolved 
in ethanol and GuHCl in water. The other compounds were dissolved in DMSO. GPC-N114 
was used in a concentration of 10 μM unless stated otherwise.
Viruses and infections
Coxsackievirus B3 (strain Nancy) was obtained by transfection of RNA transcripts of the 
full-length infectious clone p53CB3/T7 linearized with SalI into BGM cells33. EMCV, strain 
mengovirus, was obtained in a similar manner by transfection of RNA derived from cDNA 
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clone pM16.1 into BHK-21 cells34. EV68, EV70, EV71 (BrCr), E11 (Gregory), CVA16 (G-10) and 
CVA21 (Coe) were obtained from the National Institute for Public Health and Environment 
(RIVM, the Netherlands). Poliovirus 1-3 Sabin reference strains were obtained from dr. J 
Martin (NIBSC, UK). Human rhinoviruses 2 and 14 were supplied by Joachim Seipelt (Medical 
University of Vienna, Austria). ERAV (NM11/67) was a gift from David Rowlands and Toby 
Tuthill (University of Leeds, UK). Saffold virus (type 3) was described previously35. The FMDV 
strains O1 Manisa and A22 Iraq 24/64 were used
36.
For virus infections, virus was added to subconfluent cell layers and allowed to adsorb 
for 30 minutes, after which virus was removed and fresh (drug-containing) medium was 
added to the cells. At the indicated times p.i. the cells were freeze-thawed three times to 
release intracellular virus particles. Virus titers were determined by endpoint titration ac-
cording to the method of Reed and Muench and expressed as 50% cell culture infective 
doses (CCID50)/ml37.
Multicycle CPE-reduction assays
The antiviral activity of compounds was determined as published previously11,36. In short, 
the medium was removed from cells grown in 96-well plates and a serial dilution of com-
pound in medium with 2% FCS was added after which the cells were infected with virus 
at the lowest MOI sufficient for full CPE development in infected, untreated cultures after 
three days of incubation at 37°C. To quantify the level of CPE by MTS assay, the medium was 
then replaced with AQueous One Solution Cell Proliferation Reagent (Promega) diluted in me-
dium and incubated at 37°C for 1-2 h. Subsequently, absorbance at 498 nm was measured. 
The measured values were used to calculate the cell viability ranging from 0% (full CPE with 
infected, untreated cultures) to 100% (uninfected, untreated cultures). The 50% effective 
concentration (EC50) was defined as the concentration of compound that resulted in a 50% 
reduction in virus-induced CPE and was calculated using logarithmic interpolation.
Subgenomic replicon assay
The subgenomic replicons of CVB3 (pRib-LUC-CB3/T7) and EMCV (pEMCV-FLuc) en-
code the cDNA clones of the corresponding virus except that the P1 area encoding the cap-
sid proteins has been (partially) replaced by the code for firefly luciferase23,38. The plasmids 
were linearized with MluI or BamHI, respectively. RNA transcribed from the linearized plas-
mids was used to transfect BGM cells plated in 24-well plates using the DEAE-dextran meth-
od as described previously23. After transfection, cells were treated with DMSO or compound 
and incubated at 37°C. At 2, 4, 6, and 8 h post-transfection, cells were washed with PBS, 
lysed and luciferase levels were determined with the Luciferase Assay System (Promega) 
according to the manufacturer’s instructions.
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Metabolic labeling
For metabolic labeling of proteins, BGM cells were grown in 24-well plates to subconfluence 
and infected with CVB3 at an MOI of 50. At 5 h post-infection, the medium was replaced 
with 300 μl of methionine-free medium for 30 min. Subsequently, the cultures were pulse-
labeled in methionine-free medium supplemented with [35S]Met in the absence or pres-
ence of 50 μM GPC-N114 for 30 min. At 6 h post-infection, cells were lysed with lysis buffer 
[50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 % Nonidet P-40, 0.05 % SDS]. Laemmli 
sample buffer was added to the lysates, boiled for 5 min and analyzed on a 10% polyacryl-
amide gel containing SDS. The gels were fixed in 30% methanol-10% acetic acid, rinsed in 
DMSO, fluorographed with 20% 2,5-diphenyloxazole in DMSO, dried, and exposed to Kodak 
XAR film.
Generation of GPC-N114-resistant virus
To obtain drug-resistant virus, three independent virus pools of CVB3 and EMCV were seri-
ally passaged in the presence of a concentration series of GPC-N114 on subconfluent to 
confluent Vero cultures in 96-well plates. The amount of CPE was assessed after 3 to 4 days. 
The next round of infection was performed using supernatant collected from the culture 
with the highest concentration of compound that still exhibited full CPE. This procedure was 
repeated 32 times (CVB3) or until there was a clear increase in the concentration required 
for inhibition of CPE (EMCV). Viral RNA was isolated from the resistant virus pools using the 
GenElute Mammalian Total RNA Miniprep Kit (Sigma Aldrich) and used for sequencing of the 
parts of the genome that encode the nonstructural proteins. The PCR product containing 
the mutations found in the virus pools generated in this procedure was digested with PinAI 
and NruI and cloned into pM16.1 to replace the corresponding wt sequence. The resulting 
infectious clones pM16.1-3D-M300V and pM16.1-3D-I304V were sequenced to confirm the 
presence of the mutations. Subsequently, recombinant virus was generated as described 
above and the presence of the resistance mutations was again confirmed by sequencing.
Protein expression and purification for biochemical activity assays
Recombinant CVB3 3Dpol and the RdRP domain of DENV NS5 (NS5-RdRP) were obtained 
as previously described39,40. For expression and purification of EMCV 3Dpol, the coding se-
quence of 3Dpol (polyprotein domain from amino acid position 1834 to 2293) was amplified 
on EMCV cDNAs (pM16.1 wt, 3D-M300V, and 3D-I304V) and cloned into pETG20A (kindly 
provided by Dr. Arie Geerlof) by Gateway recombination (Life Technologies), downstream 
a cleavable Hexahistidine-Thioredoxin tag using a two-step PCR protocol. The protein was 
expressed in E. coli Rosetta (DE3) pLysS strain (Novagen) at 17°C in Tur*best Broth (Arcadia 
Biotech). The purification of the protein and the tag removal were performed in non-dena-
turing conditions as previously described41. The final Size Exclusion Chromatography step 
was performed in 10 mM Hepes, 300 mM NaCl, 2mM dithiotreitol, pH 7.5.
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Polymerase activity assays
The conditions for the polymerase elongation activity assays were adapted from conditions 
reported previously10,40. EMCV 3Dpol filter-binding polymerase activity assays were conduct-
ed in a mix of 50 µl containing 50 mM MOPS pH 7.0, 10 mM KCl, 4 mM MgCl2, 9% glycerol, 2 
µM dT15 (Invitrogen) annealed to 350 nM poly(rA) (GE Healthcare, average size 519 nt) (i.e., 
a molar ratio dT15:poly(rA) of 5.7:1), 1 µM EMCV 3Dpol, 50/100/200 or 500 µM UTP and 2 
µCi [3H]UTP (GE Healthcare, 35.5 Ci/mmol). The reaction mix excluding UTP was incubated 
with either DMSO or GPC-N114 with a constant concentration of 5% DMSO for 2 minutes 
after which the reaction was started by addition of labeled and unlabeled UTP. Samples 
of 10 µl were taken after 0, 10, 20 and 30 min of incubation at 30 °C and added to 50 µl 
of 100 mM EDTA in 96-well sample plates to stop the reaction. Mixtures were then trans-
ferred onto glass fiber filter mats with DEAE active groups (DEAE filtermat, Wallac) using a 
Filtermat Harvester (Packard Instruments). Filtermats were washed three times with 0.3 M 
ammonium formate pH 8.0, twice with water, and once with ethanol after which they were 
dried and transferred into sample bags. Liquid scintillation fluid was added to the sample 
bags and incorporation of radiolabeled UTP was measured in counts per minute using a 
Wallac MicroBeta TriLux Liquid Scintillation Counter.
For the DENV NS5 elongation assay the reaction mixture contained 50 mM HEPES pH 
8.0, 10 mM KCl, 10 mM DTT, 5 mM MgCl2, 2 µM dT15 annealed to 350 nM poly(rA), 0.4 µM 
DENV NS5-RdRP, 20 µM UTP and 2 µCi [3H]UTP. 10 µl samples were taken after 0, 30, 60, and 
90 minutes. Subsequently, the same procedure was followed as for EMCV 3Dpol.
The CVB3 3Dpol reaction mixture contained 50 mM Tris pH 7.0, 10 mM KCl, 0.8 mM 
MgCl2, 9% glycerol, 2 µM dT15 annealed to 350 nM poly(rA), 20 nM CVB3 3D
pol, 2/5/10/20 
µM UTP and 0.5 µCi [3H]UTP. 10 µl samples were taken after 0, 5, 10, and 15 minutes. For the 
order-of-addition experiment with CVB3 3Dpol, a reaction premix was assembled as above 
but without poly(rA)/dT15, GPC-N114 and UTP. To this premix either a range of concentra-
tions of GPC-N114 or 80 nM dT15 annealed to 14 nM poly(rA) were added. After an incuba-
tion of 1 min at RT, the other component was added to the mix followed by an incubation 
of several minutes at 30°C. The reaction was started by addition of UTP, and samples were 
taken after 0, 3, 6, and 9 minutes.
The data were fitted using non-linear regression using Graphpad Prism 5.0.3. Ki values 
averaged from at least three independent experiments were statistically compared between 
EMCV 3Dpol wt and the 3Dpol mutants using a Student’s t-test.
Modeling of EMCV 3Dpol
A homology model of EMCV 3Dpol was built using the homology modeling experiment in the 
YASARA&WHAT IF Twinset42. As a template we used the experimentally solved X-ray struc-
ture of the FMDV RNA polymerase (PDB-file 1u09)4. The percentage of identical residues 
between both proteins was 44%, sufficient to build a reliable homology model.
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Protein expression and purification for crystallography
Recombinant CVB3 3Dpol was over-expressed essentially as previously described39, except 
that the expression was carried out at 20°C. Stored pellets were resuspended in a cold lysis 
buffer containing 50 mM Tris HCl pH 9.0, 500 mM NaCl, 10 mM imidazole, 0.1% (v/v) Triton 
X-100, 5% glycerol, 1 mg/ml lysozyme and 10 µg/ml DNase, and cells were lysed by sonica-
tion. Cellular debris was pelleted by centrifugation and the soluble fraction was filtrated 
and loaded into a 5 ml HisTrapTM HP column (GE Healthcare). The protein was eluted using 
an imidazole gradient (10-500 mM) in 50 mM Tris pH 8.0 and 300 mM NaCl. Protein frac-
tions were dialyzed against 20 mM Tris pH 9.0, 600 mM NaCl, 15% glycerol, 0.5 mM TCEP 
and further purified by size-exclusion chromatography on a Superdex 200 16/60 column 
(GE Healthcare). Purified protein was concentrated to 5 mg/ml in the same buffer, using 
a Vivaspin concentrator (10.000 MWCO PES, Sartorius Stedim Biotech). The quality of the 
protein obtained was checked by SDS-PAGE. Expression and purification of the recombinant 
FMDV 3Dpol was previously described4.
Crystallization and data collection
Crystals of isolated CVB3 3Dpol were obtained by the sitting-drop vapor-diffusion method at 
16°C in 96-well plates (MRC, Swissci AG) using a Cartesian automated drop dispenser to mix 
250 nl of 5 mg/ml protein solution with an equal volume of reservoir solution, containing 
50 mM Tris pH 7.5, 24.5% (w/v) glycerol, 1.29 M ammonium sulfate. Highly reproducible 
crystals of 25x25x25 µm in size appeared between 2-3 days. FMDV 3Dpol was crystallized as 
described previously4. Protein/inhibitor complexes were prepared by soaking both CVB3 
and FMDV 3Dpol crystals in the inhibitor solution for ~72h. The inhibitor solution contained 
100 µM GPC-N114/GPC-N143 in 2.5% DMSO, 0.65 M ammonium sulfate, 12.5% glycerol 
and 25 mM Tris pH 7.5 for CVB3 3Dpol crystals, and 100 µM GPC-N114 in 2.5% DMSO, 17% 
PEG4K, 0.1 mM ammonium acetate, and 50 mM sodium citrate pH 5.6 for FMDV 3Dpol crys-
tals. Crystals were then transferred to a cryo-protecting solution, containing 30% glycerol in 
the respective crystallization buffer prior to cooling by immersion in liquid nitrogen. The two 
datasets were collected at 100K by using synchrotron radiation at the European Synchrotron 
Radiation Facility (ESRF, Grenoble) on a Pilatus 6M S/N 60-104 detector at beamline ID 29, 
λ=0.977Å. Diffraction images were processed with iMOSFLM43 and internally scaled with 
SCALA (CCP4i44), achieving resolutions of 2.9Å, 2.7Å and 2.1Å for the CVB3 3Dpol–GPC-N114, 
CVB3 3Dpol–GPC-N143 and FMDV 3Dpol–GPC-114 crystals, respectively. Data collection sta-
tistics are given in Table 2. Coordinates have been deposited at the PDB with accession 
codes 4IPO and 4IPK for the complexes CVB3 3Dpol–GPC-N114 and FMDV 3Dpol–GPC-N114, 
respectively.
Structure determination and refinement
The initial electron density maps of the CVB3 3Dpol–GPC-N114, CVB3 3Dpol–GPC-N143 and 
FMDV 3Dpol–GPC-N114 complexes were obtained after rigid-body fitting of the coordinates 
155
7
A novel picornavirus polymerase inhibitor
of the 3Dpol apoenzymes (PDB ids. 3DDK for CVB3 and 1UO9 for FMDV) to the new unit 
cells (Table 2), using the program Refmac545,46. In both structures, the weighted 2|Fo|-|Fc| 
and |Fo|-|Fc| difference map showed the presence of extra densities that permitted the 
initial positioning of the inhibitor molecules. Inhibitor structure files were generated using 
“Online SMILES Translator and Structure File Generator” (http://cactus.nci.nih.gov/trans-
late/) and its respective CIF dictionaries were created by Grade47. Several cycles of automatic 
refinement, performed with Refmac5, were alternated with manual model rebuilding using 
Coot48. The refinement statistics are summarized in Table 2.
Acknowledgments
We acknowledge Kim Donckers, Stijn Delmotte, and Caroline Collard Keyzer for their excel-
lent assistance in the acquisition of part of the antiviral data as well as Violaine Lantez, 
Julie Lichière and Marilyne Blémont for the production of the recombinant polymerases. We 
thank Esteban Domingo for providing the FMDV polymerase. This work was supported by 
research grants from the SILVER Large Scale Collaborative Project (grant agreement number 
260644) project of the European Union 7th Framework, the European Virus Archive (EVA) 
project (European FP7 Capacities Project number 153 228292), the “Convenant K.U. Leuven-
Radboud University Nijmegen” framework, GOA/10/014 (for work performed at KULeuven), 
NWO-VICI grant no. 91812628 (F.J.M. van Kuppeveld), FWO Krediet aan Navorsers no. 
1.5.206.11 (A. De Palma). The funders had no role in study design, data collection and analy-
sis, decision to publish, or preparation of the manuscript. The authors declare that there are 
no conflicts of interest.
156 Chapter 7
References
 1.  Tapparel, C., F. Siegrist, T. J. Petty, and L. Kaiser. 2013. Picornavirus and enterovirus diversity with 
associated human diseases. Infect.Genet.Evol. 14:282-293.
 2.  Knowles, N. J., T. Hovi, T. Hyypiä, A. M. Q. King, A. M. Lindberg, M. A. Pallansch, A. C. Palmenberg, 
P. Simmonds, T. Skern, G. Stanway, T. Tamashita, and R. Zell. 2012. Picornaviridae, p. 855-880. In: 
A. M. Q. King, M. J. Adams, E. B. Carstens, and E. J. Lefkowitz (eds.), Virus Taxonomy: Classifica-
tion and Nomenclature of Viruses: Ninth Report of the International Committee on Taxonomy of 
Viruses. Elsevier, San Diego.
 3.  Appleby, T. C., H. Luecke, J. H. Shim, J. Z. Wu, I. W. Cheney, W. Zhong, L. Vogeley, Z. Hong, and N. 
Yao. 2005. Crystal structure of complete rhinovirus RNA polymerase suggests front loading of 
protein primer. J.Virol. 79:277-288.
 4.  Ferrer-Orta, C., A. Arias, R. Perez-Luque, C. Escarmis, E. Domingo, and N. Verdaguer. 2004. Struc-
ture of foot-and-mouth disease virus RNA-dependent RNA polymerase and its complex with a 
template-primer RNA. J.Biol.Chem. 279:47212-47221.
 5.  Hansen, J. L., A. M. Long, and S. C. Schultz. 1997. Structure of the RNA-dependent RNA poly-
merase of poliovirus. Structure. 5:1109-1122.
 6.  Love, R. A., K. A. Maegley, X. Yu, R. A. Ferre, L. K. Lingardo, W. Diehl, H. E. Parge, P. S. Dragovich, 
and S. A. Fuhrman. 2004. The crystal structure of the RNA-dependent RNA polymerase from hu-
man rhinovirus: a dual function target for common cold antiviral therapy. Structure. 12:1533-
1544.
 7.  Thompson, A. A. and O. B. Peersen. 2004. Structural basis for proteolysis-dependent activation of 
the poliovirus RNA-dependent RNA polymerase. EMBO J. 23:3462-3471.
 8.  Wu, Y., Z. Lou, Y. Miao, Y. Yu, H. Dong, W. Peng, M. Bartlam, X. Li, and Z. Rao. 2010. Structures of 
EV71 RNA-dependent RNA polymerase in complex with substrate and analogue provide a drug 
target against the hand-foot-and-mouth disease pandemic in China. Protein Cell 1:491-500.
 9.  Campagnola, G., M. Weygandt, K. Scoggin, and O. Peersen. 2008. Crystal structure of coxsacki-
evirus B3 3Dpol highlights the functional importance of residue 5 in picornavirus polymerases. 
J.Virol. 82:9458-9464.
 10.  Gruez, A., B. Selisko, M. Roberts, G. Bricogne, C. Bussetta, I. Jabafi, B. Coutard, A. M. De Palma, J. 
Neyts, and B. Canard. 2008. The crystal structure of coxsackievirus B3 RNA-dependent RNA poly-
merase in complex with its protein primer VPg confirms the existence of a second VPg binding site 
on Picornaviridae polymerases. J.Virol. 82:9577-9590.
 11.  Ferrer-Orta, C., A. Arias, C. Escarmis, and N. Verdaguer. 2006. A comparison of viral RNA-depen-
dent RNA polymerases. Curr.Opin.Struct.Biol. 16:27-34.
 12.  Ferrer-Orta, C., R. Agudo, E. Domingo, and N. Verdaguer. 2009. Structural insights into replication 
initiation and elongation processes by the FMDV RNA-dependent RNA polymerase. Curr.Opin.
Struct.Biol. 19:752-758.
 13.  Crotty, S., C. E. Cameron, and R. Andino. 2001. RNA virus error catastrophe: direct molecular test 
by using ribavirin. Proc.Natl.Acad.Sci.U.S.A 98:6895-6900.
 14.  Hardy, J. A. and J. A. Wells. 2004. Searching for new allosteric sites in enzymes. Curr.Opin.Struct.
Biol. 14:706-715.
 15.  Campagnola, G., P. Gong, and O. B. Peersen. 2011. High-throughput screening identification of 
poliovirus RNA-dependent RNA polymerase inhibitors. Antiviral Res. 91:241-251.
 16.  Chen, T. C., H. Y. Chang, P. F. Lin, J. H. Chern, J. T. Hsu, C. Y. Chang, and S. R. Shih. 2009. Novel antivi-
ral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71. Antimicrob.Agents 
Chemother. 53:2740-2747.
 17.  Durk, R. C., K. Singh, C. A. Cornelison, D. K. Rai, K. B. Matzek, M. D. Leslie, E. Schafer, B. Marchand, 
A. Adedeji, E. Michailidis, C. A. Dorst, J. Moran, C. Pautler, L. L. Rodriguez, M. A. McIntosh, E. Rie-
der, and S. G. Sarafianos. 2010. Inhibitors of foot and mouth disease virus targeting a novel pocket 
of the RNA-dependent RNA polymerase. PLoS One 5:e15049.
 18.  Furuta, Y., K. Takahashi, K. Shiraki, K. Sakamoto, D. F. Smee, D. L. Barnard, B. B. Gowen, J. G. Ju-
lander, and J. D. Morrey. 2009. T-705 (favipiravir) and related compounds: Novel broad-spectrum 
inhibitors of RNA viral infections. Antiviral Res. 82:95-102.
 19.  Harrison, D. N., E. V. Gazina, D. F. Purcell, D. A. Anderson, and S. Petrou. 2008. Amiloride deriva-
tives inhibit coxsackievirus B3 RNA replication. J.Virol. 82:1465-1473.
 20.  Hung, H. C., T. C. Chen, M. Y. Fang, K. J. Yen, S. R. Shih, J. T. Hsu, and C. P. Tseng. 2010. Inhibition 
of enterovirus 71 replication and the viral 3D polymerase by aurintricarboxylic acid. J Antimicrob.
Chemother. 65:676-683.
157
7
A novel picornavirus polymerase inhibitor
 21.  Rodriguez, P. L. and L. Carrasco. 1992. Gliotoxin: inhibitor of poliovirus RNA synthesis that blocks 
the viral RNA polymerase 3Dpol. J Virol. 66:1971-1976.
 22.  Purstinger, G., A. M. De Palma, G. Zimmerhofer, S. Huber, S. Ladurner, and J. Neyts. 2008. Synthe-
sis and anti-CVB 3 evaluation of substituted 5-nitro-2-phenoxybenzonitriles. Bioorg.Med.Chem.
Lett. 18:5123-5125.
 23.  van Kuppeveld, F. J., J. M. Galama, J. Zoll, and W. J. Melchers. 1995. Genetic analysis of a hydro-
phobic domain of coxsackie B3 virus protein 2B: a moderate degree of hydrophobicity is required 
for a cis-acting function in viral RNA synthesis. J Virol. 69:7782-7790.
 24.  Etchison, D., S. C. Milburn, I. Edery, N. Sonenberg, and J. W. Hershey. 1982. Inhibition of HeLa cell 
protein synthesis following poliovirus infection correlates with the proteolysis of a 220,000-dal-
ton polypeptide associated with eucaryotic initiation factor 3 and a cap binding protein complex. 
J Biol.Chem. 257:14806-14810.
 25.  Ferrer-Orta, C., A. Arias, R. Perez-Luque, C. Escarmis, E. Domingo, and N. Verdaguer. 2007. Se-
quential structures provide insights into the fidelity of RNA replication. Proc.Natl.Acad.Sci.U.S.A 
104:9463-9468.
 26.  Kortus, M. G., B. J. Kempf, K. G. Haworth, D. J. Barton, and O. B. Peersen. 2012. A template RNA 
entry channel in the fingers domain of the poliovirus polymerase. J Mol.Biol. 417:263-278.
 27.  Arias, A., J. J. Arnold, M. Sierra, E. D. Smidansky, E. Domingo, and C. E. Cameron. 2008. Deter-
minants of RNA-dependent RNA polymerase (in)fidelity revealed by kinetic analysis of the poly-
merase encoded by a foot-and-mouth disease virus mutant with reduced sensitivity to ribavirin. J 
Virol. 82:12346-12355.
 28.  Gong, P. and O. B. Peersen. 2010. Structural basis for active site closure by the poliovirus RNA-
dependent RNA polymerase. Proc.Natl.Acad.Sci.U.S.A 107:22505-22510.
 29.  Garriga, D., A. Navarro, J. Querol-Audi, F. Abaitua, J. F. Rodriguez, and N. Verdaguer. 2007. Acti-
vation mechanism of a noncanonical RNA-dependent RNA polymerase. Proc.Natl.Acad.Sci.U.S.A 
104:20540-20545.
 30.  Garriga, D., C. Ferrer-Orta, J. Querol-Audi, B. Oliva, and N. Verdaguer. 2013. Role of Motif B Loop 
in Allosteric Regulation of RNA-Dependent RNA Polymerization Activity. J Mol.Biol.
 31.  Niyomrattanakit, P., Y. L. Chen, H. Dong, Z. Yin, M. Qing, J. F. Glickman, K. Lin, D. Mueller, H. Voshol, 
J. Y. Lim, S. Nilar, T. H. Keller, and P. Y. Shi. 2010. Inhibition of dengue virus polymerase by blocking 
of the RNA tunnel. J.Virol. 84:5678-5686.
 32.  Wang, L. Z., G. L. Kenyon, and K. A. Johnson. 2004. Novel mechanism of inhibition of HIV-1 reverse 
transcriptase by a new non-nucleoside analog, KM-1. J Biol.Chem. 279:38424-38432.
 33.  Wessels, E., D. Duijsings, R. A. Notebaart, W. J. Melchers, and F. J. van Kuppeveld. 2005. A proline-
rich region in the coxsackievirus 3A protein is required for the protein to inhibit endoplasmic 
reticulum-to-golgi transport. J Virol. 79:5163-5173.
 34.  Duke, G. M. and A. C. Palmenberg. 1989. Cloning and synthesis of infectious cardiovirus RNAs 
containing short, discrete poly(C) tracts. J Virol. 63:1822-1826.
 35.  Zoll, J., H. S. Erkens, K. Lanke, L. F. Verduyn, W. J. Melchers, E. Schoondermark-van de Ven, M. 
Roivainen, J. M. Galama, and F. J. van Kuppeveld. 2009. Saffold virus, a human Theiler’s-like car-
diovirus, is ubiquitous and causes infection early in life. PLoS Pathog. 5:e1000416.
 36.  Goris, N. E., P. L. Eble, M. C. de Jong, and K. De Clercq. 2009. Quantification of foot-and-mouth 
disease virus transmission rates using published data. ALTEX. 26:52-54.
 37.  Reed, L. J. and H. Muench. 2012. A simple method of estimating the fifty per cent endpoints. Am 
J Hyg 27:493-497.
 38.  Aminev, A. G., S. P. Amineva, and A. C. Palmenberg. 2003. Encephalomyocarditis virus (EMCV) 
proteins 2A and 3BCD localize to nuclei and inhibit cellular mRNA transcription but not rRNA 
transcription. Virus Res. 95:59-73.
 39.  Jabafi, I., B. Selisko, B. Coutard, A. M. De Palma, J. Neyts, M. P. Egloff, S. Grisel, K. Dalle, V. Cam-
panacci, S. Spinelli, C. Cambillau, B. Canard, and A. Gruez. 2007. Improved crystallization of the 
coxsackievirus B3 RNA-dependent RNA polymerase. Acta Crystallogr.Sect.F.Struct.Biol.Cryst.Com-
mun. 63:495-498.
 40.  Selisko, B., H. Dutartre, J. C. Guillemot, C. Debarnot, D. Benarroch, A. Khromykh, P. Despres, M. P. 
Egloff, and B. Canard. 2006. Comparative mechanistic studies of de novo RNA synthesis by flavivi-
rus RNA-dependent RNA polymerases. Virology 351:145-158.
 41.  Lantez, V., K. Dalle, R. Charrel, C. Baronti, B. Canard, and B. Coutard. 2011. Comparative produc-
tion analysis of three phlebovirus nucleoproteins under denaturing or non-denaturing conditions 
for crystallographic studies. PLoS.Negl.Trop.Dis. 5:e936.
 42.  Krieger, E., G. Koraimann, and G. Vriend. 2002. Increasing the precision of comparative models 
with YASARA NOVA--a self-parameterizing force field. Proteins 47:393-402.
158 Chapter 7
 43.  Leslie, A. G. W. and H. R. Powell. 2007. Processing Diffraction Data with Mosflm, p. 41-51. In: R. 
Read and J. L. Sussman (eds.), Evolving Methods for Macromolecular Crystallography., vol. 245. 
Springer, Dordrecht, the Netherlands.
 44.  Potterton, E., P. Briggs, M. Turkenburg, and E. Dodson. 2003. A graphical user interface to the 
CCP4 program suite. Acta Crystallogr.D.Biol.Crystallogr. 59:1131-1137.
 45.  Murshudov, G. N., A. A. Vagin, and E. J. Dodson. 1997. Refinement of macromolecular structures 
by the maximum-likelihood method. Acta Crystallogr.D.Biol.Crystallogr. 53:240-255.
 46.  Murshudov, G. N., P. Skubak, A. A. Lebedev, N. S. Pannu, R. A. Steiner, R. A. Nicholls, M. D. Winn, 
F. Long, and A. A. Vagin. 2011. REFMAC5 for the refinement of macromolecular crystal structures. 
Acta Crystallogr.D.Biol.Crystallogr. 67:355-367.
 47.  Smart, O. S., Womack, T. O., Sharff, A., Flensburg, C., Keller, P., Paciorek, W., Vonrhein, C., and 
Bricogne, G. Grade, version 1.1.0. 2011. Cambridge, United Kingdom, Global Phasing Ltd. 
Ref Type: Generic
 48.  Emsley, P. and K. Cowtan. 2004. Coot: model-building tools for molecular graphics. Acta 
Crystallogr.D.Biol.Crystallogr. 60:2126-2132.
159
7
A novel picornavirus polymerase inhibitor
Supplementary Figures
Supplementary Figure S1. Effect of GPC-N114 on cell viability and picornavirus replication. (A) 
GPC-N114 does not affect cell viability. BGM cells were treated with GPC-N114 for 8 h after which 
cell viability was determined with an MTS assay. Cell viability is expressed as percentage of DMSO-
treated cells. Experiments were performed in triplicate and mean values ± SD are depicted. (B) 
Antiviral activity of GPC-N114 against picornaviruses. BGM cells were infected with the indicated 
viruses at an MOI of 0.5. GPC-N114 (10 µM) was added immediately after infection. At 0, 8 and 24 h 
p.i. virus titers were determined by endpoint titration. Experiments were done in triplicate and mean 
values ± SD are shown.
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Supplementary Figure S2. GPC-N114 does not affect polyprotein processing. BGM cells were 
infected with CVB3 at MOI 50. At 5 h p.i. cells were starved for methionine for 30 min after which 
produced proteins were labeled with [35S]Met in the presence of DMSO or 50 µM GPC-N114 for 
another 30 min. Subsequently, proteins were analyzed by SDS-PAGE.
Supplementary Figure S3. GPC-N114 has no effect on DENV NS5 RdRP elongation activity. 
DENV NS5 RdRP elongation activity in the presence of a range of concentrations of GPC-N114 was 
determined by measuring incorporation of [3H]UTP using poly(rA)/dT15 as template-primer. The 
activity observed with DMSO was set at 100%. Experiments were performed in triplicate and values 
shown are mean ± SD.
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Supplementary Figure S4. Stereoviews of Fo-Fc omit maps (contoured at 3.0 σ) around the inhibitors 
pockets, for the (A) CVB3 3Dpol–GPC-N114 and (B) FMDV 3Dpol–GPC-N114 complexes. The inhibitor 
contacting residues in the polymerase binding pocket are also indicated.
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Supplementary Figure S5. Sequence alignment of picornavirus RdRPs. The strictly conserved 
residues are in red blocks and similar residues in blue boxes. The residues interacting with GPC-N114 
are marked by green (CVB3) and blue squares (FMDV).
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Supplementary Figure S6. GPC-N143. (A) Antiviral activity of GPC-N143 against CVB3 and EMCV. 
The experiment was performed as in Figure 1C. Experiments were performed in triplicate and mean 
values ± SD are depicted. (B) GPC-N143 does not affect cell viability. The experiment was performed 
as in Supplementary Figure S1A. Experiments were performed in triplicate and mean values ± SD 
are depicted. (C) Structural formula of GPC-N143. (D) Stereoview of Fo-Fc omit maps (contoured at 
3.0 σ) around the inhibitor pocket for the CVB3 3Dpol–GPC-N143 complex. The inhibitor contacting 
residues in the polymerase binding pocket are indicated.
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Abstract
Proteolytical cleavage of the picornaviral polyprotein is essential for viral replication. 
Therefore, viral proteases are attractive targets for antiviral therapy. Most assays available 
for testing proteolytical activity of proteases are performed in vitro, using heterologously 
expressed proteases and peptide substrates. To deal with the disadvantages associated with 
in vitro assays, we modified a cell-based protease assay for picornavirus proteases. The as-
say is based on the induction of expression of a firefly luciferase reporter by a chimeric tran-
scription factor in which the viral protease and cleavage sites are inserted between the GAL4 
binding domain and the VP16 activation domain. Firefly luciferase expression is dependent 
on cleavage of the transcription factor by the viral protease. This biosafe assay enables test-
ing the effect of compounds on protease activity in cells while circumventing the need for 
infection. We designed the assay for 3C proteases (3Cpro) of various enteroviruses as well as 
of viruses of several other picornavirus genera, and show that the assay is amenable for use 
in a high-throughput setting. Furthermore, we show that the spectrum of activity of 3Cpro 
inhibitor AG7088 (rupintrivir) not only encompasses enterovirus 3Cpro but also 3Cpro of foot-
and-mouth disease virus (FMDV), an aphthovirus. In contrary, AG7404 (compound 1), an 
analogue of AG7088, had no effect on FMDV 3Cpro activity, for which we provide a structural 
explanation.
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Introduction
Picornaviruses are small positive-sensed RNA viruses. The single open reading frame is di-
vided into three regions: P1, encoding the structural proteins, and P2 and P3, encoding 
the nonstructural proteins. In some viruses, the P1 region is preceded by a small leader 
(L) protein. The viral polyprotein is cleaved by viral proteases resulting in the release of 
the viral proteins and some stable precursors. In all picornaviruses, the 3C protease (3Cpro) 
is responsible for the majority of the cleavages within the viral polyprotein. Some picor-
navirus genera encode an additional protease. 2Apro, expressed by members from the ge-
nus Enterovirus, cleaves between the P1 and P2 regions. Lpro, expressed by Aphthovirus and 
Erbovirus members, autocatalytically cleaves itself from P1 at its C terminus.
In addition to their function in polyprotein processing, viral proteases target a variety 
of host proteins for efficient virus replication. These include proteins involved in transla-
tion, transcription, immune signaling, or nucleocytoplasmic traffic. E.g., enterovirus 2Apro 
and aphthovirus Lpro impair cap-dependent translation through cleavage of initiation fac-
tor eIF4G, leading to a translational host shut-off1-4. Cleavage of eIF4AI by FMDV 3Cpro and 
poly(A)-binding protein by enterovirus 2Apro and 3Cpro also contribute to the host shut-off5,6.
Viral proteases provide an attractive target for antiviral therapy against picornaviruses 
because of their essential role in the virus replication cycle and the absence of cellular ho-
mologues7. As yet, no antiviral therapy has been approved to treat picornavirus infections. 
Most human pathogens can be found in the genus Enterovirus, e.g., poliovirus (PV), cox-
sackievirus, enterovirus 71 (EV71), and human rhinovirus (HRV). These viruses cause a va-
riety of diseases including acute flaccid paralysis, aseptic meningitis, respiratory infections, 
and hand-foot-and-mouth disease. The highly contagious foot-and-mouth disease virus 
(FMDV), an Aphthovirus member, is one of the most important animal pathogens, causing 
outbreaks among livestock with enormous economical impact.
The compound AG7088 (also known as rupintrivir) was developed as a potent inhibi-
tor of HRV 3Cpro 8. AG7088 is an irreversible peptidomimetic with an α,β-unsaturated ester. 
Further studies revealed that AG7088 was also able to inhibit replication of other enterovi-
ruses9-12. However, the clinical development was halted because of limited activity in clinical 
trials with natural HRV infections13. AG7404 (also known as compound 1) is an analogue of 
AG7088 with improved oral bioavailability14. AG7404 displays antiviral activity in vitro and 
is safe and well-tolerated in vivo, but clinical development was discontinued13. Recently, we 
reported the synthesis of a series of 3Cpro inhibitors, which, like AG7088, are peptidic α,β-
unsaturated esters15. Of these series, the compound SG85 was the most potent inhibitor, 
with antiviral activity against EV71, PV, echovirus 11, and HRV15.
Current assays available for testing of proteolytic activity are mostly performed in vitro 
using heterologously expressed protease and a peptide substrate. However, such cell-free 
assays for compound testing have some drawbacks. First, compounds able to inhibit proteo-
lytical activity in these assays may be unable to cross the plasma membrane. Secondly, in 
vitro assays are unable to assess cell toxicity. Thirdly, compounds that require cellular acti-
vation will not be identified as a hit in a non-cell-based assay. To deal with these issues, we 
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have adapted a cell-based assay developed previously for EV71 3Cpro (Figure 1)10. We have 
extended the assay to multiple picornavirus 3Cpro and applied the assay to test the spectrum 
of 3Cpro inhibitors AG7088 and SG85. We demonstrate that our cell-based protease assay is 
an easy and biosafe assay for testing protease activity and the effect of inhibitors, and that 
it is amenable for use in high-throughput set-up.
Results
Principle of the protease assay
The principle of the protease assay is the induction of firefly luciferase (FLuc) expression 
from a reporter plasmid in the absence of proteolytic activity of the viral protease (Figure 
1). Expression of this reporter plasmid, pG5luc, is regulated by a transcription factor com-
posed of the DNA-binding domain of Gal4 (Gal4BD) and the transactivating domain of VP16 
(VP16AD). In between these domains, we inserted part of the CVB3 polyprotein containing 
3Cpro and neighboring cleavage sites (Δ3A-3B-3Cpro-Δ3D). Proteolytical activity of 3Cpro leads 
to cleavage of the chimeric protein at the 3Cpro cleavage sites and as a consequence, the 
transcription factor lacks its VP16AD domain and no Fluc is expressed. However, in the case 
of an inactive protease no proteolytic cleavage occurs and the full-length fusion protein 
transactivates expression of FLuc. Renilla luciferase (RLuc), independently expressed from a 
different promoter on the plasmid expressing the protease construct, serves as a measure 
for transfection efficiency and indirectly for cell viability. 
The CVB3 3Cpro protease assay
To test whether this CVB3 3Cpro protease assay is functional, we analyzed proteins produced 
upon overexpression of protease constructs by Western blot using α-GAL4BD antibody. In 
COS-1 cells transfected with controls pBind and pBind-VP16, GAL4BD (reported to run at 
~17 kDa 16) and GAL4BD-VP16AD (~27 kDa) were detected, respectively (Figure 1B). When 
overexpressing pBind-3Cpro(CVB3)-VP16, a band migrating slightly slower than GAL4BD ap-
peared, corresponding to fragment GAL4BD-Δ3A produced by cleavage of fusion protein 
GAL4BD-Δ3A-3B-3Cpro-Δ3D-VP16. Upon treatment with AG7088, a band of same molecular 
mass (i.e., ~53 kDa) was detected as in cells transfected with a 3Cpro construct that was 
rendered inactive by mutation of the catalytic site (C147A) 17, demonstrating that this was 
the uncleaved full-length product. AG7088-treated cells transfected with pBind-3Cpro(CVB3)-
VP16 also expressed a protein with molecular mass corresponding to the predicted size of 
GAL4BD-Δ3A-3B, indicating that cleavage is not completely blocked in the presence of 50 
µM AG7088. Notwithstanding this, these data show the suitability of this assay for deter-
mining 3Cpro activity.
To determine whether 3Cpro cleavage activity is reflected in luciferase levels produced, 
we measured FLuc and RLuc activity in cells co-transfected with pBind-3Cpro(CVB3)-VP16 
and the pG5luc reporter plasmid. Treatment with 50 μM AG7088 resulted in ~40-fold in-
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crease in FLuc levels compared to untreated, suggesting that transactivation of the reporter 
plasmid is reversely correlated to 3Cpro activity (Figure 1C, left panel). The levels of FLuc 
obtained upon AG7088-treatment were similar to those obtained with the inactive mutant 
3Cpro [C147A]. RLuc levels were not affected by AG7088-treatment or catalytic activity of 
3Cpro (Figure 1C, right panel), so FLuc/RLuc ratios can be used to correct for possible differ-
ences in transfection efficiency.
When testing a range of concentrations of AG7088, we observed a dose-dependent in-
crease in FLuc/RLuc ratio (Figure 1D). With concentrations of ≥10 µM, FLuc/RLuc ratios were 
similar to the levels observed with the inactive mutant. The observation that some cleavage 
occurred in the presence of 50 µM AG7088 (Figure 1B) indicates that cleavage does not 
need to be completely inhibited for FLuc levels to be maximal. Nevertheless, the EC50 value 
of 1.7 µM (95% CI: 1.4-2.0 µM) for AG7088 with CVB3 3Cpro is in the same range as the EC50 
value of 0.3 µM (95% CI: 0.2-0.3 µM) that we observed in a CPE-reduction multicycle assay 
using CVB3 (Table 1), suggesting that this protease assay is a good indicator for the potency 
of an inhibitor in virus infection.
Together, these results show that our cell-based protease assay is suitable for measur-
ing protease activity and the effect of protease inhibitors or mutations.
Gal4BD
pBind-3Cpro(CVB3)-VP16:
- Inhibitor:
+
+++++
+ Inhibitor:
∆3A 3B 3Cpro ∆3D VP16AD
GAL4 GAL4 GAL4GAL4GAL4 TATA Firefly luciferase
Gal4BD
∆3A 3B
3Cpro
∆3D V
P16AD
GAL4 GAL4 GAL4GAL4GAL4 TATA Firefly luciferase
Gal4BD
∆3A
3B 3Cpr
o
∆3D V
P16AD
Figure 1. Principle and evaluation of the cell-based protease assay. (A) A protease expression 
construct is co-transfected with the pG5luc reporter plasmid into COS-1 cells. The protease 
construct expresses a chimeric protein which contains a GAL4 binding domain (GAL4BD) and a VP16 
activation domain (VP16AD) between which part of the CVB3 polyprotein (15 C-terminal amino 
acids of 3A, 3B, 3Cpro, and 15 N-terminal acids of 3D) is inserted. Active protease cleaves the chimeric 
protein at the 3Cpro cleavage (arrow). If the protease is catalytically inactive, binding of GAL4BD to the 
GAL4 sequences in the reporter plasmid recruits VP16AD to the transcription start site, resulting in 
induction of FLuc expression. Continued on the next page...
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Figure 1 (continued). Principle and evaluation of the cell-based protease assay. (B) The fusion 
protein is 3Cpro-dependently cleaved. Plasmids pBind, pBind-VP16, pBind-3Cpro(CVB3)-VP16, or 
pBind-3Cpro[C147A](CVB3)-VP16 were co-transfected with pG5luc into COS-1 cells. The next day, 
cells were lysed and the proteins were separated by SDS-PAGE and stained with α-GAL4BD and 
α-Tubulin antibodies. (C,D) Inhibition of 3Cpro activity results in induction of FLuc expression. COS-1 
cells were co-transfected with protease constructs in combination with the pG5luc reporter and 
immediately treated with DMSO or AG7088 at 50 µM (C) or at the indicated concentrations (D). At 
16 h post transfection, the cells were lysed and FLuc and RLuc were measured. Experiments were 
performed in triplicate and mean values ± SD are depicted.
Table 1. Potency of 3Cpro inhibitors against CVB3 and FMDV (3Cpro)
EC
50
 
(95% CI, in µM)
Protease assay Multicycle CPE-reduction assay
CVB3 FMDV CVB3 FMDV
AG7088 1.1 (0.9-1.3) 13.9 (12.6-15.2) 0.3 (0.2-0.3) 22.4
AG7404 3.6 (3.0-4.3) >100 ND ND
SG85 4.1 (4.0-4.3) 34.4 (31.7-37.3) 0.5 (0.2-0.7) 44.9
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Suitability of the cell-based protease assay for use in high-throughput screening
To assess whether the assay is of sufficient quality for use in a high-throughput setting, 
we calculated the Z’-factor18. Assays with a Z’-factor ≥ 0.5 are considered excellent can-
didates for high-throughput screening. To this end, cells were co-transfected with pBind-
3Cpro(CVB3)-VP16 and pG5luc and treated with DMSO (negative control) or 50 µM AG7088 
(positive control). This yielded a Z’-factor of 0.57 (using log-transformed FLuc values) or 
0.74 (using values corrected per sample for transfection efficiency, i.e., FLuc/RLuc ratios), 
indicating that the assay is excellent for use in a high-throughput screen (data not shown 
and Figure 2A). 
Keeping measurement costs low is of great importance for large-scale testing. There-
fore, we tested whether it is possible to use GFP as a read-out to eliminate the need for 
reagents for measuring protease activity. No GFP signal from the pG5EGFP reporter could be 
detected in cells co-transfected with pBind-3Cpro(CVB3)-VP16, whereas GFP was visible upon 
incubation with AG7088 or upon expression of the catalytic-site mutant of 3Cpro (Figure 2B).
Both results demonstrate that the assay is useful for high-throughput testing.
Figure 2. Suitability of the CVB3 3Cpro assay for high-throughput screening. (A) Determination of 
the Z′ factor for the CVB3 3Cpro assay. COS-1 cells were co-transfected with pBind-3Cpro(CVB3)-VP16 
and pG5luc, treated with 50 µM AG7088 and luciferase levels were measured the next day. The 
Gaussia curves displayed were fitted using nonlinear regression. (B) EGFP can also be used as a 
reporter for protease activity. COS-1 cells were co-transfected with pBind-3Cpro(CVB3)-VP16 or the 
C147A mutant and pG5EGFP, treated with 50 µM AG7088 and EGFP was imaged after 2 days.
A
B
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Figure 3. AG7088 and SG85 inhibit enterovirus 3Cpro and FMDV 3Cpro. (A) AG7088 and SG85 
display activity against enterovirus 3Cpro and FMDV 3Cpro. Cells co-transfected with the constructs 
for the indicated proteases and pG5luc reporter were treated with 50 µM AG7088 or SG85 and 
the next day the luciferase levels were measured. Displayed are the FLuc levels. (B,C) AG7088 and 
SG85, but not AG7404 inhibit FMDV 3Cpro, albeit with lower potency than CVB3 3Cpro. Cells co-
transfected with pG5luc and the CVB3 or FMDV 3Cpro constructs were treated with a range of con-
centrations of AG7088 or AG7404 (B) or SG85 (C). The dashed lines represent the values obtained 
for the respective inactive mutants (upper dashed line) or the values obtained for the untreated wt 
constructs (lower dashed line). All experiments were performed in triplicate and values represent 
the mean FLuc ± SD.
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The spectrum of activity of AG7088 and SG85
To enable us to determine the spectrum of potential protease inhibitors, we then designed 
equivalent 3Cpro constructs for representative members of different picornavirus genera, in-
cluding enteroviruses (EV71, PV, HRV14), an aphthovirus (FMDV), cardioviruses (encepha-
lomyocarditis virus, EMCV,  and Saffold virus, SAFV), a parechovirus (human parechovirus, 
HPeV), and a hepatovirus (hepatitis A virus, HAV). Cleavage of the fusion proteins was con-
firmed by Western blot (data not shown).
We tested the inhibitory activity of 3Cpro inhibitors AG7088 and SG85 against these 
picornavirus 3C proteases. As anticipated, expression of FLuc in the absence of compound 
was comparable to that observed with pBind-3Cpro(CVB3)-VP16 for most 3Cpro constructs, 
although levels were somewhat higher in the case of SAFV, HPeV, and HAV (Figure 3A). RLuc 
activity was decreased in cells expressing the FMDV 3Cpro fusion protein (Supplementary Fig-
ure S1), possibly as result of cleavage of eIF4AI by 3Cpro 5. Therefore, FLuc values were used 
for data analysis instead of FLuc/RLuc ratios.
FLuc expression was induced upon treatment with 50 µM AG7088 or SG85 in cells 
transfected with all enterovirus 3Cpro constructs (Figure 3A, left panel). In contrast, no effect 
was observed on reporter activity upon expression of constructs for EMCV, SAFV, HPeV, or 
HAV 3Cpro, suggesting that these proteases are insensitive to AG7088 and SG85. As predicted 
by the protease assay, 50 μM AG7088 displayed no significant activity against EMCV and 
SAFV in growth curves of EMCV and SAFV (Supplementary Figure S2). Remarkably, AG7088 
and SG85-treatment increased FLuc expression in cells expressing FMDV 3Cpro to similar lev-
els as observed for catalytically inactive FMDV 3Cpro (H46Y or C163G)19. These data indicate 
that FMDV 3Cpro is sensitive to AG7088 and SG85 and that both protease inhibitors have a 
similar spectrum of activity. 
The effects of AG7088, AG7404 and SG85 on FMDV 3Cpro activity 
A more elaborate testing of the FMDV and CVB3 3Cpro constructs with concentration series 
of AG7088 and SG85 illustrated that both compounds are less potent against FMDV than 
against CVB3 (Figures 3B, 3C and Table 1), in line with them having been originally designed 
against enteroviruses.
AG7088 and SG85 were able to inhibit FMDV-induced CPE on BHK-21 cells in a multi-
cycle CPE-reduction assay with an EC50 value of 22.4 µM and 44.9 µM, respectively, indicat-
ing that 3Cpro inhibition by AG7088 and SG85 impaired replication of FMDV (Table 1).
The sensitivity of FMDV 3Cpro to AG7088 led us to test whether this protease was also 
susceptible to AG7404, the orally bioavailable analog of AG7088. Remarkably, this com-
pound displayed little or no inhibitory activity towards FMDV 3Cpro, while the activity against 
CVB3 3Cpro was comparable to that observed for AG7088 (Figure 3B and Table 1).
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Rationale for the differences in the potencies of AG7088, AG7404, and SG85 towards 
FMDV 3Cpro
We utilized computational modeling techniques to explain the observed differences in in-
hibitory activity of AG7088, AG7404 and SG85 (Figure 4A) towards FMDV 3Cpro. Induced fit 
docking was used to predict the binding mode of AG708820, the most potent inhibitor of 
FMDV 3Cpro of the three compounds, to FMDV 3Cpro. A recent crystal structure of FMDV 3Cpro 
complexed with a peptide substrate (Figure 4B)21 reveals that the so-called β-ribbon that 
separates the S2 and S4 subsites of the protease is slightly longer in FMDV 3Cpro compared to 
other 3C proteases, as for example seen in the complex of HRV2 3Cpro with AG7088 (Figure 
4C)22,23. The models we generated suggest interactions with this loop to be mainly respon-
sible for the observed selectivity profile of the three compounds assayed.
Figure 4D shows the obtained model of AG7088 bound to FMDV 3Cpro, with the 
β-ribbon highlighted in blue. The model suggests extensive tight hydrophobic interactions 
between the P3 position of AG7088 and the β-ribbon of FMDV 3Cpro. The ring closure pres-
ent at the P3 position of AG7404 is predicted to clash with the β-ribbon of FMDV 3Cpro, pro-
viding a rationale for the observed inactivity of AG7404 toward FMDV 3Cpro. SG85, which has 
intermediate potency compared to AG7088 and AG7404, contains a t-butyl ether of serine 
as its P3 side chain. This introduces more steric bulk compared to AG7088, but allows for 
more flexibility when compared to AG7404, potentially explaining the observed intermedi-
ate activity of SG85.
Discussion 
In this study, we developed an assay for the measurement of protease activity of 3Cpro of 
various enteroviruses as well as of other picornaviruses (Figure 1), based on the principle 
described previously for EV71 3Cpro 10, and we have applied this assay to test the spectrum 
of activity of three 3Cpro inhibitors. A major advantage of this assay is that it is cell-based, 
in contrast to most protease assays available. As a consequence, compounds that cannot 
penetrate the plasma membrane or have adverse cellular effects are selected out when 
searching for protease inhibitors. Another advantage is that the assay depends on an in-
crease in read-out signal upon inhibition of protease activity. This precludes the identifica-
tion of false-positive hits on the basis of an aspecific reduction in reporter activity because 
of toxicity. Also, compounds that require cellular activation will not be accurately evaluated 
in a non-cell-based assay.
The nature of the cell-based assay allows easy expansion of the range of proteases. In 
contrast, in vitro assays require production of recombinant enzyme which can be time-con-
suming and potentially cumbersome. The assay could also be applied to proteases of other 
plus-strand RNA viruses, such as hepatitis C virus, dengue virus, and SARS coronavirus. One 
example for which our cell-based assay would be advantageous, is NS2B/NS3pro of dengue 
virus (family Flaviviridae). NS3 protease activity is most commonly tested with a construct 
in which the polypeptide chains of the co-factor NS2B and the protease domain of NS3 are 
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linked by a nonapeptide linker. Optimal activity of this construct in vitro requires a high pH 
of 9.0 potentially leading to protonation of compounds and hence false-positive or false-
negative hits in screens24. 
An assay should preferentially be suitable for use in a high-throughput setting. We 
showed that the assay is excellent for use in a high-throughput setting, as exemplified by 
a Z’-factor of 0.74 for CVB3 3Cpro (Figure 2D). It would be advisable to also test the assay 
with non-reversible protease inhibitors before applying it in a high-throughput screening, 
to confirm that the assay can also identify such inhibitors. Several adaptations to further 
optimize the assay for use in large-scale screens may be possible. We here provide a proof 
of principle for use of GFP as read-out instead of FLuc (Figure 2B). Although this reporter is 
less sensitive, it is more cost-efficient. In addition, cell lines with stable constructs that are 
inducible, may be used. 
The availability of expression constructs for a wide range of picornavirus 3Cpro, enabled 
us to test the spectrum of activity of 3Cpro inhibitors AG7088 and SG85. We showed that 
both compounds inhibited 3Cpro of all enterovirus tested, i.e., CVB3, EV71, PV, and HRV14, 
but they had no effect on processing by 3Cpro of EMCV, SAFV, HPeV, or HAV. A recent publi-
cation reported that inhibition of HAV replication by AG7088 is strain-dependent, and also 
found no effect on the strain we used (HM175)25. Interestingly, both compounds inhibited 
Figure 4. Rationale for the different potencies of AG7088, AG7404, and SG85 towards FMDV 
3Cpro. (A) Chemical structures of AG7088, AG7404 and SG85. The protease pockets targeted by the 
different chemical moieties are outlined on top. (B) The β-ribbon of FMDV 3Cpro (highlighted in blue) 
as observed in a recent crystal structure21. (C) HRV2 3Cpro in complex with AG7088 (in orange) with 
the β-ribbon highlighted in red23. (D) Generated model of FMDV 3Cpro in complex with AG7088, with 
the β-ribbon highlighted in blue.
A B C
D
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3Cpro of FMDV, albeit with a lower potency than CVB3 3Cpro. Testing in multicycle CPE-reduc-
tion assays revealed that our assay accurately predicted that the compounds possessed an-
tiviral activity. While this study was in progress, AG7088 was shown to inhibit FMDV 3Cpro in 
an in vitro FRET assay using fluorogenic substrates with recombinant 3Cpro (IC50= 4.21 ± 1.97 
µM)26, corroborating our finding. The assay presented and the insights developed here may 
help as a tool to design potent protease inhibitors of FMDV, a highly contagious zoonotic 
virus that can cause outbreaks with an enormous economic impact. 
In conclusion, we have presented a protease assay that enables measuring protease 
activity and the inhibitory activity of compounds in a cellular environment. Currently, we are 
further expanding this assay to proteases of other virus families.
Materials and methods
Cells
COS-1 monkey kidney cells, Hela cells and baby hamster kidney (BHK-21) cells were cultured 
in DMEM with 10% FCS and 1% penicillin/streptomycin at 37°C with 5% CO2. The culture 
medium was suppplemented with 0.6 mg /ml geneticin (G418 sulphate) for Huh-T7 cells, a 
derivative of human hepatocellular carcinoma cells that constitutively expresses a T7 RNA 
polymerase27.
Plasmids
Plasmids pBind, pAct and pG5luc were derived from the CheckMate™ Mammalian Two-
Hybrid System (Promega). pBind-VP16 was produced by ligating the VP16AD-coding se-
quence amplified from pAct into the XbaI and NotI sites of the multiple cloning site of pBind. 
pBind-VP16 was subsequently used for cloning all protease constructs using the SalI and 
MluI sites between GAL4BD and VP16AD. Mutagenesis was performed using the Quikchange 
II Site-Directed Mutagenesis Kit (Agilent). pG5EGFP was constructed by inserting the EGFP-
coding sequence amplified from pEGFP-N1 (Clontech) into the NcoI and PpuMI restriction 
sites of pG5luc. Templates and primers used for PCR are shown in the Supplementary Table.
Compounds
AG7088 and SG85 were synthesized as described previously15,28. AG7404 was a kind gift of 
Pfizer. Compound stocks were dissolved in DMSO and stored at -20°C.
Western blot
COS-1 cells were seeded in 12- or 6-well plates. The next day, the medium was replaced with 
(compound-containing) medium. Cells plated in 12-well plates were co-transfected with 700 
ng protease construct and 700 ng pG5luc using 4.2 μl Fugene according to the manufac-
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turer’s instructions. For 6-well plates, 1750 ng of each plasmid was transfected using 10.5 
μl Fugene. The next day, the cells were harvested and lysis buffer (40 mM Tris-HCl, 150 
mM NaCl, 10 mM EDTA, 1% NP40 supplemented with Complete protease inhibitor cocktail 
(Roche)) was added to the cell pellet. The cell lysate underwent two rounds of vortexing and 
10’-incubations at 4°C, followed by centrifugation for 10’ at 13,000 rpm. Laemmli was added 
to the supernatant. The proteins were separated by SDS-PAGE on 12.5% polyacrylamide gel 
(analysis of fusion protein fragments) or 7.5% polyacrylamide gel (analysis eIF4G cleavage). 
Proteins were detected using mouse monoclonal anti-GAL4BD antibody (Clontech), rabbit 
polyclonal anti-eIF4GI antibody (A300-502A, Bethyl Laboratories), or rat anti-tubulin alpha 
antibody (AbD Serotec) followed by appropriate monoclonal IRDye secondary antibodies 
(Li-Cor Biosciences). Imaging was done with the Odyssey system.
Protease assay
COS-1 cells were seeded into 96-well plates. The next day, subconfluent monolayers were 
transfected with 100 ng protease construct and 100 ng pG5luc reporter plasmid using 0.6 
µl Fugene. The transfection mix was added to the cells on which the medium had been re-
placed with DMSO- or compound-containing medium. After ~16 h, the cells were lysed with 
passive lysis buffer and luciferase activities were measured with the Dual-Glo Luciferase 
Assay System (Promega). 
For experiments with the EGFP read-out, the experiment was performed as described 
above except that pG5EGFP was transfected instead of pG5luc and cells were incubated for 
~48 h before imaging with an EVOS fl digital fluorescence microscope (AMG). Cells were 
fixed, permeabilized, and stained with α-GAL4BD antibody to check for similar transfection 
efficiencies.
Graphpad Prism 5.0.3 was used for statistical analysis. EC50 values were calculated using 
non-linear regression setting the values obtained for the inactive mutants and the untreated 
wt constructs as top and bottom constraints, respectively. The Z’-factor was calculated from 
21 values per condition using the following formula: Z’= 1-3(SD
DMSO
 + SD
AG7088
)/|mean
DMSO
 - 
mean
AG7088
|.
Multicycle CPE-reduction assay
Multicycle CPE-reduction assays were performed as described previously29,30. CVB3 strain 
Nancy (from infectious clone p53CB3/T7) was tested on Huh-T7 cells and the FMDV strain 
O1 Manisa on BHK-21 cells
31,32. In short, cells seeded in 96-well plates were treated with se-
rial dilutions of compound and infected with virus at low MOI. After three-day incubation, 
cell viability was measured by MTS assay (AQueous One Solution Cell Proliferation Assay, 
Promega).
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Molecular docking
All molecular-docking studies were performed by using the flexible docking program 
Fleksy20. The crystal structure of FMDV 3Cpro complexed with a peptide substrate (21, PDB 
ID: 2WV4) solved at 2.5 Å resolution was used as the receptor structure. The structure was 
prepared for docking by removing the peptide from the complex. Subsequently, hydrogen 
atoms were added to the structure, and their positions were optimized by using the Yasara 
program (http://www.yasara.org). Otherwise, default parameters as described previously 
were applied20.
Virus infections
Subconfluent layers of cells seeded in 24-well plates were infected with EMCV (strain men-
govirus, derived from the infectious clone pM16.1, a kind gift from A. Palmenberg) or SAFV8 
at an MOI of 0.1. Virus was allowed to adsorb for 30 min, after which cells were washed and 
fresh medium containing 50 μM AG7088 or DMSO was added. At the indicated time points, 
cells were subjected to three cycles of freeze-thawing and virus titers were determined by 
endpoint titration. EMCV titers were determined on BHK-21 cells and SAFV titers on Hela 
cells. 
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182 Chapter 8
Supplementary Table & Figures
Su
pp
le
m
en
ta
ry
 T
ab
le
. C
lo
ni
ng
 s
tr
at
eg
y
Pl
as
m
id
s
Vi
ru
s
PC
R
 t
em
pl
at
e
Fo
rw
ar
d 
pr
im
er
 (5
’-
3’
)
Re
ve
rs
e 
pr
im
er
 (5
’-
3’
)
Co
ns
tr
uc
t 
pG
5E
G
FP
pE
G
FP
-N
1
CA
CA
AC
CA
TG
G
TG
AG
CA
AG
G
G
CT
G
AG
G
AC
CT
TT
AC
TT
G
TA
CA
G
CT
CG
TC
C
pB
in
d-
V
P1
6
pA
ct
G
CA
G
TC
TA
G
AC
AG
AT
G
AA
G
CT
AC
TG
TC
TT
CT
AT
C
CC
TG
G
CG
G
CC
G
CG
AT
CC
CG
G
AC
CC
G
G
G
G
AA
TC
CC
pB
in
d-
3C
pr
o (
CV
B3
)-
V
P1
6
CV
B3
 N
an
cy
p5
3C
B3
/T
73
1
G
CA
G
G
TC
G
AC
TG
G
CT
G
G
AA
TC
AT
AT
AT
AT
AA
T
CC
TG
AC
G
CG
TC
TG
G
AA
AC
CC
G
G
CG
TC
CT
TT
G
pB
in
d-
3C
pr
o (
EV
71
)-
V
P1
6
EV
71
 B
rC
r-
TR
pE
V
71
(B
rC
r-
TR
)3
3
G
CA
G
G
TC
G
AC
TT
G
TG
TC
TC
TT
G
TT
TA
TG
TC
AT
CC
TG
AC
G
CG
TT
CA
AC
CT
CC
CG
G
TT
TC
TC
TG
pB
in
d-
 3
Cp
ro
(H
RV
14
)-
V
P1
6
H
RV
14
 1
05
9
pW
R3
.2
63
4
G
CA
G
G
TC
G
AC
CA
TT
AG
G
TA
TT
G
TT
TA
TG
TC
AT
T
CC
TG
AC
G
CG
TG
AT
TT
AT
G
TT
AA
AC
TC
CC
TA
A
pB
in
d-
3C
pr
o (
PV
1)
-V
P1
6
PV
1 
M
ah
on
ey
pX
pA
-R
en
R-
PV
35
G
CA
G
G
TC
G
AC
TG
G
CT
G
G
AG
TT
G
TC
TA
TG
TC
A
CC
TG
AC
G
CG
TT
TG
G
AT
AT
CC
CA
CT
TC
CT
TC
pB
in
d-
 3
Cp
ro
(F
M
D
V
)-
V
P1
6
FM
D
V
 O
1K
pM
R1
53
6
G
CA
G
G
TC
G
AC
TG
AA
CT
CC
G
AG
CC
TG
CC
CA
AC
C
CC
TG
AC
G
CG
TT
CA
CG
TG
AA
CG
CG
CT
CT
TC
CA
pB
in
d-
 3
Cp
ro
(E
M
CV
)-
V
P1
6
EM
CV
, M
en
go
pM
16
.1
37
G
CA
G
G
TC
G
AC
TG
G
TG
AG
AC
CA
G
AC
TT
G
G
TG
CG
CC
TG
AC
G
CG
TG
G
G
G
TA
CA
TG
G
AT
G
CG
CG
G
A
pB
in
d-
 3
Cp
ro
(S
A
FV
)-
V
P1
6
SA
FV
3
pS
P7
2-
SA
FV
3*
G
CA
G
G
TC
G
AC
TG
G
TG
TG
TC
CA
G
CC
CC
TG
TC
C
CC
TG
AC
G
CG
TG
CG
G
AA
CG
TG
CA
CA
AC
TG
TG
pB
in
d-
 3
Cp
ro
(H
Pe
V
)-
V
P1
6
H
Pe
V
1
H
Pe
V
1 
st
oc
k3
8
G
CA
G
G
TC
G
AC
TG
CT
TT
TG
G
TC
AC
TA
AA
AT
T
CC
TG
AC
G
CG
TT
AT
TG
AT
AT
AC
AT
G
G
G
TT
G
T
pB
in
d-
 3
Cp
ro
(H
AV
)-
V
P1
6
H
AV
 H
M
17
5
pH
AV
/7
39
G
CA
G
G
TC
G
AC
TG
TA
TA
AG
CA
TT
TC
TC
CC
G
C
CC
TG
AC
G
CG
TA
G
AC
CA
CA
TT
CA
TT
G
AA
CA
C
M
ut
ag
en
es
is
 p
ri
m
er
s
pB
in
d-
3C
pr
o [
C1
47
A
](
CV
B3
)-
V
P1
6
CA
AG
AG
CA
G
G
CC
AG
GC
TG
G
TG
G
AG
TG
CT
C
G
AG
CA
CT
CC
AC
CA
GC
CT
G
G
CC
TG
CT
CT
TG
pB
in
d-
 3
Cp
ro
[H
46
Y]
(F
M
D
V
)-
V
P1
6
CT
TA
CC
TC
G
TG
CC
TC
G
TT
AT
CT
CT
TC
G
CA
G
AG
AA
G
CT
TC
TC
TG
CG
AA
G
AG
AT
A
AC
G
AG
G
CA
CG
AG
G
TA
AG
pB
in
d-
 3
Cp
ro
[C
16
3G
](
FM
D
V
)-
V
P1
6
CA
AG
G
CT
G
G
TT
AC
GG
CG
G
AG
G
AG
CC
G
T
AC
G
G
CT
CC
TC
CG
CC
G
TA
AC
CA
G
CC
TT
G
Pr
im
er
s 
an
d 
te
m
pl
at
es
 u
se
d 
fo
r 
th
e 
cl
on
in
g 
of
 t
he
 p
ro
te
as
e 
ex
pr
es
si
on
 c
on
st
ru
ct
s.
 R
es
tr
ic
tio
n 
si
te
s 
ar
e 
un
de
rl
in
ed
 a
nd
 m
ut
at
ed
 n
uc
le
oti
de
s 
ar
e 
sh
ow
n 
in
 b
ol
d.
*C
on
ta
in
s 
th
e 
se
qu
en
ce
 d
es
cr
ib
ed
 in
 Z
ol
l e
t 
al
.40
. T
he
 c
on
st
ru
cti
on
 o
f t
hi
s 
in
fe
cti
ou
s 
cl
on
e 
w
ill
 b
e 
de
sc
ri
be
d 
el
se
w
he
re
.
183
8
Application of a cell-based protease assay
Supplementary Figure S2. AG7088 and SG85 do not inhibit EMCV and SAFV. Hela cells were 
infected with EMCV or SAFV at MOI of 0.1. Immediately after infection 50 μM AG7088 or DMSO was 
added to the cells. After 0/8/24/48 h, cells were lysed by freeze-thawing and the total virus titer was 
determined by endpoint titration. The dotted line indicates the detection limit, *=not detectable.
Supplementary Figure S1. AG7088 and SG85 inhibit enterovirus 3Cpro and FMDV 3Cpro. Levels of 
Fluc, RLuc and the calculated ratio from the experiment displayed in Figure 3A.
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Summary
The genus Enterovirus of the family Picornaviridae includes many important human patho-
gens, such as poliovirus (PV), coxsackievirus, enterovirus 71 and rhinovirus. These viruses 
can cause a wide variety of diseases, ranging from mild to potentially fatal. Efficient vaccines 
against PV have almost succeeded to globally eradicate PV, but development of vaccines 
against all enteroviruses is not feasible due to the enormous amount of serotypes (almost 
300 identified to date). At the moment, no antiviral drugs are available and treatment is 
limited to symptomatic and supportive care. For these reasons, antiviral drugs are urgently 
needed. In addition, antiviral drugs may be beneficial to contain any posteradication out-
breaks of PV which may occur after stopping of the global vaccination program. Therefore, 
the aim of this thesis was to identify and characterize targets in the replication cycle of en-
teroviruses for antiviral therapy and compounds with antiviral activity against enteroviruses. 
These compounds may either exert their antiviral activity by targeting viral proteins or host 
factors that are essential for virus replication. Furthermore, by studying the mechanism of 
action of enterovirus inhibitors, we aim to increase our knowledge of the viral replication 
process and the requirements. This information may in turn benefit the search for new an-
tiviral drugs, for example by identifying new drug targets.
In CHAPTER 2, we have studied the effects of two putative inhibitors of the cellular 
protein GBF1 on enterovirus replication. The guanine nucleotide exchange factor GBF1 is an 
essential host factor for replication of enteroviruses. At the early secretory pathway, GBF1 
activates the GTPase Arf1 by stimulating GTP exchange. Activated Arf1 then regulates mem-
brane trafficking through the recruitment of effector proteins. Inhibition of GBF1 by the 
fungal metabolite Brefeldin A (BFA) strongly impairs enterovirus replication. The compound 
Golgicide A (GCA) was proposed to be an inhibitor of GBF1, with a similar mechanism of ac-
tion as BFA, but with higher specificity1. AG1478 was also reported to inhibit GBF1 activity, 
but in a different, probably indirect manner2. Consequently, we investigated whether these 
compounds would share the antiviral effect of BFA. We found that GCA inhibited enterovirus 
replication, but this was not the case for AG1478, supporting the idea that this latter com-
pound does not inhibit GBF1 in the same manner as the other compounds. A further major 
finding supporting this idea is that the effects of AG1478 on the function and integrity of 
the secretory pathway could be rescued by overexpression of Arf1, which was not the case 
for BFA and GCA. Both GCA, which unlike BFA does not target other large Arf activators, and 
AG1478, which disrupts secretory pathway integrity and function by a different mechanism 
than BFA and GCA, provide important new tools to further dissect the role of GBF1 in en-
terovirus RNA replication. 
CHAPTER 3 describes the identification and characterization of a new antiviral com-
pound, TTP-8307. The spectrum of antiviral activity of TTP-8307 encompassed most, but not 
all, enteroviruses. To study the mechanism of action of the compound, TTP-8307-resistant 
coxsackievirus B3 (CVB3) mutants were selected by passaging 10 times in the presence of 
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TTP-8307. These mutants harbored mutations in the viral protein 3A, a membrane protein 
implicated in the viral modification of secretory pathway membranes. Previously, a variety 
of mutations in 3A had been shown to confer resistance to enviroxime, an antiviral com-
pound identified in the late 1970s of which the mechanism of action remained unknown. 
We showed that the TTP-8307-resistant mutants were cross-resistant to enviroxime, sug-
gesting that these antiviral compounds have a similar or related mechanism of action. 
Subsequently, in CHAPTER 4 we showed that GW5074 also is an inhibitor of entero-
virus replication, and that this kinase inhibitor, as well as enviroxime, act by inhibiting the 
activity of PI4KIIIβ, a lipid kinase that had just been identified as an essential host factor for 
enterovirus replication3. We also showed that enviroxime- and GW5074-resistant viruses 
(i.e., the viruses with the single point mutations identified in CHAPTER 3) could replicate in 
the absence of high levels of PI4P, the product of PI4KIIIβ. These results demonstrate that 
viruses are so versatile that they can even bypass the need for host factors for virus replica-
tion.
In CHAPTER 5, NIH Clinical Collection compound library, a collection of small mole-
cules that have a history of use in human clinical trials, was screened for inhibitors of CVB3. 
This screen revealed that itraconazole (ITZ), a compound which is in use as an antifungal 
drug, has antiviral activity. Known targets of ITZ, such as hCYP51, CYP3A4 or the hedgehog 
pathway were investigated if they mediated the antiviral activity of ITZ, but this appeared 
not to be the case. Interestingly, the antiviral activity of ITZ could be counteracted by the 
same mutations in 3A that provided protection against PI4KIIIβ inhibitors, suggesting a simi-
lar mechanism of action. However, ITZ had no effect on PI4KIIIβ activity. Also, unlike PI4KIIIβ 
inhibitors, ITZ inhibited virus replication of cardioviruses, providing further evidence for a 
different target. Several lines of evidence suggested that the antiviral activity of ITZ involves 
OSBP and/or ORP4, both of which are sterol-binding proteins implicated in sensing and 
transfer of sterols at membrane contact-sites. Further investigation is required to determine 
the role for OSBP/ORP4 in enterovirus and cardiovirus replication.
CHAPTER 6 reports on the antiviral activity of fluoxetine, an anti-depressant (brand 
name Prozac) that was also identified in a screen of the NIH Clinical Collection. The antiviral 
spectrum of activity of fluoxetine encompassed some enteroviruses, but not all. The obser-
vation that mutations in the viral protein 2C of CVB3 offered protection to the compound, 
suggested that fluoxetine targets 2C. 2C has been implicated in many different aspects of 
virus replication, but its exact function is unknown. 2C is an ATPase, but fluoxetine had only 
a modest effect on 2C’s ATPase activity. This finding suggests that fluoxetine targets another 
activity of 2C.
In CHAPTER 7, we studied the antiviral activity of the small molecule GPC-N114. GPC-
N114 inhibited virus replication of both enteroviruses and cardioviruses at the RNA replica-
tion stage. No resistant CVB3 variants were obtained despite many passages in the presence 
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of GPC-N114. In the cardiovirus EMCV, mutations in the viral RNA-dependent RNA poly-
merase 3Dpol conferred resistance to the compound. Accordingly, GPC-N114 inhibited in vi-
tro elongation activity of CVB3 and EMCV 3Dpol. Analysis of the three-dimensional structure 
of 3Dpol in complex with GPC-N114 revealed that the compound, a non-nucleoside analog, 
bound at the site where the templating nucleotide is located during the RNA replication 
process. This result suggests that GPC-N114 may interfere with template binding. This hy-
pothesis was confirmed in functional studies. Collectively, these findings show that GPC-
N114 inhibits picornavirus replication by affecting the binding of the RNA template to 3Dpol, 
making this the first picornavirus inhibitor with this mechanism of action.
Finally, in CHAPTER 8 we describe the development of a cell-based assay for determin-
ing the capability of compounds to inhibit picornaviral protease activity. Inhibition of pro-
tease activity results in the induction of expression of a firefly luciferase reporter. A major 
advantage of this assay is that it is cell-based, in contrast to most protease assays available, 
allowing to select for non-toxic and cell-permeable compounds. We showed that the assay 
could accurately predict the potential of compounds to inhibit virus replication, with IC50 
values obtained for several compounds in the same range as those determined with virus 
infections. In addition, the assay was versatile, applicable to CVB3 3Cpro and 2Apro and could 
easily be extended to 3Cpro of different genera. In combination with the excellent properties 
for use in a high-throughput setting, this assay could be a valuable tool for the discovery and 
validation of protease inhibitors.
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General Discussion
Impairing viral replication can be achieved in two manners: either by targeting viral proteins 
with direct-acting antiviral compounds or by targeting cellular factors. In this thesis com-
pounds of both groups have been discussed.
Direct-acting antiviral compounds
The majority of antiviral drugs used in the clinic have viral proteins as targets, with most 
drugs targeting the viral polymerase or the proteases. This is the most obvious strategy for 
antiviral therapy, with the advantage that viral proteins are not required for cell viability and 
targeting thus has no detrimental effect on cellular function.
Polymerase inhibitors
Targeting of the viral polymerase can be an efficacious method for antiviral treatment, which 
is illustrated by the fact that first-line treatment of HIV currently consists of two polymerase 
inhibitors4. Polymerase inhibitors can be divided into nucleoside/ nucleotide analogues and 
non-nucleoside inhibitors (NNI). 
In CHAPTER 7, we describe the identification of GPC-N114 as a novel non-nucleoside 
inhibitor of the RNA-dependent RNA polymerase (RdRP) 3Dpol. GPC-N114 impaired 3Dpol ac-
tivity by affecting the binding of the template to 3Dpol. A question that is left open is whether 
GPC-N114 competes with the template for binding to 3Dpol or whether the template is able 
to bind the 3Dpol–GPC-N114 complex, but in a nonproductive manner. Electrophoretic mo-
bility shift assays need to be done to determine if preincubation of 3Dpol with the compound 
prevents binding to template-primer duplexes in order to answer this question.
GPC-N114 has several properties that are commendable for antiviral drugs. It is a 
broad-spectrum antiviral compound, inhibiting all tested viruses from both the enterovirus 
and cardiovirus genus. In addition, CVB3 did not become resistant to GPC-N114 despite over 
30 passages in the presence of the compound. This characteristic would be very advanta-
geous in a clinical setting. To determine whether GPC-N114 has potential for clinical devel-
opment, several issues need to be addressed. Animal studies are required to determine 
if GPC-N114 is well-tolerated in vivo. GPC-N114 structurally belongs to the nitroaromat-
ics, a group of chemicals which are often toxic, mutagenic, or carcinogenic5. On the other 
hand, the presence of NO2-groups is not necessarily deleterious, because multiple other 
nitroaromatics such as chloramphenicol, nitrazepam, or nitrofurantoin have been approved 
for clinical use6. In vivo experiments are necessary for obtaining a final answer on the ques-
tion of toxicity. Also, it needs to be established if GPC-N114 also displays antiviral activity in 
a mouse model of CVB4-induced pancreatitis. However, formulation of this compound for 
in vivo administration has so far proven difficult and requires either further efforts to obtain 
a good compound formulation or optimization of the structure of GPC-N114. At the mo-
ment, structure-based drug design is being used to develop analogs of GPC-N114 without 
NO2-groups and hopefully improved solubility properties. In addition, in silico drug design 
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is being applied to develop novel structurally unrelated compounds targeting the pocket 
identified in CHAPTER 7 using pharmacophores. Thus, even if GPC-N114 turns out not to be 
suitable for clinical development, the information gathered in this study may still contribute 
to antiviral drug discovery.
Very few of the hits identified in CPE-based screens with CVB3 performed at the auto-
mated screening facility of the Rega institute turn out to have the polymerase as target. This 
contrasts with other RNA viruses such as hepatitis C virus and bovine viral diarrhea virus for 
which a number of NNIs have been identified. A possible explanation for this observation 
might be the difference in the mechanism of initiation7,8. In the primer-dependent picornavi-
rus RdRP the active site is accessible and the central cavity is sufficiently wide to fit the single 
stranded template plus the VPg primer during initiation and the double-stranded product 
during elongation. In contrast, RdRPs that have a de novo initiation mechanism such as hep-
atitis C virus NS5B have additional protrusions extending from the thumb domain compared 
to picornavirus RdRPs. These protrusions act as a priming platform during the initiation of 
RNA replication but block the exit of an extended dsRNA product, so a large conformational 
change has to take place to permit elongation. Therefore, stabilization of the priming plat-
form by binding of an NNI at an allosteric site provides an additional mechanism of inhi-
bition of polymerase activity for de novo RdRPs compared to the more rigid picornavirus 
RdRPs, possibly explaining the higher quantity of inhibitors identified for these polymerases.
Protease inhibitors
Other common targets for antiviral therapy are the viral proteases since these are essential 
for correct processing of the viral polyproteins and cellular homologues are absent. Protease 
inhibitors developed for HIV and hepatitis C virus, such as atazanavir and telaprevir, have 
demonstrated the suitability of these targets for antiviral therapy. In CHAPTER 8 we describe 
a cell-based and biosafe assay for testing the effects of compounds on protease activity. We 
showed that the assay is a valid method for testing the proteolytic activity of CVB3 3Cpro, 
and that the assay can also be adapted to test 3Cpro of other enteroviruses or 2Apro. This 
cell-based assay could serve as a tool for screening for novel protease inhibitors. The advan-
tage of cell-based assays over in vitro or in silico methods is that these are able to identify 
compound toxicity and take into account possible cellular metabolization of compounds. 
Though we have focused our efforts now on developing tools for studying the activity of pi-
cornavirus proteases, the assay would also be of use for other viral proteases. For example, 
the most commonly used in vitro test for dengue virus NS2B/NS3 protease requires an un-
physiologically high pH9, so a cell-based assay is suspected to yield more relevant results.
Most of the protease inhibitors developed so far – such as the in CHAPTER 8 studied 
AG7088 (rupintrivir), AG7404 (compound 1), and SG compounds – are peptidomimetic ac-
tive site inhibitors which have been designed based on the cleavage site recognized by the 
targeted protease. Alternatives to peptidomimetics are non-peptidic competitive inhibitors 
or allosteric inhibitors. The latter type of inhibitors impairs proteolytical activity or substrate 
binding in a noncompetitive manner by binding the enzyme outside of the active site. Inter-
est has increased in allosteric site inhibitors, because for the competitive compounds the 
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occurrence of resistance mutations in the active site often gives cross-resistance to other 
competitive inhibitors10,11. In antiviral research, the discovery of the first allosteric inhibi-
tor of hepatitis C virus NS3 protease12, illustrates the potential of small non-peptidic mol-
ecules as allosteric inhibitors in this for virus proteases largely unexplored field. In contrast 
to peptidomimetics design, screening a small molecule library has the advantage that this 
is not specific for a certain binding site or mechanism of action and thus has the potential 
to identify allosteric inhibitors. In combination with the advantages of cellular assays, our 
cell-based protease assay could make a valuable contribution in the identification of novel 
non-peptidic protease inhibitors, both of the allosteric type and the competitive type.
2C-targeting compounds
The viral protein 2C, one of the most conserved enterovirus proteins13, has been reported 
to be the target of a number of enterovirus inhibitors, for example of guanidine hydrochlo-
ride (GuHCl), MRL-1237, HBB, and TBZE-02914-18. In CHAPTER 6 we describe the discovery 
of a new inhibitor of enterovirus replication, fluoxetine, which also targets 2C. Deciphering 
Figure 1. Chemical structures of 2C-targeting compounds.
MRL-1237
HBB
GuHCl
TBZE-029 Fluoxetine
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the mechanisms of action of 2C inhibitors has been seriously hampered by an incomplete 
understanding of the function of 2C. The protein 2C has been implicated in many viral pro-
cesses (such as RNA replication, RNA binding, the induction of membrane rearrangements, 
encapsidation, and uncoating), but its exact function has not been elucidated yet. Based 
on the presence of several conserved motifs, the protein has been predicted to act as a 
helicase, but no one has yet been able to prove this function experimentally. 2C displays 
ATPase activity, which is required for the RNA unwinding activity of helicases, but none of 
the compounds displayed a strong effect on the ATPase activity of 2C, although contradic-
tory results were reported for GuHCl14,19. Determining the function(s) of 2C and establishing 
functional assays is crucial for elucidating the mechanism of action of 2C inhibitors. A recent 
publication has shown that 2C of a picorna-like virus exhibits RNA chaperone activity, exem-
plified by nonspecific nucleic acid helix destabilizing and annealing acceleration activities20. 
Both of these activities were independent of the ATPase activity. Thus, establishing whether 
enterovirus 2C also displays RNA chaperone activity and whether this is the activity of 2C 
that is targeted by this set of inhibitors, is an interesting avenue to pursue in the search for 
the mechanism of action of 2C-inhibitors. 
Assigning 2C as the target of 2C inhibitors was based on the observation that muta-
tions in 2C conferred resistance to these compounds. In CHAPTER 6 we showed that CVB3 
carrying three mutations in 2C (i.e., 2C-A224V, I227V, A229V) was resistant to fluoxetine. 
This mutant was previously found in CVB3 pools obtained upon culturing in the presence 
of the enterovirus inhibitor TBZE-029 and was also found to be cross-resistant to 2C in-
hibitors GuHCl, MRL-1237, HBB, and TBZE-02914-18. Thus, these three residues (i.e., 224, 227, 
and 229) appear to be of critical importance for determining the sensitivity to all of these 
2C inhibitors. One possible explanation for the cross-resistance observed is that the com-
pounds directly bind 2C at the same pocket and that the resistance mutations render the 
compound-binding pocket insusceptible to the compounds. The hypothesis that the com-
pounds directly interact with 2C, and each with slightly different compound-protein inter-
actions, is consistent with two observations. Firstly, the resistance profiles of the inhibitors 
proved similar, but not identical, when testing the sensitivity of mutant viruses containing 
only one or two of the three mutations14. Secondly, the compounds have different spec-
tra of antiviral activity, with GuHCl inhibiting all tested enteroviruses, MRL-1237 and HBB 
inhibiting a somewhat more narrow range of enteroviruses and TBZE-029 and fluoxetine 
inhibiting solely enteroviruses from the human enterovirus (HEV) B and D species, i.e., the 
species that contain the “AGSINA motif” which contains the residues mutated in compound-
resistant CVB3 (A224GS227INA229)
18,21-24. These different spectra of activity could be a result 
of small differences in the binding pockets of 2C of the various viruses. Binding studies are 
required to determine if the compounds bind directly to 2C and if the resistance mutations 
preclude binding. Secondly, assuming there is a direct interaction, an analysis of the three-
dimensional structure of 2C, alone and in complex with inhibitors, is likely to yield important 
insight into the compound-protein interactions. However, 2C has so far remained refractory 
to crystallization, but efforts are still continuing. 
Despite the fact that the functions of 2C have not yet been elucidated, 2C appears to 
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be a promising target for antiviral therapy. The fact that many compounds have been found 
to target 2C implies that 2C is easily targeted, possibly as a result of an easily accessible com-
pound-binding pocket. The potential of 2C as a drug target in vivo was demonstrated by the 
observation that a 2C-targeting compound with very potent anti-enteroviral activity in the 
nanomolar range identified at the Rega Institute, KU Leuven, was very efficient in inhibiting 
the CVB4-induced pancreatitis and viral replication in the pancreas of CVB4-infected mice25. 
For fluoxetine the relatively modest potency compared to plasma concentrations achieved 
in vivo and reported side effects could possibly obstruct the use for antiviral therapy in vivo. 
Whether 2C fluoxetine and other 2C-inhibitors can serve as a scaffold to design more potent 
inhibitors remains to be determined. As anticipated above, in order to advance the develop-
ment of 2C inhibitors, deciphering the function and structure of 2C is of great importance.
Antiviral compounds targeting host factors
The alternative to targeting viral proteins with antiviral compounds, is to target cellular host 
factors that are required for efficient virus replication. For a few of the host factors known, 
inhibitors with antiviral activity have been identified.
GBF1
One of the best-studied host factors for enteroviruses is GBF1. GBF1 has a central role in 
membrane trafficking by mediating GDP-to-GTP exchange of Arf1, the GTPase that recruits 
many effector proteins (e.g., COP-I) upon activation. Inhibition of GBF1 by Brefeldin A (BFA) 
leads to a complete block of virus replication. BFA inhibits GBF1 activity by stabilizing GBF1 
in a non-productive complex with ARF1-GDP on membranes. In CHAPTER 2 we describe 
that of two novel putative GBF1 inhibitors, only GCA, but not AG1478, was an enterovirus 
inhibitor, consistent with its proposed effect on GBF1. GCA was shown to bind GBF1 in the 
same pocket as BFA, so it is likely that also GCA works by stabilizing an abortive complex 1. In 
contrast, the other compound, AG1478, did not affect enterovirus replication, even though 
the effects of AG1478 on the early secretory pathway were similar to those of BFA and GCA 
with respect to Golgi complex dispersal, localization of Arf1 and COP-I 2. 
The reason why inhibition of GBF1 by BFA or GCA blocks enterovirus replication is not 
known. The fact that AG1478 has many effects in common with these enterovirus inhibitors 
without affecting enterovirus replication makes this compound a useful tool to help eluci-
date this question. For example, the Golgi complex is believed to be an important source for 
replication membranes and is the site at which viral RNA replication is initiated. The obser-
vation that enterovirus replication is unaffected in cells in which the Golgi complex has been 
fragmented by AG1478, suggests that GBF1 is not required for productive virus replication 
just to maintain an intact Golgi complex. In addition, Arf1 does not localize at replication 
membranes in CVB3-infected cells upon AG1478-treatment (preliminary data, H.M. van der 
Schaar and F. van Kuppeveld), suggesting that while Arf1 is activated and present on replica-
tion membranes during enterovirus infection26, this might not be obligatory. This is in line 
with a hypothesis put forward by Belov et al., who proposed that the antiviral effect of BFA 
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is not due to impaired Arf1 activation, but rather because the formation of the abortive 
Arf1-GDP-BFA-GBF1 complex renders GBF1 unavailable for use by the virus27. These obser-
vations demonstrate the contribution AG1478 can make to increasing our understanding in 
the requirements for enterovirus replication. A further dissection of the similarities and dif-
ferences in the effects of AG1478 and BFA/GCA on GBF1 and other factors of the secretory 
pathway is expected to provide further insight.
PI4KIIIβ/PI4P/OSBP/ORP4
During infection with positive-strand RNA viruses replication organelles are formed as a re-
sult of remodeling of cellular membranes. The complex mechanism of the generation of 
replication organelles has not been elucidated yet. Among other things, the role of lipid-
modifying cellular enzymes in this process has been subject of investigation. For example, 
the flaviviruses dengue virus, West Nile virus and yellow fever virus were shown to ma-
nipulate cellular fatty acid synthesis to alter the membrane lipid composition28,29. During the 
course of this PhD project, phosphatidylinositol 4-kinase IIIβ (PI4KIIIβ), a kinase responsible 
for the synthesis of the pool of PI4P lipids at the Golgi complex30, was identified as a novel 
host factor for enteroviruses3. 
We and others showed that the antiviral activity of the enterovirus replication inhibi-
tors enviroxime, GW5074, T-00127-HEV1, and PIK93 is mediated by inhibition of the kinase 
activity of PI4KIIIβ31. In CHAPTER 4 we established that certain mutations (i.e., V45A, I54F, 
and H57Y) in the non-structural protein 3A could offer protection against these inhibitors. It 
is difficult to envisage how these mutations convey resistance since the target of these com-
pounds is not a viral protein but a host cell protein and resistance hence cannot involve al-
teration of the drug-binding pocket. Moreover, the function of the target in replication is yet 
poorly understood. We demonstrated that the CVB3 compound-resistant mutants 3A-V45A 
and 3A-H57Y have gained the ability to replicate in the absence of or with low levels of PI4P 
lipids. The underlying mechanism, however, is still unclear, in part of because the function 
of PI4P lipids in replication is yet unknown. More insight in the role of I4KIIIβ and PI4P in en-
terovirus RNA replication is mandatory to explore the resistance mechanism of the mutants.
It was remarkable to observe that some compounds to which the 3A-mutants are 
cross-resistant, do not affect PI4KIIIβ activity (i.e., ITZ, AN-12-H5, and T-00127-HEV2)31,32. In-
stead, their antiviral activity seems to be related to the sterol-binding proteins OSBP and/or 
ORP4, since knockdown of these proteins enhances the antiviral effect of these compounds. 
Also, the compounds affect the subcellular localization of OSBP. Preliminary results indicate 
that also 25-hydroxycholesterol (25-HC) and OSW-1, both ligands of OSBP and ORP4, have 
an inhibitory effect on enterovirus and cardiovirus replication (preliminary results, J. Strat-
ing, L. Albulescu, and F. van Kuppeveld), which was also previously reported for 25-HC with 
PV32. Though this does not prove that ITZ also acts directly on OSBP and ORP4, it does dem-
onstrate that directly targeting these proteins has an antiviral effect, so it is possible that 
also ITZ works in this manner.
The role for PI4P lipids and OSBP/ORP4 in virus replication remains to be established. 
The fact that a single point mutation such as 3A-H57Y can offer protection to both groups of 
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inhibitors suggests that PI4KIIIβ/PI4P and OSBP/ORP4 are functionally related in enterovirus 
infection. The exact function of PI4P lipids is yet unknown. One possibility is that PI4P-rich 
domains facilitate membrane reorganizations by altering membrane properties such as cur-
vature (Figure 2)33. Alternatively or additionally, the function of PI4P lipids may be to recruit 
viral proteins, e.g., 3Dpol 3, or cellular proteins with PI4P-binding PH domains. Interestingly, 
both OSBP and ORP4 contain a PH domain, providing a possible link between PI4KIIIβ/PI4P 
and OSBP/ORP4. For OSBP it has been shown that its PH domain mediates PI4P-binding34. If 
this is also the case for ORP4 remains to be studied. Thus, one possibility is that in entero-
virus infection the PI4P lipids synthesized by PI4KIIIβ serve to recruit OSBP/ORP4 to replica-
tion sites (Figure 2). OSBP and ORP4 are (oxy)sterol-binding proteins which are implicated 
in non-vesicular sterol transport, lipid sensing, cell signaling, and vesicle transport and have 
been proposed to act as sterol sensors and transporters35. A possible function of OSBP/ORP4 
in virus replication could therefore be to modify the membrane composition by transfer 
of sterols, thereby altering membrane properties to facilitate viral replication. The amount 
of cholesterol, for example, affects membrane curvature and fluidity. Further studies will 
reveal whether OSBP and ORP4 indeed are recruited during virus infection to replication 
sites and whether this is required for productive infection. If so, it would be interesting to 
investigate the possibility that the bypass mechanism of the resistant mutants to circumvent 
the requirement of PI4KIIIβ/PI4P entails an alternative mechanism for recruitment of OSBP/
ORP4. It is important to emphasize that the current results do not give an answer as to 
whether OSBP and ORP4 are essential for enterovirus and cardiovirus replication and thus 
truly represent novel host factors. An alternative explanation for our observations could 
be that the increased level of OSBP (and ORP4?) on the Golgi complex renders the mem-
branes unfit to support viral replication, for example because of an altered sterol content of 
the membranes. It is also important to note that OSBP and ORP4 can form heterodimers36. 
Hence, it remains unresolved whether both OSBP and ORP4 are independently involved in 
virus replication or if one of them is involved only indirectly through the heterodimerization 
Figure 2. A possible model of PI4K and OSBP/ORP4 in enterovirus and cardiovirus replication. 
Either PI4KIIIβ (enterovirus) or PI4KIIIα (cardiovirus) is recruited to replication sites where they then 
synthesize PI4P lipids, resulting in PI4P-rich membranes. PI4P lipids could have multiple functions 
in virus replication, such as altering membrane properties like curvature and recruiting the viral 
polymerase 3Dpol (as suggested for CVB3). OSBP and/or ORP4 may be recruited through their PI4P-
binding PH domains and may possibly form heterodimers.
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with the other.
In contrast to enteroviruses, cardioviruses do not require PI4KIIIβ for replication and 
are therefore unaffected by treatment with PI4KIIIβ inhibitors. On the other hand, they are 
sensitive to OSBP/ORP4-targeting compounds, reflecting differences in the spectrum of an-
tiviral activity of the two groups of compounds and in the host requirements. Extending on 
the highly putative model outlined above, a possibility is that cardioviruses have developed 
an alternative mechanism to induce high levels of PI4P lipids to recruit OSBP/ORP4 (Figure 
2). Indeed, preliminary data suggest that the IIIα isoform of PI4K is a novel host factor for 
cardioviruses (C. Dorobantu, Q. Feng, F. van Kuppeveld, unpublished).
Overall, PI4KIIIβ represents an interesting target for antiviral therapy against enterovi-
ruses. Interestingly, the kinase has also been shown to be important for replication of hepa-
titis C virus (HCV), although this may be genotype-dependent3,37-41. The suitability of PI4KIIIβ 
as a drug target in vivo is currently under debate. Recently, Novartis identified some novel 
small molecule inhibitors of PI4KIIIβ that were shown to have no cytotoxic effects when test-
ed on a large panel of tumor cell lines and primary human fibroblasts. However, these inhibi-
tors interfered with lymphocyte proliferation and chemokine secretion in a mixed leukocyte 
reaction42. In another recent study it was described that chemical inhibition of PI4KIIIβ by 
a small molecule identified by Boehringer Ingelheim as well as by T-00127-HEV1 was lethal 
to mice43. In contrast, we observed no obvious adverse effects (and certainly not lethality) 
upon testing a PI4KIIIβ inhibitor identified in collaboration with biotech company Galapagos 
in a mouse model, while it resulted in an inhibitory effect on in vivo CVB4 replication and 
CVB4-induced pancreatitis44. This suggests that inhibition of PI4KIIIβ is not deleterious per se 
and that the adverse effects observed in the other studies could be due to off-target effects. 
Although the possibility of aspecificity was investigated for the inhibitors used in the toxicity 
experiments, this was only done by testing the effects on a panel of kinases. However, it is 
also possible that the PI4KIIIβ inhibitors target proteins other than kinases, as exemplified 
by the inhibition of deacylase Sirtuin 5 and glutamate dehydrogenase by GW507445,46. Thus, 
further studies are required to determine if the lethality observed should be attributed to 
inhibition of PI4KIIIβ or to off-target effects and if PI4KIIIβ is a safe target in vivo.
The OSBP/ORP4-targeting compounds, such as ITZ and OSW-1, have not been test-
ed yet in an animal infection model. The steady-state concentration of ITZ in the plasma 
achieved with standard antifungal treatment is 2.8 µM, a concentration which has an an-
tiviral effect in vitro. Thus, it is plausible that treatment with ITZ results in antiviral activity 
in doses with acceptable side effects. However, animal experiments will need to be done 
to determine if ITZ is sufficiently potent to inhibit virus replication in vivo. In each case, ITZ 
could serve as a scaffold for development of novel OSBP/ORP4 targeting compounds.
Taken together, the study of the compounds that select for mutations in 3A and their 
targets represents an interesting field both for antiviral drug development and for furthering 
the understanding of enterovirus and cardiovirus replication mechanisms.
197
9
Summary & General discussion
Targeting of host factors for antiviral therapy: a promising strategy?
The last decade, interest has increased in developing antiviral therapy targeting host fac-
tors, culminating thus far in the successful development of one host-targeting antiviral drug: 
maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor47. The strategy to use host 
factors as targets for antiviral therapy has been advocated with the idea that it may be ben-
eficial with respect to two important issues in antiviral therapy: broad-spectrum activity and 
the reduced likelihood of resistance development.
Broad-spectrum activity is a very desirable feature of an antiviral drug. Especially since 
standard diagnostics does not routinely include sero- or genotyping, it is favorable if a drug 
displays antiviral activity against most or all viruses within a genus. Targeting host factors 
may enhance the chances of having broad-spectrum activity because the requirement for 
specific host factors is often conserved among related viruses. Although it is possible that 
the requirement for a host factor varies between viruses within a genus, most host factors 
are likely to be shared. One illustrative example of this is ITZ, for which the spectrum of an-
tiviral activity encompasses all tested viruses of both the enterovirus and even cardiovirus 
genus.
Also, a high genetic barrier to resistance is a highly sought-after property of antiviral 
compounds. Though not in all cases, for many of the compounds described in this thesis, 
resistant virus mutants were obtained for at least one virus (CHAPTERS 2-7), illustrating a 
great problem in the treatment of viruses and pathogens in general. For bacteria, the resis-
tance to antibiotics is increasing to the point where experts predict that we might be return-
ing to the pre-antibiotic era 48. Likewise, drug resistance is also for viruses a big problem. 
For example, the prevalence of transmitted drug-resistant HIV is estimated to be 5-15%49. 
Therefore, it is possible that also in the treatment of picornaviruses the development of 
drug-resistance will become a problem once drugs are introduced in the clinic. One may 
speculate that because of the acute nature of picornavirus infections and hence short treat-
ment periods, drug-resistance may present a smaller problem for this group of viruses than 
for viruses that cause chronic infections such as HIV. However, the wide-spread resistance of 
influenza A virus to amantadine and rimantadine (with >90% of isolated H3N2 viruses resis-
tant)50,51 argues otherwise and signals that drug-resistance may indeed be a realistic prob-
lem in the clinic, also for viruses that require only short-term treatment. On the other hand, 
the fact that we observed resistance when culturing virus in the presence of compound in 
lab conditions, does not automatically mean that these mutants will also emerge in vivo and 
subsequently establish themselves in circulating virus strains. This depends on factors such 
as the treatment regimen (e.g., monotherapy versus combination therapy) and fitness of 
resistant virus mutants. Even if resistance can develop against inhibitors in vitro, these drugs 
might still be useful in the clinic when administered prudently. Nevertheless, a high barrier 
to resistance is highly desired.
The chance of developing drug-resistance is believed to be lower when the antivi-
ral targets are essential cellular factors. Unlike viral targets, cellular targets are unlikely to 
mutate in response to therapy. However, this approach is based on the assumption that 
viruses are not capable of mutating in such a way that they can overcome inhibition of a 
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critical host factor. Several examples have demonstrated that this is not necessarily true. 
For example, HIV-1 can become resistant to the CCR5 antagonist maraviroc by switching to 
the co-receptor CXCR4 or by gaining the ability to bind to the antagonist-modified form of 
CCR552,53. More specific for enteroviruses, PV could become resistant to the GBF1-inhibitor 
BFA by acquiring mutations in 2C and 3A54. Furthermore, our finding described in CHAP-
TER 4 that CVB3 mutants with single point mutations in 3A have become independent of 
PI4KIIIβ/PI4P shows that RNA viruses can even become resistant to inhibitors of an essential 
host factor and use a bypass mechanism for replication independent of (high levels of) a 
critical lipid. Collectively, these findings illustrate that viruses can even become resistant 
to host-targeting antiviral compounds. On the other hand, PV could not become resistant 
to the geldanamycin, an inhibitor of the chaperone protein Hsp90 which is required for 
encapsidation55. Moreover, alisporivir, an inhibitor of cyclophilin A in clinical development 
for the treatment of HCV, appears to have a high genetic barrier to resistance both in vitro 
and in vivo56-59, suggesting that targeting host factors may indeed decrease chances of resis-
tance development, although it is no guarantee. Thus, targeting host factors may still prove 
a good, though not perfect, strategy.
A potential downside of targeting host factors is that the chances of adverse effects 
of drug treatment are higher when inhibiting cellular targets than when targeting viral pro-
teins. However, one should realize that in general most drugs have host targets. In fact, this 
is the case in all diseases in which no pathogen is involved, demonstrating that targeting 
host proteins is not necessarily problematic. For example, inhibitors of the HCV host factor 
cyclophin A, a protein that makes up 0.1-0.4% of the total cellular protein content60, general-
ly have a good safety profile and any adverse effects observed rather seem to be associated 
with the specific inhibitor than with the target61. Multiple reasons may explain why targeting 
host factors may be a feasible approach61. First, not all proteins are essential for cell viability. 
Moreover, in some cases viral replication may require higher levels of protein activity than 
is needed for maintaining a proper cellular function, creating a window for inhibiting virus 
replication without affecting cell viability. Also, it may be the case that the cellular target has 
a redundant function, but that viruses can only utilize the targeted protein.
All in all, targeting host factors is a strategy worthwhile to pursue, notwithstanding the 
usefulness of direct-acting antiviral compounds.
Conclusion and future perspectives
In this thesis we have made a significant contribution to the battle against enterovirus infec-
tions in three ways: by identifying novel compounds with antiviral activity, by furthering the 
knowledge on enterovirus infections through elucidating the mechanism of action of these 
compounds, and by providing tools for the identification of new inhibitors. 
The future of antiviral drug development will be shaped by the advances made in the 
field of enterovirus replication mechanisms. Identification of novel host factors will provide 
novel targets for antiviral therapy. Though targeting host factors has some advantages, the 
more traditional direct-acting inhibitors should not be dismissed because of the wealth of 
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expertise in using viral proteins as drug targets and their proven use in the treatment of for 
example HIV. Though the development of antiviral therapy represents a big challenge, the 
progress made in the last couple of years raises hope that it is an achievable goal.
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Inleiding
Dit proefschrift handelt over virussen uit een familie genaamd Picornaviridae (Latijns), of 
picornavirussen in gewoon Nederlands. De familie van picornavirussen kan ingedeeld wor-
den in meerdere geslachten. Hiervan zijn de enterovirussen voor de mens het belangrijkste 
geslacht, omdat deze de meeste ziekteverwekkers voor de mens bevat. Enkele voorbeelden 
hiervan zijn poliovirus, coxsackievirus en enterovirus 71. Deze virussen kunnen een vers-
cheidenheid aan ziektes veroorzaken zoals poliomyelitis (=kinderverlamming), ontsteking 
van het hart en hersenvliesontsteking. Ook de rhinovirussen vallen onder de enterovirus-
sen. Rhinovirussen veroorzaken bij gezonde mensen een simpele verkoudheid, maar kun-
nen hele kwalijke gevolgen hebben bijvoorbeeld bij astma patiënten, die er een ernstige 
verergering van de luchtwegklachten van kunnen krijgen.
Op dit moment zijn er geen medicijnen beschikbaar om enterovirusinfecties te bestri-
jden en kunnen alleen de symptomen behandeld worden. Het ontwikkelen van vaccins om 
alle enterovirus infecties te voorkomen is niet haalbaar omdat er ongeveer 300 enterovirus-
sen zijn en ieder vaccin normaal gesproken maar tegen 1 virus kan beschermen. Om deze 
reden was het doel van dit proefschrift om nieuwe moleculen te vinden die enterovirus-
sen kunnen remmen die later eventueel kunnen dienen als medicijn. Medicijnen kunnen 
namelijk meestal op meerdere op elkaar lijkende virussen aangrijpen.
Om nieuwe virusremmers te vinden, is het nodig om inzicht te hebben in hoe het virus 
zich vermenigvuldigt en wat het daar voor nodig heeft. Virussen zijn obligate intracellulaire 
parasieten, wat inhoudt dat ze zich niet zelfstandig kunnen vermenigvuldigen, oftewel rep-
liceren, maar dat ze hiervoor een cel nodig hebben. Een enterovirus bestaat uit een streng 
RNA, als drager van de genetische informatie, die omgeven is door een mantel van virusei-
witten. Als het virus de gastheercel binnenkomt, komt het RNA vrij en worden viruseiwitten 
gemaakt aan de hand van de genetische informatie die opgeslagen is in het virale RNA. In 
eerste instantie wordt er een zogenaamd polyproteine gemaakt, dit is een fusie van alle 
eiwitten. De virale proteases (eiwitknippende enzymen) zorgen ervoor dat dit grote fusie-
eiwit in individuele eiwitten wordt geknipt. Deze losse eiwitten zorgen ervoor dat het RNA 
wordt vermenigvuldigd en dat de nieuwe RNA strengen worden ingepakt in viruseiwitten 
om nieuwe virusdeeltjes te maken. Deze komen vrij als de cel kapot gaat. Dit hele proces is 
één replicatiecyclus. 
Iedere stap in de replicatiecyclus kan dienen als aangrijpingspunt om de vermenigvul-
diging van het virus te remmen. Virusremmers kunnen dan ook vele verschillende werkings-
mechanismen hebben. Wat het werkingsmechanisme betreft kunnen remmers in twee gro-
epen ingedeeld worden: de remmers die aangrijpen op viruseiwitten (waarvan voorbeelden 
worden besproken in HOOFDSTUKKEN 2-5) en degenen die aangrijpen op eiwitten van de 
gastheercel die nodig zijn voor replicatie van het virus (beschreven in HOOFDSTUKKEN 6-8).
In dit proefschrift worden nieuwe antivirale middelen geïdentificeerd. Dit is in de 
meeste gevallen gedaan door moleculen te zoeken die ervoor zorgen dat cellen een virusin-
fectie overleven. Van moleculen die via deze methode geïdentificeerd worden, weten we 
alleen dat ze het virus remmen, maar het achterliggende mechanisme is onbekend. Daarom 
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is van deze middelen het werkingsmechanisme bestudeerd. De redenen hiervoor zijn ten 
eerste om de werking van het middel te doorgronden. Daarnaast dient dit om een beter 
inzicht te krijgen in de replicatiestrategieën van het virus en bijvoorbeeld welke eiwitten of 
lipiden het virus nodig heeft om zichzelf te vermenigvuldigen. Deze kennis kan op zijn beurt 
gebruikt worden om de zoektocht naar nieuwe antivirale middelen te faciliteren.
Resultaten 
Enkele jaren geleden heeft onderzoek naar de virusreplicatiestrategieën uitgewezen dat 
GBF1, een eiwit gemaakt door de gastheercel, essentieel is voor replicatie van het virus, 
ook al is nog niet precies bekend waarom. In een ongeïnfecteerde cel speelt GBF1 een be-
langrijke rol in het regelen en intact houden van de secretieroute van de cel. De cellulaire 
secretieroute is een systeem van membranen en daaraan gerelateerde factoren wat ervoor 
zorgt dat eiwitten worden gemaakt en getransporteerd naar de goede plek in of buiten de 
cel. Remming van de functie van GBF1, door bijvoorbeeld het stofje BFA, zorgt ervoor dat 
de secretieroute uiteenvalt en niet meer functioneel is. Tijdens virusinfectie wordt de secre-
tieroute onherkenbaar veranderd om replicatie van het virus mogelijk te maken. Als GBF1 
geremd wordt door behandeling met BFA kan het virus zich niet meer vermenigvuldigen. 
Ook van de moleculen GCA en AG1478 is recent door anderen beschreven dat zij de functie 
van GBF1 remmen. Om deze reden is in HOOFDSTUK 2 het effect van deze moleculen op vi-
rusreplicatie bestudeerd. We hebben gevonden dat alleen GCA enterovirusreplicatie remde, 
maar AG1478 had geen effect. Dit suggereert dat AG1478 een ander werkingsmechanisme 
heeft dan de andere twee moleculen. Desondanks had AG1478 veel effecten gemeen met 
GCA en BFA met betrekking tot de secretieroute. Een analyse van de verschillen en de over-
eenkomsten tussen de effecten van de moleculen, kan waarschijnlijk bijdragen tot het oph-
elderen van de reden waarom GBF1 nodig is voor de vermenigvuldiging van het virus.
HOOFDSTUK 3 beschrijft de identificatie van een nieuw molecuul met antivirale werking, 
namelijk TTP-8307. Dit molecuul remde de meeste enterovirussen. TTP-8307 doet dit door 
aan te grijpen op de stap in de replicatiecyclus waarin het RNA gekopieerd wordt, dus niet 
op het hechten van het virus aan de cel, het de cel binnenkomen of het inpakken van het 
virale RNA in de eiwitmantel. Om meer inzicht te krijgen in het werkingsmechanisme van de 
remmer, is er resistentiekweek gedaan. Dit houdt in dat het virus gekweekt wordt in aan-
wezigheid van de remmer. Virussen maken regelmatig foutjes bij het kopiëren van het RNA, 
waardoor er mutante virussen ontstaan. Als een bepaalde mutant een voordeel heeft ten 
opzichte van de andere virusvarianten, bijvoorbeeld als deze mutant resistent is tegen een 
remmer, dan zal deze mutant de bovenhand krijgen. Dit is het bekende principe van “the 
survival of the fittest”. Het opsporen van de locatie van de mutaties die verantwoordelijk 
zijn voor de resistentie geeft een aanwijzing voor welk viraal eiwit betrokken is bij het werk-
ingsmechanisme van de remmer. In het geval van TTP-8307 waren de mutaties gelokaliseerd 
in het stuk van het virale RNA dat codeert voor het eiwit 3A. Dit eiwit is betrokken bij de 
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veranderingen van de membranen van de secretieroute tijdens infectie.
Het antivirale middel enviroxime is eind jaren 70 al gevonden, maar het werkings-
mechanisme was desondanks nog steeds onbekend. Wel was destijds gevonden dat resis-
tentie-mutaties in 3A zaten. Het bleek dat de TTP-8307-resistente mutanten ook resistent 
waren tegen enviroxime, wat suggereert dat het werkingsmechanisme van de twee molecu-
len gerelateerd is. 
Vervolgens hebben we in HOOFDSTUK 4 laten zien dat GW5074 ook een remmer is van 
enterovirus replicatie. We hebben aangetoond dat de antivirale werking van GW5074 en 
enviroxime te wijten was aan remming van het cellulaire eiwit PI4KIIIβ, een eiwit wat lipiden 
maakt genaamd PI4P. Van PI4KIIIβ en het product PI4P was vlak daarvoor door een andere 
onderzoeksgroep bewezen dat ze essentieel zijn voor de vermenigvuldiging van enterovirus-
sen en dat het virale eiwit 3A hiermee te maken heeft. In HOOFDSTUK 4 laten we verder 
zien dat de GW5074- en enviroxime resistente virussen konden repliceren in de afwezigheid 
van hoge hoeveelheden PI4KIIIβ en PI4P in tegenstelling tot het wildtype virus (= zonder 
mutaties). Deze resultaten zijn opmerkelijk, omdat juist gedacht werd dat het voor een virus 
heel lastig is om resistentie te ontwikkelen tegen remmers die op gastheerfactoren aangri-
jpen. Dit in tegenstelling tot remmers die direct op virale eiwitten aangrijpen, aangezien 
het virus zo kan muteren dat de remmers het eiwit niet meer kunnen herkennen. Deze 
resultaten demonstreren dat virussen heel flexibel zijn en zelfs zo kunnen muteren dat ze 
bepaalde (gastheer)factoren niet meer nodig hebben.
In HOOFDSTUK 5 is er van een verzameling stofjes getest of deze een antivirale werking heb-
ben tegen enterovirussen. Al deze compounds zijn al voor andere doeleinden onderzocht 
in klinische studies, waardoor er reeds veel informatie over beschikbaar is. In deze studie 
is gevonden dat het antischimmelmiddel itraconazol antivirale werking heeft. Uit eerder 
onderzoek naar itraconazol is al naar voren gekomen dat itraconazol effect heeft op meer-
dere cellulaire eiwitten, maar uit onze studie is gebleken dat de tot nu toe bekende effecten 
van itraconazol niet de oorzaak zijn van de antivirale werking. Het bleek dat de mutaties in 
3A die zorgden voor resistentie tegen TTP-8307, enviroxime en GW5074 ook zorgden voor 
een verminderde gevoeligheid voor itraconazol, wat een gerelateerd werkingsmechanisme 
suggereert. Opmerkelijk genoeg bleek itraconazol geen effect te hebben op PI4KIIIβ, het 
doeleiwit van GW5074 en enviroxime. Een ander verschil met de PI4KIIIβ remmers, is dat 
itraconazol niet alleen enterovirussen remde, maar ook virussen uit het geslacht Cardiovirus. 
Ook dit suggereert dat itraconazole op een andere manier werkt dan de PI4KIIIβ remmers. 
Enkele bevindingen wijzen erop dat de antivirale werking van itraconazol in plaats daarvan 
te maken heeft met OSBP en ORP4. Dit zijn twee eiwitten waarvan bekend is dat ze eigen-
schappen van membranen kunnen beïnvloeden, zoals de samenstelling. Opheldering van de 
precieze rol van deze eiwitten in virusreplicatie en de details van het werkingsmechanisme 
van itraconazol, vereist nog verder onderzoek.
In HOOFDSTUK 6 is vervolgens beschreven dat bovengenoemde studie ook het antidepres-
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sivum fluoxetine, beter bekend onder de naam Prozac, heeft geïdentificeerd als virusrem-
mer. Een aantal mutaties in het virale eiwit 2C zorgden ervoor dat het virus resistent werd 
tegen deze remmer. Van 2C is bekend dat het op vele punten in de replicatiecyclus een rol 
speelt, maar op welke manier precies is niet bekend. Om deze reden is het moeilijk om te 
onderzoeken hoe fluoxetine op dit eiwit aangrijpt. Wel is bekend dat 2C voor één of meer-
dere van zijn functies het energiemolecuul ATP verbruikt. Experimenten hebben uitgewezen 
dat fluoxetine geen effect heeft op het vermogen van 2C om ATP te verbruiken. Dit sugger-
eert dat fluoxetine 2C op een andere manier remt of beïnvloedt.
Vervolgens is in HOOFDSTUK 7 de nieuwe virusremmer GPC-N114 beschreven. GPC-N114 
remde replicatie van enterovirussen en cardiovirussen. Het verkrijgen van resistent cox-
sackievirus (een enterovirus) is niet gelukt ondanks langdurige pogingen. Dit wijst er op 
dat coxsackievirus moeilijk resistentie ontwikkelt tegen deze stof, wat een voordeel zou zijn 
bij gebruik van het middel in de kliniek. EMCV, een cardiovirus, werd wel resistent na het 
enkele weken te kweken in aanwezigheid van GPC-N114. De mutaties die verantwoordelijk 
waren voor de resistentie zaten in het deel van het RNA dat codeerde voor 3Dpol, het vi-
rale eiwit dat het RNA van het virus kopieert. Verder onderzoek wees uit dat deze kopieer-
functie van het enzym geremd was. Verschillende aanwijzingen suggereerden dat dit komt 
doordat het enzym het te kopiëren RNA niet meer goed kan binden als het stofjeal aan 
het enzym gebonden is. Voor picornavirussen zou dit de eerste virusremmer zijn met dit 
werkingsmechanisme.
Als laatste wordt in HOOFDSTUK 8 een nieuwe methode beschreven die gebruikt kan wor-
den om de activiteit van virale proteases te meten. Proteases zijn essentieel in de replica-
tiecyclus van het virus, omdat zij ervoor zorgen dat de individuele virale eiwitten geknipt 
worden uit de lange eiwitketen die in eerste instantie gemaakt wordt. Dit is nodig omdat de 
eiwitten anders hun functie niet uit kunnen oefenen. Omdat virale proteases zo belangrijk 
zijn voor virusreplicatie, worden ze beschouwd als aantrekkelijke aangrijpingspunten voor 
antivirale therapie. Uiteraard zijn er voor het ontwikkelen van protease remmers methodes 
nodig om protease activiteit en het effect van potentiële remmers daarop te meten. Op het 
moment zijn de meeste methodes die hiervoor gebruikt worden biochemisch van aard, wat 
inhoudt dat er opgezuiverde proteases gebruikt worden die in een kunstmatige omgeving 
bestudeerd worden. De methode die wij ontwikkeld hebben meet daarentegen de protease 
activiteit in cellen. Dit heeft meerdere voordelen, zoals dat in deze methode een eventueel 
toxisch effect van moleculen op de cellen gedetecteerd kan worden en dat het moleculen 
selecteert die niet de cel in kunnen komen. Gebruikmakende van deze celgebaseerde meth-
ode hebben we twee eerder beschreven remmers van het 3C protease (AG7088 en SG85) 
onderzocht. Hieruit bleek dat ze in onze methode even actief waren als tijdens een /virusin-
fectie, wat er op wijst dat onze methode een goede indicatie geeft voor hoe sterk de mol-
eculen het virus remmen. Verder hebben we aangetoond dat de methode eenvoudig uit te 
breiden is naar 3C proteases van andere virussen in de picornavirus familie. Hiervan gebruik 
makende hebben we aan kunnen tonen dat de remmers naast de enterovirus proteases 
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waarvoor ze ontwikkeld zijn, ook het 3C protease remmen van mond-en-klauwzeervirus, 
een virus dat onder het geslacht Aphthovirus valt. Samenvattend, hebben we een methode 
ontwikkeld die zeer bruikbaar is voor het in de cel testen van potentiële protease remmers, 
wat de methode een waardevol gereedschap zou kunnen maken voor het ontdekken van 
nieuwe protease remmers.
Concluderende opmerkingen
Zoals hierboven beschreven, is er in dit proefschrift getracht een bijdrage te leveren aan de 
ontwikkeling van antivirale therapie tegen enterovirussen. Ten eerste hebben we nieuwe 
virusremmers geïdentificeerd. Verder heeft het bestuderen van het werkingsmechanisme 
van de remmers geleid tot een toename in de kennis over de replicatiecyclus en nieuwe aan-
grijpingspunten voor antivirale therapie. Als laatste is er een nieuwe methode ontwikkeld 
die bij kan dragen aan het vinden van nieuwe protease remmers.
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